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Prostate cancer
Prostate cancer (PC) is the second most common cancer in men worldwide [1]. The 
disease presents itself mostly in men above the age of 50 and the incidence increases 
with age. The clinical behavior of PC is very diverse. Some tumors are indolent, do 
not cause any symptoms and arise as microscopic, well-differentiated foci that may 
never become clinically manifest. However, a significant proportion of PC patients 
presents with or will develop aggressive tumors that lead to morbidity, metastases 
and ultimately to death. The estimated incidence of PC in Europe in 2012 was 417,000, 
with 92,000 death reported. [2]. Recurrence in patients with PC is common during 
the first decade after treatment with curative intent, including radical prostatectomy 
(RP), brachytherapy or external radiotherapy. Cancer specific survival (CSS) at 10-years 
follow-up after RP is 84-90%, while post external radiotherapy the CSS vary between 
77-95% [3]. 
The initial systemic treatment in metastatic PC is based on androgen deprivation. 
Nevertheless, after an initial response to anti-hormonal therapy, the majority of PC 
patients will ultimately progress and reach a castration-resistant (CR) state. Progression 
towards castration-resistant prostate cancer (CRPC) is common within 18-36 months 
[3]. In these patients, chemotherapy has proven to slow down androgen independent 
tumor growth. In particular, docetaxel, a registered agent from the taxane class, was 
introduced as first-line chemotherapy [4]. Its effect is largely based on interaction with 
microtubules [5]. Docetaxel plus estramustine or prednisone was found to significantly 
reduce the prostate-specific antigen (PSA) value and improve overall survival when 
compared to mitoxantrone-prednisone therapy. In combination with prednisone, 
docetaxel also appeared to be useful in achieving significant improvement of pain 
palliation and quality of life [4, 6]. These clinical results have resulted in the regimen 
of docetaxel and prednisone once every three weeks becoming the current recognized 
standard chemotherapeutic treatment of CRPC [6].
Although these successes with docetaxel have improved clinical outcome of PC, the 
progressive development of chemotherapy resistance in PC remains a major
problem and new chemotherapeutic agents that circumvent resistance are urgently 
needed. Cabazitaxel is found to be such an agent, being accepted as the second-line 
cytotoxic modality in metastatic CRPC. Its role is based on the possibility of exerting 
antitumor activity on docetaxel-resistant neoplasms [7, 8]. Clinical studies, including 
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the phase III trial on the treatment of hormone-refractory metastatic PC previously 
treated with docetaxel-containing regimen (TROPIC study), demonstrated a 30% 
reduced risk of death, associated with a prolonged survival up to 2.4 months [7, 
9], in favor of cabazitaxel-prednisone versus mitoxantrone-prednisone. Currently, 
cabazitaxel-prednisone is the only chemotherapeutic option with demonstrated 
survival advantage for the treatment of patients with metastatic CRPC who have 
progressed under docetaxel-based chemotherapy [9, 10].
In the beginning of this decennium, molecular profiling studies have improved the 
knowledge about the heterogeneous biological behavior of PC. It was found that even 
in the presence of a castrate range <1.7 nmol/L of testosterone in the blood of CRPC 
patients, a proportion of these tumors remains dependent on androgen-receptor (AR) 
signaling for growth [11]. Five potential mechanisms of development of CRPC were 
described, based on ligand and AR dependence [12]. Series of progressive changes 
in intracellular AR signaling in CRPC in comparison to newly diagnosed (untreated) 
tumors were identified and validated, with AR overexpression being the most frequently 
identified phenotype [11]. Based on these observations, a multitude of therapeutic 
options against CRPC was recently proposed, including agents that interfere with 
androgenic stimulation of tumor growth (e.g., abiraterone, enzalutamide) [13–16] in 
as well as pre- or post- chemotherapy settings, immunotherapy (sipuleucel-T) [17], and 
bone-seeking radiopharmaceuticals (e.g., Radium-223 [18]). An example of a patient 
with metastatic CRPC, demonstrating AR overexpression and a good response on 
Enzalutamide is presented in Figure 1.
Abiraterone acetate inhibits androgen biosynthesis by irreversibly blocking CYP17, 
an essential enzyme in testosterone and estrogen synthesis [13]. When combined 
with low-dose prednisone, Abiraterone improves survival of patients with CRPC [13, 
14]. Enzalutamide is an antiandrogen agent with demonstrated potential to inhibit 
nuclear translocation of the AR and DNA binding. Double-blind, phase III studies 
have demonstrated Enzalutamide to significantly prolong the survival of men with 
metastatic CRPC after chemotherapy [15], but also to significantly decrease the risk 
of disease progression and death, and to delay the initiation of chemotherapy in 
men with metastatic PC [16]. Sipuleucel-T is an active cellular immunotherapeutic 
which prolongs survival among men with asymptomatic or minimally symptomatic 
metastatic CRPC [17]. Radium-223 dichloride is an alpha emitter which selectively 
binds to areas of increased bone turnover in metastatic lesions. The emitted high-
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energy alpha particles with short range radiation induce double-stranded DNA breaks, 
resulting in a highly localized cytotoxic effect in the target areas [18]. 
Figure 1. Patient with CRPC, before and after therapy with Enzalutamide (MDV3100). (Illustration reproduced with 
permission from Scher et al., Ref. 11).
Sagittal and coronal views of two PET scans, 1 h after administration of 16β-18F-fluoro-5α-dihydrotestosterone 
(FDHT), in the same patient with CRPC, are presented. The top row shows the fused PET/CT images at baseline and 
the bottom row the fused PET/CT scan 4 weeks after treatment with Enzalutamide. Both the sagittal and coronal 
images, at baseline and 4 weeks after start of Enzalutamide therapy, show a reduction in FDHT accumulation in 
the tumor within the vertebrae, compared with the cardiac and aortic blood pool, in which FDHT metabolites 
circulate bound to serum proteins. 
However, despite the variety of therapeutic options, proper sequencing (e.g., modality, 
timing) in individual patients with PC is unclear. Furthermore, the economic impact of 
these therapies has to be taken into account, due to the relatively high costs. To this end, 
it is essential, both from an ethical and an economical perspective, to opt for tailored 
therapies. This means developing “instruments” able to identify which phenotype 
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is predominant within individual PC patients and timely evaluating the response to 
therapy, thus avoiding futile costly and toxic treatments.
Role of imaging in prostate cancer
Accurate diagnostic “instruments” in PC are essential, since therapeutic options vary 
greatly with stage and grade of the disease, specific patterns of metastatic spread (i.e., 
hematogeneous and/ or lymphatic) and dominant phenotype [19, 20]. Conventional 
imaging techniques, including transrectal ultrasound, computed tomography (CT) 
and magnetic resonance imaging (MRI), are used routinely in PC, but their diagnostic 
accuracy is suboptimal [21]. Multimodality imaging has improved patient care over 
the past decade. Non-invasive, integrated positron emission tomography/ computed 
tomography (PET/CT) has proven to be a valuable diagnostic tool by combining in vivo 
metabolic and anatomic information [22]. PET/CT is used extensively in oncology for 
diagnosis, initial staging, restaging, therapy planning, and response monitoring of a 
variety of malignancies [23, 24].
PET is a functional imaging technique based on the detection of coincident photons 
originating from the annihilation of emitted positrons with electrons from adjacent 
tissues. PET uses radiotracers, which are biomolecules labeled with neutron-deficient 
nuclei (i.e., positron emitters). Before and upon intravenous administration of a 
standard dose radiotracer to the patient, the radioisotope decays, emitting a positron. 
After traveling a short path (1-2 mm) in tissue, the positron will annihilate with an 
electron, generating two 511 keV photons, which are emitted in opposite direction. PET 
detectors register the annihilation photons in coincidence. The spatial distribution of 
the radiotracer is obtained through the acquisition, storage, corrections (e.g., for the 
attenuation, scatter, normalization) and finally reconstruction of the emission images 
[25]. 
In an attempt to achieve accurate registration of the anatomical and functional images, 
the first combined PET/CT imaging system was introduced in 1998. The dual modality 
offers several potential advantages above the conventional imaging techniques. First 
of all, it fulfills a supplementary and complementary role. PET allows visualization of 
increased uptake of the tracer in areas which are (in)compatible with physiological 
biodistribution. CT, on the other hand, enables the exact localization of these areas 
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and helps to increase the specificity of PET, by identifying benign causes for enhanced 
tracer uptake. Secondly, the (low-dose) CT data generate an attenuation map to correct 
PET data, thus improving the visual quality and quantitative accuracy of the correlated 
acquisitions. Nowadays, fully three-dimensional PET/CT systems are state of the art, 
with time-of-flight (TF) capability (i.e., high resolution allowing the exact calculation 
of the location of the photon’s events) which improves the signal to noise ratio [26]. 
PET is an extremely sensitive imaging modality for which only small amounts of 
radiolabelled molecules (tracers, ~nM) need to be injected. The measurement of 
the tracer distribution allows for quantitative assessment of tissue function without 
affecting the underlying physiology [27]. Appropriate quantification of a new 
radiopharmaceutical requires kinetic modeling. This implies dynamic PET scanning 
starting at injection of the tracer and arterial blood sampling (to acquire the arterial 
input function and to measure potential tracer metabolites). With current PET 
scanners, the field of view of such dynamic scans is limited to about 15-25 cm. However, 
hybrid imaging techniques (e.g., PET/CT, PET/MRI) using new specific tracers might 
enable a quantitative assessment of response in metastatic sites (e.g., in lymph nodes 
and bone), using a single, non-invasive scan procedure, in a whole body (WB) setting. 
Acquisitions in WB setting are essential in the context of malignancy, since these allow 
characterizing all possible metastatic lesions in the body. 
The quantitative approach, although reliable, is technically demanding. For clinical 
practice it is important to develop simple and accurate quantitative methods, which 
are complementary to visual image interpretation, thus minimizing the interobserver 
variability [28]. PET data analysis methods can be divided in three major groups:
1. qualitative analysis or visual assessment, 
2. semi-quantitative analysis, including standardized uptake value (SUV) 
and lesion-to-background ratio, and 
3. absolute quantitative analysis, including (a) nonlinear regression (NLR), 
(b) Patlak graphical analysis and (c) simplified quantitative methods. 
Visual, qualitative assessment of the attenuated and non-attenuated PET images is 
the basis of any PET study interpretation. A pathological [18F]fluoromethylcholine 
([18F]FCH) avid lesion is defined as a focus with higher choline uptake than the 
surrounding background, incompatible with accumulation in a physiological site. The 
major concern regarding this assessment is the significant inter- and intra-observer 
variability of PET image interpretation [28].
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SUV is the most popular PET semi-quantitative index in the Nuclear Medicine field 
[28]. It provides a measure of radiotracer metabolism and is defined as the tissue 
concentration of tracer, as measured by PET, divided by the injected dose, normalized 
to patient weight, multiplied by a decay factor. SUV estimation is a semi-automated 
procedure, being readily calculated with current software available by the PET 
scanners. Moreover, SUV is a function of several factors such as: time interval between 
intravenous administration of the tracer and image acquisition, residual activity in 
the syringe/ infusion system, decay of the injected dose and partial volume effects 
[31]. However, standardization of procedures is required and yet only available for [18F]
fluorodeoxyglucose ([18F]FDG) [29].
NLR analysis employs the estimation of the net rate of tracer influx (Ki) from dynamic 
PET data and a standard two or more tissue compartment models, based on arterial 
input function. It represents a quantitative method with the advantage of being 
independent of uptake period, by also providing insight into various rate constants [28].
Patlak graphical analysis expresses the regional concentration of a tracer at time t 
after injection. It is more robust than NLR method, but has the same disadvantage of 
dynamic scanning, which makes its implementation complex for clinical practice.
Simplified kinetic method requires a single static scan and few venous blood samples 
during the scan acquisition. The samples are further needed to scale a population –
derived average plasma curve. The method has the advantage of estimating tracer 
metabolism without dynamic scanning and with a reduced blood sampling protocol. 
However, it implies validation in a large patient population sample [28].
Only a decade after the successful implementation of PET/CT, integration of PET with 
magnetic resonance imaging (PET/MRI) was introduced as the next hybrid imaging 
option. Strengths of MRI include its high soft tissue contrast, high spatial resolution, 
and lack of exposure to ionizing radiation. Since these two modalities (i.e., PET 
and MRI) are not easily combined in a single scanner, the design has taken years of 
technical research. Several hybrid PET/MRI systems are currently available clinically: 
an integrated system housing both components in a single gantry, or a geometrically 
separated PET and MRI on either side of a rotating table [30]. The former has the 
obvious advantage of truly simultaneous image acquisition, and the latter does not 
require any concession for either component, being also equipped with time of flight 
(TF) capability. 
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Whilst in the case of PET/CT, the merged modality quickly found its way in routine 
daily practice, PET/MRI is facing a number of technical challenges (e.g.,  presence of 
well-controlled magnetic and radio frequency fields; accurate MR-based attenuation 
correction maps) that never were an issue for PET/CT [27]. These issues require a high 
level of multidisciplinary collaboration in order to capitalize the full multiparametric 
potential of PET/MRI. However, the current challenge is to make PET/MRI suitable for 
clinical practice. Current clinical applications with PET/MRI are still in their infancy. 
Radiolabeled choline
The complex and heterogeneous biology of PC poses major challenges and 
opportunities. The implementation of performant PET hard- and soft-ware, together 
with the advances in the molecular biology of PC, offer possibility for development 
of new imaging biomarkers and promising radiotracers. For multimodality imaging 
techniques (e.g., PET/CT, PET/MRI) several radiopharmaceuticals are available to 
detect and quantitate physiologic and metabolic pathways. The most commonly used 
oncological PET tracer, [18F]FDG, shows limited sensitivity for the detection of androgen 
dependent PC [31]. In contrast, encouraging results have been reported on the use of 
both 11C and 18F labeled choline derivates as PET tracers for PC [32–36]. 
The amino acid choline is an important precursor for the biosynthesis of 
phosphatidylcholine, a key component of the cell membrane phospholipids. Following 
transport into the cell, choline is phosphorylated by choline kinase to phosphocholine 
and trapped within the cell [37]. Most types of cancer, including PC, are characterized 
by increased choline transport and over-expression of choline kinase, in response to 
enhanced demand of phosphatidylcholine in highly proliferating cells [21, 38]. Because 
of its longer half-life (110 versus 20 minutes) and better spatial resolution due to the 
shorter positron range of 18F, [18F]FCH seems to be more convenient for routine clinical 
use than 11C-labeled choline [39]. Normal biodistribution of [18F]FCH shows relatively 
high uptake in the salivary glands, pancreas, liver, spleen, and kidneys; variable uptake 
in the bowel; and excretion into urine [40].
Since the uptake of [18F]FCH overlaps among normal, benign, and malignant prostate 
tissues [41], there are mixed results, with the potential utility of this radiotracer in 
the diagnosis and staging of primary PC [42]. At present, [18F]FCH is used mainly for 
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restaging of PC in case of biochemical relapse, with a diagnostic performance that 
appears to improve with increasing PSA level, although it is not recommended for 
routine use when the PSA level is less than 1 ng/mL [36]. A systematic review and meta-
analysis [43] on the role of choline PET or PET/CT by biochemical relapse of PC showed 
a pooled sensitivity and specificity to identify all recurrent/ metastatic localizations 
(prostatic region, bone, or lymph node) of 86% (95% CI 83–88%) and 93% (95% CI 
90–95%), respectively.
If uptake of radiolabeled choline would reflect viable tumor tissue, changes over time 
of the choline signal might serve as a measure of response to therapy. For monitoring 
response to systemic treatment in metastasized PC, however, accurate quantification is 
required. To date, [18F]FCH biodistribution and radiation dosimetry have been studied 
[40, 44–46], but full kinetic analysis has not yet been reported.
Response evaluation and prediction in prostate cancer
The actual response to (chemo)therapeutic regimens in individual PC patients is 
variable. It is important to monitor therapeutic (in)efficacy in time, to prevent patients 
from undergoing futile and expensive therapy for too long, since alternative and 
potentially effective drugs are available. Presently, monitoring of progression is based 
on a response metrics construct requiring various diagnostic tests, including PSA 
measurement, CT and bone scintigraphy [47]. The limitations of the current approach 
are related to the heterogeneity of metastasized PC (i.e., coexistence of androgen 
sensitive and insensitive components with different impact on e.g., PSA [48]) and to 
its skeletal predominance (with bone- and CT-scans having difficulties in timely and 
accurately detecting response). Therefore, there is a clear need for alternative and more 
accurate response monitoring methods [49–51]. 
With each new radiopharmaceutical the challenge is to validate reliable simplified 
quantitative procedures, applicable in daily clinical practice, in WB setting. Whether 
[18F]FCH could also be employed in monitoring treatment response in PC patients 
receiving docetaxel and cabazitaxel therapy is unclear. Definitive data from clinical 
studies have not yet become available. Nevertheless, experiments in-vitro have shown 
promising results on the use of PET tracers to monitor anti-androgen treatment or 
chemotherapy [52, 53].
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Summarizing, PET imaging is a promising approach, both in clinical and research 
applications. PET allows for quantitative measurements with high sensitivity, yielding 
non-invasive information about biological processes through the body. Standard 
methods of PET quantification are difficult to implement in daily clinical practice. 
Simplified methods of quantification are available but should be validated versus the 
standard methods. To distinguish biological change from noise, repeatability of a tracer 
should be known. Due to the increasing role of [18F]FCH PET in PC, clinically feasible 
protocols, based on reliable and repeatable indices characterizing tumor activity, are 
essential for monitoring response to therapy. Complex quantitative analysis methods 
are likely to become widely available in clinical setting. This enhances the potential of 
radiolabeled choline PET to “tailor” treatment by timely evaluating the effectiveness of 
therapy, thus avoiding ineffective, costly or risky treatments.
Outline of this thesis
The aim of the present thesis was to investigate the role of [18F]FCH as a potential 
response evaluation tool in patients with prostate cancer. 
In chapter two we studied the diagnostic role of dual-phase [18F]FCH PET/CT in a 
clinical setting. Therefore, we analyzed whether time-trends of enhanced [18F]FCH in 
lymph nodes of PC patients can help to discriminate reactive from malignant ones, and 
whether single time point SUV measurements may also suffice.
In chapter three we studied an alternative potential application of [18F]FCH in metastatic 
PC. In this context, we investigated whether uptake of [18F]FCH, in comparison with [18F]
FDG, accurately reflects chemotherapy efficacy at the tumor cell level in PC. 
In chapter four we investigated how [18F]FCH can be reliably measured in a routine 
clinical setting. For this purpose, pharmacokinetic modeling of dynamic PET data in 
combination with arterial blood sampling was used to determine the appropriate 
plasma input compartment model for [18F]FCH. In addition, the validity of using 
simplified methods for quantification of [18F]FCH was assessed. 
In chapter five we investigated whether the simplified methods for [18F]FCH uptake 
measuring, as proposed in chapter four, are repeatable in daily practice. For this 
purpose, we assessed repeatability of various quantitative [18F]FCH parameters in PC, 
also including metabolic tumor volume and total lesion choline uptake. 
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In chapter six we performed a clinical and technical validation of [18F]FCH in PC. 
Therefore, we compared image quality and quantitative accuracy of PET/MRI and PET/
CT systems with identical TF PET gantries, using phantom and clinical studies.
In chapter seven results are generally discussed and summarized, including the 
perspectives.
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ABSTRACT
PURPOSE
The purpose of this study was to investigate whether time-trends of enhanced [18F]
fluoromethylcholine ([18F]FCH) in lymph nodes (LN) of prostate cancer (PC) patients 
can help to discriminate reactive from malignant ones, and whether single time point 
standardized uptake value (SUV) measurements also suffice.
METHODS
25 PC patients with inguinal (presumed benign) and enlarged pelvic LN (presumed 
malignant) showing enhanced [18F]FCH uptake at dual-phase PET/CT were analyzed. 
Associations between LN status (benign versus malignant) and SUVmax and SUVmeanA50, 
determined at 2 min (early) and 30 min (late) post injection (p.i.), were assessed. We 
considered two time-trends of [18F]FCH uptake: type A (SUV early > SUV late) and 
type B (SUV late ≥ SUV early). Histopathology and/or follow-up were used to confirm 
the assumption that LN with type A pattern are benign, and LN with type B pattern 
malignant.   
RESULTS
Analysis of 54 nodes showed that LN status, time-trends, and ‘late’ (30 min p.i.) SUVmax 
and SUVmeanA50 parameters were strongly associated (P < 0.0001).  SUVmax relative 
difference was the best LN status predictor. All but one inguinal LN showed a decreasing 
[18F]FCH uptake over time (pattern A), while 95% of the pelvic nodes presented a stable 
or increasing uptake (pattern B) type.
CONCLUSION
Time-trends of enhanced [18F]FCH uptake can help to characterize lymph nodes in 
prostate cancer patients. Single time-point SUV measurements, 30 min p.i., may be a 
reasonable alternative for predicting benign versus malignant status of lymph nodes, 
but this remains to be validated in non-enlarged pelvic lymph nodes.
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INTRODUCTION
Choline-based PET has proven value in several neoplasms, and especially in prostate 
cancer (PC) [1, 2]. [18F]FCH PET/CT seems to become a useful imaging tool to solve the 
clinical problem of rising serum prostate-specific antigen (PSA) after initially treated 
PC [3-5], with PET/CT sensitivity being proportionally related to the PSA level [6, 7]. 
Choline is the precursor of phosphatidylcholine, an essential phospholipid of cell 
membranes. The phosphorylation process is catalyzed by choline kinase (CK) [2]. In PC, 
enhanced choline uptake is explained by both increased mitogenic activity as well as 
up regulation of CK [8]. However, the signal is not tumor specific [9, 10]. Since biopsy of 
presumed regional lymph node metastases is often not trivial due to their localization 
in PC, false positive readings may induce serious problems in the clinical context. 
Both [18F] and [11C]-labeled choline derivates have been developed and studied as 
possible metabolic imaging tools in the detection of primary PC, regional LN and 
distant metastases [11, 12]. The main advantages of [18F] over [11C]-labeled tracers are 
the longer half-life (110 min versus 20 min) and a better spatial resolution due to the 
shorter positron range of 18F. However, [18F]choline is excreted in urine [13] and this 
can compromise the interpretation of the pelvic area. Since [18F]FCH is rapidly cleared 
from the blood pool, acquisition protocols have been designed with imaging of the 
pelvis prior to bladder filling (within minutes after injection), followed by a whole body 
scan after e.g., 30 min [1, 14–16] – the dual-phase protocol. Patterns of tracer uptake 
as a function of time have shown to be helpful in discriminating intraprostatic tracer 
uptake [8, 15] as well as sites of suspected haematogeneous metastases [17].
It was suggested that increasing or stable [18F]FCH uptake over time (3-7 min versus 
30-60 min after injection) was compatible with malignancy, while a decreasing tracer 
uptake is associated with benign status [8, 15, 17]. For lymph node assessment this 
hypothesis has not been validated. Beheshti et al. [8] described an interesting early [18F]
FCH wash-out pattern of false-positive LN in the preoperative setting of 130 patients 
with high and intermediate risk for disseminated PC. This phenomenon was deemed 
highly important for the differentiation of malignant versus benign nodes. However, 
the study could not support this finding with a statistically relevant number of lesions.
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In the present study we investigated whether time-trends of enhanced [18F]FCH uptake 
in lymph nodes  can help to discriminate between benign and malignant sites, and we 
explored whether single time point SUV measurements may also suffice. 
MATERIALS AND METHODS
Patients
Formal ethical approval for performing this retrospective study was obtained from 
the Medical Ethics Committee of the VU University Medical Center, Amsterdam, the 
Netherlands (approval date June 2012, reference 2012/254). This approval states that 
written informed consent from participants is wavered since the study does not fall 
within the scope of the Medical Research Involving Human Subjects Act (section 16.2 
WMO, 26th February 1998).
We retrospectively studied [18F]FCH PET/CT scans of 66 consecutive patients with 
prostate cancer (median age, 63 years; range, 50-80 years), performed  at the VU 
University Medical Center, Amsterdam, The Netherlands, between January 2009 
and March 2011. Three main clinical indications (I) for PET/CT were: I1. PSA relapse in 
previously treated PC (n=39); I2. newly diagnosed PC (n=16) and I3. staging of patients 
with suspected oligometastases (typically skeletal, identified with other imaging 
modalities), in newly diagnosed or already treated PC (n=11). 
Patient characteristics [age, Gleason score (Gl), serum PSA at diagnosis and at the time 
of performing the PET/CT] were gathered, including the date and the type of previous 
therapy [e.g., radical prostatectomy (RP), external-beam radiation therapy (EBRT), 
brachytherapy (BT), pelvic lymph node dissection (PLND), anti-androgen therapy 
(ADT) or the combination of these].
Inclusion criteria were: dual-phase [18F]FCH PET/CT performed in patients with 
histopathologically proven PC; enhanced [18F]FCH uptake in any inguinal nodes and 
in pelvic LN with a short axis diameter ≥ 8 mm, visible at early and/ or late PET scan. 
Patients with multiple malignancies (e.g., one or more other types of carcinoma apart 
from the PC) were excluded. 
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PSA relapse, suspected to be associated with residual or recurrent disease, was defined 
as a serum concentration level above 0.2 ng/ml, after RP and after the combination 
of RP with other types of therapy. A rising PSA level > 2 ng/ml above the nadir value in 
patients treated by means of EBRT was considered suspect for persistent or recurrent 
disease [18]. Increased serum PSA was confirmed by two consecutive exams for all 
patients. The maximal time interval between performing the PET/CT scan and the last 
PSA determination was 14 days. 
Based on histology, the primary PC was classified as low (Gl <7), intermediate (Gl = 7) 
and high grade (Gl > 7), according to the modified Gleason Grading System [19].    
Lymph node classification
We classified lymph nodes as benign or malignant using the following approach: 
inguinal lymph nodes with enhanced [18F]FCH uptake were considered benign since 
the prostatic lymph node drainage pattern does not include inguinal nodes [20–22]. 
Pelvic nodes with a short axis diameter ≥ 8mm were classified as malignant [23]. 
Additional confirmation was obtained using histopathology (whenever feasible), 
and with clinical follow-up of 6-12 months in all patients. Follow-up consisted of PSA 
measurements over time (as above mentioned) and/or evaluation of other imaging 
(i.e., contrast-enhanced abdominopelvic CT, pelvic MRI). We applied the following 
radiological criteria to classify change [24]:  an increase by 30% versus initial size as 
progression, a decrease by 30% as regression, and intermediate values or no change 
in size as stable.
Therefore, malignancy was defined as a positive histopathological result; radiologically 
confirmed progression in size of the pertaining lymph nodes; decrease or normalization 
of serum PSA and radiological response after therapy, providing these were the only 
abnormal findings on the initial PET/CT scan; decrease or normalization of serum PSA 
with nodal regression after RT, with the RT field including the site of the suspected LN. 
Synthesis of [18F]FCH
[18F]FCH was synthesized according to the methods proposed by DeGrado et al. 
[1, 25] and Iwata et al. [26], with minor modifications and by use of automated 
modules built in-house [27]. In short, cyclotron produced [18F]fluoride was reacted 
with dibromomethane, the formed [18F]fluorobromomethane was purified and used 
in the alkylation of 2-(dimethylamino)ethanol to obtain 2.6±0.9 GBq [18F]FCH after 
semi-preparative high performance liquid chromatography (HPLC) purification, 
reformulation in aqueous 0.9% NaCl and sterile filtration.
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The radiochemical purity was > 99.5% and no chemical impurities were detected as 
assessed by analytical radio/ultra-violet-HPLC (UV-HPLC). Residual concentrations 
of dibromomethane (0-8 ppm) and 2-(dimethylamino)ethanol (95±40 ppm) were 
determined by flame ionization detector - gas chromatography (FID-GC). Absence of 
bacterial endotoxins in the product was confirmed by an Endosafe portable test system 
(PTS) reader (Charles River) and all samples were tested for sterility.
PET/CT Imaging
All studies were performed on a Gemini TF-64 PET/CT scanner (Philips Medical Systems, 
Best, the Netherlands) with an axial field per view of 18 cm. Low-dose CT (LD-CT) was 
collected using a beam current of 30 to 50 mAs at 120 keV. CT was reconstructed using 
an image matrix size of 512x512 resulting in voxel sizes of 1.17x1.17 mm and a slice 
thickness of 5 mm. For PET, data were reconstructed by means of a raw action ordered 
subset expectation maximization algorithm using default reconstruction parameters. 
Time of flight (TF) information was used during reconstruction. Reconstructed images 
had an image matrix size of 144x144, a voxel size of 4x4 mm and a slice thickness of 5 
mm.
All patients underwent the standard [18F]FCH image acquisition protocol at our 
institution: following the LD-CT, ‘early’ PET image acquisition started 2 min after 
intravenous injection of 4 MBq/kg [18F]FCH, using a 35 cm scan trajectory over the pelvic 
region (2 min/bed position); patients were asked to void 20 min post injection (p.i.), 
and at 30 min p.i. a ‘late’ whole body PET sequence was started, from mid-thigh to the 
skull vertex, again using 2 min acquisitions/ bed position. Patient preparation was 
similar to that required for FDG PET [28].  
PET/CT data analysis
PET/CT images were evaluated by an experienced nuclear medicine specialist who first 
identified all lymph nodes with enhanced FCH uptake versus their direct background 
(on early and/ or late scan time points) within the field of view of the early scan 
trajectory. Lymph node diameters were measured using the CT component of the PET/
CT scanner, and standard CT and MRI, where available.
PET and LD-CT images were converted to ECAT 7 format and regions of interest (ROIs) 
were semi-automatically drawn around every pelvic LN that met the inclusion criteria 
mentioned above, using in-house developed software, as previously described [29, 30]. 
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For lesion delineation, we used the adaptive threshold of 50% of maximum voxel value 
within tumor, the 3D volume of interest A50 (VOIA50).  This method is similar to the 
fixed threshold method, except that it adapts the threshold relative to the local average 
background, thereby correcting for the contrast between tumor and local background. 
For example, the A50 contour value corresponds to a value at 50% of the sum of the 
maximum voxel value and the local background value. The latter value is derived from 
‘background’ voxels that are identified as those voxels  located on a single voxel thick 
shell at 2.5 cm from the  edge of a 70% of maximum pixel value isocontour,  excluding 
all voxels with an SUV larger than 2.5.
SUV’s were normalized for body weight. For data-analysis, we used early (2 min p.i.) 
and late (30 min p.i.) SUVmax  and SUVmean, as well as their absolute [SUV late - SUV early] 
and relative differences [(SUV late - SUV early)/ SUV early].
Furthermore, based on literature [8], we considered two possible time-trends of [18F]
FCH uptake by comparing the SUV early and the SUV late: type A pattern (decreasing 
over time) if the SUV early > the SUV late and type B pattern (stable/ increasing over 
time) if the SUV late was equal or exceeded the SUV early. Equality of SUV’s was 
decided using the 2nd decimal. In the present context, accuracy measures relate to the 
ability of time-trends (2 versus 30 min p.i.) of tracer uptake to discriminate malignant 
and benign lymph nodes with enhanced [18F]FCH uptake. 
Statistical Analysis 
The two sample Mann-Whitney tests were performed to determine a shift in the 
median values for benign and malignant tumors. Linear mixed-effects models were 
constructed to determine the relation between SUVmax and SUVmean. Included in this 
model were tumor status (benign versus malignant) and post injection scan time 
(2 min versus 30 min) as fixed effects, as well as random slopes per patient and per 
lesion (nested within patient). The residuals were assumed to be exponential related 
to SUVmean, and pairwise interactions between SUVmean and both tumor status and scan 
time were also tested. An identical linear regression model ignoring repeated measures 
and heteroscedasticity was used to provide an R2. Receiver Operating Characteristic 
(ROC) curves were constructed to determine the thresholds maximizing specificity and 
sensitivity. The binomial distribution is used to determine 95% confidence intervals 
of the sensitivity and specificity estimates for the optimal thresholds. To ensure that 
these results are not influenced by within-patient correlations in uptake, a Monty 
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Carlo process is performed where ROC curves are produced for 500 datasets randomly 
generated so that each patient has only one lesion. The range of the sensitivities and 
specificities of the optimal thresholds from these ROC curves were visually compared 
with the sensitivities and specificities calculated using all observations. 
RESULTS
We identified 25 eligible patients who had 54 lymph nodes with enhanced [18F]FCH 
uptake that met our inclusion criteria. In 13/25 (52%) patients the PET/CT had been 
performed because of PSA relapse (I1), and in 9/25 (36%) for staging at presentation 
(I2); the remaining three patients had been referred for restaging in the context of 
presumed oligometastases (I3). The mean interval between the primary therapy and 
the time of referral to [18F]FCH PET/CT was 23 months (range: 3-48 months). In 17 
patients (pelvic group; median age: 63 years; range: 50-80 years) we found 34 enlarged 
pelvic nodes (classified as malignant, see methods), and there were 7 patients (inguinal 
group; median age: 63 years; range: 57-68 years) with 15 [18F]FCH positive inguinal LN, 
classified as benign. One patient had enhanced [18F]FCH uptake in both two inguinal 
and three enlarged pelvic nodes. In either group the median number of eligible lymph 
nodes per patient was 2 (range: 1-6). Patient characteristics are presented in Table 1. 
Table 1. Patient characteristics.
Total patients  (N=25) Pelvic group (N=17) Combined pelvic 
& inguinal (N=1)
Inguinal group (N=7)
Mean age (years) 63 (range: 50-80) 63 63 (range: 57-68)
Mean serum PSA (ng/ml) at diagnosis 51 27 18
Mean serum PSA (ng/ml) at PET time 38 37 17
Gleason score (number of patients)
< 7 4 - 2
7 7 - 4
> 7 6 1 1
Previous therapy: number of patients (indication)
EBRT (±ADT ±PLND) 5 (3×I1 + 2×I3) - 2 (2×I1)
EBRT + RP 2 (2×I1) - 1 (I1)
RP 1 (I1) - 2 (2×I1)
ADT 1 (I1) - 1 (I3)
BT 1 (I1) - -
NA 7 (7×I2) 1 (I3) 1 (I2)
N number, EBRT external -beam radiation therapy, ADT anti-androgen therapy, PLND pelvic lymph node 
dissection, RP radical prostatectomy, BT  brachytherapy , NA not applicable, I1: PSA relapse after therapy, I2: newly 
diagnosed prostate cancer, I3: staging patients with suspected oligometastases from prostate cancer
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All LN showed enhanced FCH uptake at early (2 min p.i.) as well as late (30 min p.i.) time 
points (Table 2). The long axes of the inguinal and pelvic lymph nodes were similar (11 
±2, and 12 ±3 mm, respectively); short axis diameters were slightly smaller in the former 
group (8 ±1 vs. 10 ±2 mm, respectively; P < 0.001). 
Table 2. SUV metrics of lymph nodes as a function of time.
Standard Uptake Value Benign Malignant Total
(SUV) N = 17 N = 37 N = 54
Maximum
Early (2 min p.i.)
Median 2 3.5 3
(Range) (1.4 – 8.4) (1.4 – 10) (1.4 – 10)
Late (30 min p.i.)
Median 1.4 4.3 3.2
(Range) (0.95 – 4.8) (2.2 – 11) (0.95 – 11)
Difference
Median -0.64 0.44 0
(Range) (-3.6 – -0.08) (-1.4 – 3.8) (-3.6 – 3.8)
Relative Difference 
Median -0.32 0.084 0
(Range) (-0.54 – -0.055) (-0.25 – 1.4) (-0.54 – 1.4)
MeanA50
Early (2 min p.i.)
Median 1.5 2.6 2.3
(Range) (1.1 – 5.6) (1.2 – 7.2) (1.1 – 7.2)
Late (30 min p.i.)
Median 1.1 3.4 2.6
(Range) (0.75 – 3.4) (1.8 – 8.1) (0.75 – 8.1)
Difference 
Median -0.42 0.31 0.03
(Range) (-2.2 – 0.02) (-1 – 2.7) (-2.2 – 2.7)
Relative Difference 
Median -0.29 0.11 0.013
(Range) (-0.49 – 0.019) (-0.22 – 1.4) (-0.49 – 1.4)
Difference = SUVlate – SUVearly
Relative difference = (SUVlate – SUVearly)/ SUVearly
We found highly significant associations between the LN status (inguinal/ benign 
vs. enlarged pelvic/ malignant) and the SUVmax and SUVmeanA50 30 min p.i., and their 
absolute and relative differences (P < 0.0001). The correlation between the mean and 
max SUV metrics was near-perfect (Figure 1; the linear regression model resulted in an 
almost identical relation and an adjusted R2 of 0.99). 
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Figure 1. Comparison of SUVmax and SUVmeanA50. a. Early = 2 min p.i.; b. Late = 30 min p.i.; c. Difference = SUVlate – 
SUVearly; d. Relative difference = (SUVlate – SUVearly)/ SUVearly. At the early scan time point, SUVmax = 1.40*SUVmean – 
0.07(Benign) – 0.27(Malignant); versus a reduction of -0.07 in the intercept at the late (30 min p.i.) assessment.
For further analyses we focused on the SUVmax. The number of LN with a [
18F]FCH uptake 
pattern type A (SUVearly  > SUVlate) or B (SUVearly ≤  SUVlate), in the benign and malignant 
group for the above mentioned thresholds are included in Table 3. Based on the SUVmax 
relative difference, all but one LN in the benign group showed a type A, decreasing 
uptake over time, while in the malignant group 95% (35/37) of the nodes presented a 
type B pattern uptake. From the 54 LN, only 3 nodes were found to have a stable uptake 
over time: one from the inguinal and two from the pelvic group, respectively. 
ROC analyses of uptake trends over time and of SUV’s at either time-point (Figure 2) 
showed that the SUVmax relative difference was the best predictor of the lymph node 
status, followed by the SUVmax late and the SUVmax absolute difference [see also Table 3 
for the areas under the ROC curve (AUC)]. 
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Figure 2. ROC analyses and Threshold boxplots. a. ROC analyses of SUVmax 30min p.i. assessment (late), difference 
(SUVlate – SUVearly) and relative difference [(SUVlate – SUVearly)/ SUVearly]. The grey lines represent the 500 ROC curves 
for randomly generated datasets in which only one lesion is included for each patient; the blue lines are the ROC 
curves for all 54 lesions; the red lines indicate the shortest distance to the top left hand corner; b. Threshold 
boxplots. Thresholds associated with the shortest distance to the top left hand corner in the ROC curves are 
indicated in the boxplots by the horizontal red lines.
 
The threshold of SUVmax relative difference that  maximized both sensitivity and 
specificity was -0.19, for a sensitivity of 95% (95%CI 82-99) and a specificity of 94% 
(95%CI 71-100), versus a SUVmax late threshold of 2.3, for a sensitivity of 92% (95%CI 
78-98) and a specificity of 88% (95%CI 64-99).
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Table 3. Optimal thresholds for different SUV measures.
Standard Uptake Value (SUV) Threshold Pattern type Ben Mal Sensitivity
(95% CI)
Specificity
(95% CI)
AUC
(95% QR)
SUVmax
Late (30 min p.i.) 2.32 A 15 3 92 88 0.93
B 2 34 (78-98) (64-99) (0.88-0.94)
Difference -0.31 A 16 6 84 94 0.90
B 1 31 (68-94) (71-100) (0.87-0.97)
Relative  Difference -0.19 A 16 2 95 94 0.98
B 1 35 (82-99) (71-100) (0.95-0.99)
SUVmeanA50  
Late (30 min p.i.) 1.66 A 15 0 100 88 0.95
B 2 37 (91-100) (64-99) (0.91-0.95)
Difference -0.18 A 16 7 81 94 0.89
B 1 30 (65-92) (71-100) (0.84-0.98)
Relative Difference -0.15 A 16 3 92 94 0.97
B 1 34 (78-98) (71-100) (0.92-0.99)
Pattern type: A = SUVearly  > SUVlate; B = SUVearly ≤ SUVlate
Ben benign, Mal malignant, CI confidence interval, AUC area under the ROC curve, QR quartile range
Difference = SUVlate – SUVearly
Relative difference = (SUVlate – SUVearly) / SUVearly
In the 17 patients with 34 enlarged [18F]FCH positive pelvic nodes, histopathological 
confirmation was obtained in 4 (11 LN); all had type B time trends at [18F]FCH PET/CT. 
During follow-up, 3 patients (6 LN) had radiological nodal progression; from these 
five LN had a type B pattern and one LN proved to be false negative: type A trend 
and radiological progression. In 3 other patients, with only pathologically enlarged 
pelvic lymph nodes (6 LN) to explain an elevated PSA and with a type B pattern, PSA 
normalized upon therapy, accompanied by shrinkage of these nodes. PSA decrease 
and disappearance of a solitary (type B) pelvic node was observed in another patient 
who was treated with pelvic radiotherapy that focused on a suspected recurrence in 
prostate and this lymph node. 
Six other patients (with 9 type B and 1 type A pelvic lymph nodes) were treated with 
systemic therapy, because of local recurrence and/ or skeletal metastases. Finally, the 
patient with both 2 inguinal and 3 pelvic LN (type A in the inguinal and type B in the 
pelvic nodes) was treated with RT (prostate) and ADT because of confirmed bone 
oligometastases at presentation. In these 7 patients, PSA decreased over time and 
radiological regression of all 13 enlarged pelvic nodes together with stable dimensions 
of the inguinal nodes were recorded, as well. However, this did not unequivocally 
confirm the LN status due to the use of systemic therapy for coexistent bone metastases.
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Of the inguinal nodes (14 type A and 1 type B with stable uptake over time) none showed 
signs of malignancy during follow-up; of these, in one patient a lymph node biopsy 
was tumor negative. One patient (2 LN) opted for watchful waiting policy (otherwise 
negative PET), and his PSA was stable at 0.4 ng/ml for the follow-up of 12 months. In 
another patient (type A LN) a local recurrence was treated with HIFU with good clinical 
response (PSA) and no signs of progression.  
DISCUSSION
In our referral-based spectrum of patients with enhanced [18F]FCH uptake in pelvic and 
inguinal lymph nodes, decreasing [18F]FCH uptake over time seems to be a reliable tool 
to differentiate benign and malignant nodes. Together with similar findings by others 
to classify radioactive choline positive lesions suspected to represent hematogeneous 
metastases, our results are relevant for clinical decision making and simplification of 
diagnostic procedures, e.g., in patients with elevated PSA and positive [18F]FCH PET 
findings.  Moreover, the results underline the relevance of a sequential PET imaging 
protocol after a single injection of [18F]FCH to account for the time-trend of tracer 
uptake. 
We classified disease-status as malignant for enlarged pelvic nodes, and as benign 
for inguinal nodes of any size. Our criterion of benignity was based on the typical 
prostate drainage pattern which does not include inguinal nodes, as described by 
Inoue et al. [20]. They identified by using fluorescence navigation 3 lymphatic drainage 
pathways, comprising the obturator, the external and internal iliac nodes. Similar 
drainage patterns were found by Tokuda et al. [21] in 125 patients with LN metastases. 
Weckermann et al. [22] performed both sentinel lymph node dissection and radical 
prostatectomy in 1055 patients with PC. Despite a high percentage (> 50%) of positive 
nodes identified outside the standard lymphadenectomy borders, none of them were 
found in the inguinal region. In our study we also never encountered occurrences of 
malignancy in inguinal nodes (histological analysis, clinical radiological follow-up).
We considered pelvic nodes with a short axis diameter equal or exceeding 8 mm as 
being malignant. This threshold was chosen based on the study of Jager et al. [23] 
who reported a 98% specificity for MRI using this dimension. In their meta-analysis, 
Hövels et al. [31] found that false positivity of CT / MRI (similar performance for either 
35314 Oprea.indd   37 03-12-15   16:47
Chapter 2
38
technique) at thresholds of 8-10 mm is only 7%. In an attempt to reduce the remaining 
uncertainty, a standard of reference method was used. This approach, as extensively 
described in the “Materials and Methods” section, consisted of the combination of 
histopathological examination (whenever available) and the results obtained by 
clinical or radiological follow-up. This is a commonly used procedure [32-37] to account 
for the limitations of retrospective studies. In difficult cases, biopsy of the proper 
radioactive choline avid lymph nodes was improved and verified by using a dedicated 
gamma-probe [38]. Confirmation seemed feasible in 65% of these pelvic LN (24/37). 
In 7 patients treated with ADT and/or chemotherapy for coexisting bone metastases, 
decreases of nodal diameter could not be interpreted since such changes are not 
necessarily compatible with a ‘malignant tissue’ response to treatment.  
Note that in our present context ‘sensitivity’ and ‘specificity’ should not be confused 
with ‘the accuracy of [18F]FCH PET/CT to diagnose metastatic lymph nodes in prostate 
cancer’. The results pertain to the ability of tracer uptake time-trends to classify lymph 
nodes with enhanced [18F]FCH uptake.
The relevance of uptake time-trends to characterize [18F]FCH foci has been 
demonstrated in malignant bone metastases, in recurrent PC, and in malignant zones 
of the prostate in preoperative setting [8, 15, 17]. Our findings corroborate and extend 
those of Beheshti et al. [8] who reported on 18 malignant lymph nodes showing stable 
or increasing uptake over time. The imaging protocol consisted of a dynamic PET/CT 
scan of the pelvic region for 8 min, starting 1 min p.i., followed by whole body (WB) 
images 10 min after [18F]FCH injection and optional supplementary delayed WB 
acquisitions, 90-120 min p.i., when abnormalities were detected. However, since that 
study comprised only 4 [18F]FCH positive reactive lymph nodes (with decreasing uptake 
over time) they urged for validation of these patterns in a larger study. 
In our study, all but one inguinal nodes showed decreasing [18F]FCH uptake over time 
(Figure 3), versus 95% (35/37) of the pelvic category demonstrating stable or increasing 
uptake (Figure 4). 
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Figure 3. Example of decreasing [18F]FCH uptake over time in a right inguinal lymph node (red arrow; SUVmax early: 
4.41; SUVmax late: 2.03) of a patient with newly diagnosed prostate cancer. This lymph node was classified as 
benign. Transversal sections of the Low-dose CT, PET and fused PET/CT images:  a, b and c – early phase; d, e and f 
– late phase. [18F]FCH uptake in the prostate is also visible.
Figure 4. Example of increasing [18F]FCH uptake over time in a right para-iliac lymph node (red solid arrow; SUVmax 
early: 3.02; SUVmax late: 4.35) and a left para-iliac node (red dotted arrow; SUVmax early: 3.47; SUVmax late: 4.79) of a 
patient with biological relapse after initially treated prostate cancer. These lymph nodes were classified as 
malignant. Transversal sections of the Low-dose CT, PET and fused PET/CT images:  a, b and c – early phase; d, e 
and f – late phase.
Kwee et al. [15] suggested as a possible explanation for the tracer decrease over time in 
benign zones the dephosphorylation of [18F]FCH by prostatic acid phosphatase while 
a trapping mechanism of the tracer in the malignant cells was responsible for the 
increased uptake in PC. This can only be validated with full kinetic modeling. 
Our results are at variance with those of Cimitan et al. [15] who reported no significant 
late/early [18F]FCH uptake ratios in proven local recurrent prostatic disease or 
abdominopelvic LN, when performing a dual phase [18F]FCH PET/CT in 43 patients 
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with PSA relapse. However, their dual-phase PET/CT protocol included WB scans with 
variable early and late acquisitions, 5 to 15 min p.i. and 65 to 200 min p.i., respectively. 
The discrepancy may be explained by the rapid clearance of the [18F]FCH after 
administration [14, 16], which implies that timing of the early acquisitions is crucial 
and should be done using a strict imaging protocol.
The prevalence of patients with inguinal lymph nodes showing enhanced [18F]FCH 
uptake was 12% (8/66 patients). Our finding that reactive nodes remained detectable 
over time (i.e., for 30 min after injection) seems being inconsistent with the observation 
of Price et al. [16] who found persistent uptake at the late, 45 min p.i., images in only 1 of 
4 patients with initially enhanced inguinal node uptake. We content that this variance 
results from improved signal to noise ratios with the current TF scanner generations.
Our data suggest that the type B pattern is a strong indication for malignancy, the 
PPV being 97% (35/36; see Table 3, for the best LN status predictor: SUVmax Relative 
Difference). The fact that the PPV is not 100% implies in clinical practice that, e.g. 
in case of multiple potentially malignant [18F]FCH positive LN, the ones with type B 
patterns should be the primary biopsy candidates. 
Our results also suggest that a single point measurement in the context of a whole 
body scan, starting in caudocranial direction, 30 min after injection, is a reasonable 
alternative for relative change to differentiate reactive from malignant LN in patients 
with PC. Obviously, omitting the early scan would simplify the scan procedure. 
However, compared to measuring relative changes, the use of absolute SUV’s is more 
demanding at the level of standardization. Evidently, the present results pertain to 
lymph nodes with enhanced [18F]FCH uptake and ≥ 8 mm short axis. Ascertaining the 
single time-point approach requires validation versus histopathology.
CONCLUSION
Time-trends of enhanced [18F]FCH uptake in lymph nodes of prostate cancer patients 
seem to help discriminate benign from malignant localizations. Single time-point SUV 
measurements, 30 min p.i., may be a reasonable alternative for predicting the nodal 
status, but this remains to be validated in non-enlarged pelvic lymph nodes. 
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ABSTRACT
PURPOSE
The objective of the present study is to determine whether uptake of [18F]
fluoromethylcholine ([18F]FCH) in comparison with 2-deoxy-2-[18F]-fluoro-D-glucose 
([18F]FDG) accurately reflects chemotherapy efficacy at the tumor cell level in prostate 
cancer (PC).
METHODS
The effects of docetaxel and cabazitaxel on viable tumor cell number were explored in 
four PC cell lines. Cellular uptake of [18F]FDG and [18F]FCH, was compared with the effects 
measured using sulforhodamine B (SRB) assay, cell counting and colony formation 
assay (CFA), as proximators of viable tumor cell number. Agreement between uptake 
and cell numbers was assessed by Bland-Altman plots.
RESULTS
[18F]FCH uptake in all PC cell lines significantly correlated to the cell numbers surviving 
the respective drug concentrations. Bland-Altman analysis showed that [18F]FDG 
uptake resulted in signal overestimation and higher variability after chemotherapy.
CONCLUSION
[18F]FCH uptake correlates well with viable tumor cell numbers remaining after 
docetaxel and cabazitaxel exposure. Radiolabeled choline is a potential response 
monitoring biomarker after chemotherapy for PC.
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INTRODUCTION
Prostate cancer (PC) is the second most common cancer in males worldwide [1]. The 
disease presents itself mostly in men above the age of 50 and the incidence increases 
with age. The clinical behavior of PC is very diverse. Some tumors are indolent, do 
not cause any symptoms and arise as microscopic, well-differentiated foci that may 
never become clinically manifest. However, a significant proportion of PC patients 
presents with or will develop aggressive tumors that lead to morbidity, metastases and 
ultimately to death. 
The initial systemic treatment in metastatic PC is based on androgen deprivation. 
Nevertheless, the majority of PC patients will ultimately progress and reach a 
castration resistant PC (CRPC) status after starting the anti-hormone treatment. 
Therapeutic options against CRPC include agents that interfere with androgenic 
stimulation of tumor growth (e.g., abiraterone, enzalutamide) [2–4], immunotherapy 
(sipuleucel-T) [5], chemotherapy (docetaxel, cabazitaxel) [6, 7] and bone-seeking 
radiopharmaceuticals (e.g., Radium-223) [8]. Abiraterone acetate inhibits androgen 
biosynthesis by irreversibly blocking the CYP17, an essential enzyme in testosterone 
and estrogen synthesis [2]. When combined with low-dose prednisone, Abiraterone 
improves survival of patients with CRPC [3]. Enzalutamide is an antiandrogen agent 
with demonstrated potential to inhibit nuclear translocation of the androgen receptor 
and DNA binding, inducing tumor volume reduction in xenograft models [4]. 
Sipuleucel-T is an active cellular immunotherapeutic which prolongs survival among 
men with asymptomatic or minimally symptomatic metastatic CRPC [5]. Docetaxel 
and cabazitaxel are chemotherapeutic drugs from the Taxane class. Their principal 
mechanism of action is disruption of microtubule function, resulting in cell death [6, 
7]. Radium-223 dichloride (radium-223) is an alpha emitter which selectively binds to 
areas of increased bone turnover in metastatic lesions. The emitted high-energy alpha 
particles with short range radiation induce double-stranded DNA breaks, resulting in a 
highly localized cytotoxic effect in the target areas [8]. 
However, despite the variety of therapeutic options available, the proper sequencing 
(e.g., modality, timing) in individual patients is unclear. When chemotherapy is 
indicated the initial regimen is docetaxel combined with prednisone [9, 10]. It has 
been shown that this combination significantly prolongs overall survival, compared 
to mitoxantrone [6]. For patients progressing after docetaxel, treatment with another 
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taxane, cabazitaxel, is an option. This drug significantly increases overall survival 
compared with mitoxantrone plus prednisone in men whose disease progressed on 
docetaxel [7]. 
However, the actual response to chemotherapeutic regimens in individual patients is 
variable. It is important to monitor therapeutic (in)efficacy in time, to prevent patients 
from undergoing futile therapy for too long, since alternative and potentially effective 
drugs are available. Presently, monitoring of progression is based on a response 
metrics construct requiring various diagnostic tests, including serum prostate-specific 
antigen (PSA) measurement and bone scintigraphy [11]. The limitations of the current 
approach are related to the heterogeneity of metastasized PC (i.e., coexistence of 
androgen sensitive and insensitive components with different impact on e.g., PSA [12]) 
and to its skeletal predominance (with bone- and computed tomography-scans having 
difficulties in timely and accurately detecting response). There is thus a clear need for 
alternative and more accurate response monitoring methods [13–15]. New specific 
tracers using Positron Emission Tomography (PET) in whole body setting might enable 
a quantitative assessment of response in metastatic sites (e.g., in lymph nodes and 
bone), using a single, non-invasive scan procedure.
2-deoxy-2- [18F]-fluoro-D-glucose ([18F]FDG) is a potential tracer in the monitoring of 
antimicrotubule therapy effects in PC, but its clinical use thus far has been limited, 
because [18F]FDG uptake is highly variable and mostly confined to aggressive PC cells 
[16, 17]. Therefore, other tracers are being evaluated to describe tumor physiology as 
response to treatment [18–21]. [18F]fluoromethylcholine ([18F]FCH) PET [22] has shown 
promising results in the localization of locally recurrent or metastatic disease in men 
with biochemical failure [23–25] as well as in the early detection of bone metastases 
[26, 27]. 
Whether [18F]FCH could also be employed in monitoring treatment response in 
patients receiving docetaxel and cabazitaxel therapy is unclear. Definitive data from 
clinical studies have not yet become available. Nevertheless, experiments in-vitro have 
shown promising results on the use of PET tracers to monitor anti-androgen treatment 
or chemotherapy [28]. The objective of the present study is to assess whether changes 
of [18F]FCH and/or [18F]FDG uptake in PC cells appropriately reflect chemotherapy 
induced cytotoxicity.
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MATERIALS AND METHODS
Cell lines
PC3, DU 145 and LNCaP (-FGC clone) human PC cell lines were originally obtained 
from the American Type Culture Collection, Rockville, Md., USA (ATCC# CRL 1435; 
HTB-81; CRL 1740 respectively). R3327- MATLyLu (MLL) rat prostate tumor variant 
was established in cell culture as described earlier [29, 30]. Cell lines were cultured in 
RPMI-1640 culture medium (Gibco BRL, Life technologies Europe BV, Bleiswijk, The 
Netherlands), supplemented with 10% Fetal Calf Serum (Cambrex Fetal Calf Serum EU 
Standard,#14-801F, Lonza Verviers, Belgium), 100U/mL penicillin/streptomycin (Gibco 
BRL), 1 mM sodium Pyruvate and Insulin/Transferrin/Selenite medium Supplement 
(Sigma-Aldrich Chemicals, St. Louis MO, USA) at 37º C in a humidified atmosphere of 
5% CO2/95% air. Semi-annual screening demonstrated the cultures to be mycoplasma 
free.
Drug incubations 
Docetaxel was obtained from Sigma-Aldrich chemicals (Zwijndrecht, the Netherlands) 
and was dissolved in dimethylsulfoxide to stock concentrations of 10 nM. Cabazitaxel 
was obtained from Sanofi-Aventis (Aventis Pharma, Antony Cedex, France) and 
was dissolved in Phosphate Buffered Salt Solution (10nM). All stock solutions were 
stored in aliquots at -20ºC until use. For the drug incubations the respective cell lines 
were seeded into tissue culture flasks (25 cm, #690160; Greiner Bio-One, Alphen a/d 
Rijn, The Netherlands) in cell densities of 300.000 (PC-3; DU145), 500.000 (LNCaP) 
or 30.000 (R3327-MATLyLu), respectively. After 24 hours drugs were added in the 
desired concentrations. After 3 days of drug incubation the remaining cell numbers 
were determined using a CASY cell counter (Casy TT, Roche Diagnostics, Almere, The 
Netherlands) and parallel cultures were either worked up for Colony Formation Assay 
(CFA) or incubated with 18F-radiolabeled choline and deoxyglucose. All experiments 
were performed in triplicate and were repeated at least three times. 
Sulforhodamine B (SRB) assay 
Evaluation of drug cytotoxic effects using the sulforhodamine B (SRB)- assay was 
performed as described earlier [31].  In short: 3500 PC3 cells, 3500 DU145 cells, 5000 
LNCaP cells or 1500 MLL cells were seeded in each well of 96-well plates (Cellstar 
#655180; Greiner BioOne, Frickenhausen, Germany). After 24 hours drugs were added 
in increasing concentrations and cells were incubated for 3 days. After this incubation 
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time, wells were fixed with trichloroacetic acid (1 hour at 4ºC) and stained using SRB 
solution (0.4% SRB in 1% acetic acid). The optical density was measured at 492 nm 
after reconstitution of the dye in 150 μL 10 mM Tris buffer. The values were normalized 
to cell density of control cultures (100%) and were corrected for the optical density 
values at t=0 (0%). Subsequently, inhibitory concentrations were calculated resulting 
in 10%, 50% and 90% reduction in cell numbers compared to control: IC10, IC50 and IC90 
respectively (all from 3 experiments in triplicate; means ± SEM).
Colony Formation Assay (CFA)
Cells were exposed to IC10, IC50 and IC90 concentrations of either cabazitaxel or docetaxel 
for 3 days. Subsequently, 200 cells were seeded in each well of 6-well plates for colony 
formation, as described previously [32]. After seven to ten days the colonies were fixed 
using 4% PBS buffered formaldehyde. The colonies were then stained with Giemsa-
solution and counted using a Leica stereomicroscope. All experiments were performed 
in triplicate and repeated at least three times.
To facilitate the colony formation of LNCaP cells, conditioned medium (RPMI-1640 
medium exposed for 24-48 hours to growing LNCaP cultures) was added (60:40). This 
allowed for autocrine stimulation of cell proliferation in this specific cell line. For R3327-
MATLyLu cells, a modification of the CFA technique was used in order to account for the 
low efficient adherence of these cells to culture flask surfaces, as described earlier [29]. 
Briefly, after drug exposure, MLL cells were seeded in 0.25% agar (in PBS) which was 
layered on top of semisolid agar (0.375%). 
Choline and Deoxyglucose labeling
[18F]FCH and [18F]FDG were prepared in the radiochemistry unit of the department of 
Radiology and Nuclear Medicine of the VU University Medical Center, Amsterdam, 
the Netherlands. Addition of the label (around 2 MBq) was performed 1 hour after 
replenishment of the growing cultures with fresh medium (in the case of [18F]FDG 
labeling, glucose-free RPMI 1640 medium was used for this replenishment). After 
incubation with the radiopharmaceutical for 1 hour, the cultures were washed twice 
using sterile phosphate-buffered salt solution and the uptake of the radiotracer in cells 
after trypsinization was measured using a gamma counter. The activity was calculated 
in percentage of total counts added and corrected for the cell number. All experiments 
were performed in triplicate and repeated at least three times. 
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Western Blotting 
Western blotting was performed as described previously [31]. In brief, cells were exposed 
to either cabazitaxel or docetaxel for 3 days, washed with PBS and scraped in lysis buffer 
(Cell Signaling Technology Inc., supplemented with 0.04% protease inhibitor cocktail). 
Protein amounts in the supernatants were determined by the Bio-Rad assay (Bio-Rad 
Laboratories, Veenendaal, the Netherlands); 40 µg of protein was separated on a 10% 
SDS-PAGE and electroblotted onto polyvinylidenedifluoride (PVDF) membranes 
(Millipore ImmobilonTM –FL PVDF, 0.45 µm). Subsequently, the membranes were 
blocked and incubated overnight at 4°C with the primary antibody anti-GLUT-1 
(polyclonal # ab15309; dilution 1:1000; Abcam, Cambridge, UK) or alternatively with 
anti-β actin (#A5441; 1:10,000; Sigma Aldrich Chemicals, Deisenhofer, Germany) as 
loading control. Subsequently, the membranes were incubated with the secondary 
antibody against mouse (goat-∂-mouse-IRDye (680;#926-32220), Westburg, Leusden, 
The Netherlands). The bands were scanned using an Odyssey Infrared Imager 
(Westburg) at high quality, and expression levels were quantified with the Odyssey 
software program LI-COR Biosciences.
Cell volume determinations
Using CASY TT electronic cell counter, the effects of drug incubations of docetaxel 
and cabazitaxel (at IC90 concentration level) on average cell volume were determined 
after 3 days of incubation for all cell lines. Average volume is reported in the results in 
femtoliter (fl). 
Analysis and statistics 
Agreement between uptake of radiolabeled [18F]FCH and [18F]FDG in the four PC cell 
lines and cell number was assessed by means of Bland-Altman plots, in which the 
differences between uptake of the tracer  (%) and cell number (%) were plotted against 
the averages of these values [33, 34].
RESULTS
Effect of cabazitaxel and docetaxel on prostate cancer cell viability
The drug induced effects on the four PC cell lines after an incubation of 3 days were 
assessed using the SRB assay. In Table 1, the IC10, IC50 and IC90 values were taken to 
delineate a representative and differential range of drug effect levels to be used to 
35314 Oprea.indd   51 03-12-15   16:47
Chapter 3
52
compare [18F]FCH / [18F]FDG uptake with measures of viable cell numbers after drug 
incubation. The sensitivity of the various cell lines was reflected in their differential 
pattern of sensitivity towards docetaxel and cabazitaxel.
Subsequently, the chosen concentrations (IC10, IC50 and IC90) of docetaxel and 
cabazitaxel, aimed at reflecting low, medium and highly effective treatment results, 
respectively, were used in a 3-day incubation scheme with cells from the four PC lines to 
delineate efficacy on colony forming capacity. The colony forming ability at the IC10 and 
IC90 dose levels of both drugs decreased in a dose-dependent manner and analogously 
to the SRB-derived survival values, for all cell lines (Figure 1). 
Effect of treatment on [18F]FCH and [18F]FDG signal
To evaluate the effect of docetaxel and cabazitaxel on [18F]FCH and [18F]FDG uptake, 
cells were exposed for 3 days to IC10, IC50 and IC90 concentrations of the drugs, after 
which the cellular uptake of the radiotracer was measured. In all four cell lines, a clear 
relation was observed between actual cell numbers counted after treatment and level 
of [18F]FCH and [18F]FDG uptake. Using Bland-Altman plots we analyzed the degree to 
which the [18F]FCH / [18F]FDG uptake co-varied with viable cell numbers, in response to 
drug concentration in cells from the respective cell lines (Figure 2).
Table 1.  Drug concentration (nM) ranges selected on the base of sulforhodamine B (SRB) assay-measured IC10, IC50 
and IC90 values, in prostate cancer cell lines PC3, DU145, LNCaP and MLL.  
 
 
  Docetaxel    
 
  Cabazitaxel  
IC10 IC50 IC90 IC10 IC50 IC90
PC3 0.5 1.0 10 0.5 1 10
DU145 0.5 1.0 5 0.5 2 5
LNCaP 0.5 2 10 1 5 50
MLL 2 10 50   0.5 2 10
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Figure 1. CFA-determined treatment effects of docetaxel and cabazitaxel on proliferation of prostate cancer cells 
correlated to SRB-determined toxicity levels (IC10, IC50, IC90 are drug concentrations resulting in 10, 50 and 90% 
reduction in cell numbers compared to control value, respectively). Surviving fractions are given in percentage 
compared to control ± standard deviation, carried out in triplicate using prostate cancer cell lines PC3, DU145, 
LNCaP and MLL. a effect of docetaxel. b effect of cabazitaxel. Left bar: IC10, middle bar IC50, right bar IC90.
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Figure 2. Bland-Altman plots for cellular [18F]FCH uptake in four prostate tumor cell lines (a PC-3, c DU145, e LNCaP, 
g MLL) and [18F]FDG uptake (b PC-3, d DU145, f LNCaP, h MLL), after docetaxel and cabazitaxel treatment. The x-axis 
shows the average between cell number percent and uptake percent and the y-axis shows the absolute difference 
between cell number percent and uptake percent. The straight lines indicate the average uptake after incubation 
with docetaxel (black) and cabazitaxel (red). The dotted lines indicate the limits of agreement for uptake after 
incubation with docetaxel (black) and cabazitaxel (red).
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Average difference between tracer uptake and cell number was closer to 0 for [18F]
FCH compared to [18F]FDG with the exception of DU145 cell line after treatment with 
cabazitaxel. [18F]FDG uptake overestimated the numbers of cells remaining after 
docetaxel and cabazitaxel treatment in PC3 and MLL cell lines (Table 2). Furthermore, 
agreement between uptake and cell numbers was generally worse for [18F]FDG 
when compared to [18F]FCH as can be seen from the increased limits of agreement 
(determined as 1.96 times standard deviation of the difference between tracer uptake 
and cell number) for the Bland-Altman analyses (Table 2). 
Table 2.  Comprehensive results of Bland-Altman analyses for [18F]FCH and [18F]FDG uptake compared to cell 
numbers after docetaxel (doc) and cabazitaxel (cab) treatment of prostate cancer cell lines PC3, DU145, LNCaP and 
MLL. The average difference between uptake of docetaxel (and cabazitaxel) and cell number in the Bland-Altman 
plots is given in this table (mean difference ± limits of agreement, both in percent). 
 
 
  [18F]FCH   
 
[18F]FDG 
Docetaxel Cabazitaxel Docetaxel Cabazitaxel
PC3 -5.96±27.79   5.63 ±16.83  12.08±18.07  22.42±24.42 
DU145 -4.28±28.14 -11.58±41.66   -2.78±45.53   -3.68±75.81
LNCaP -2.40±29.92  -1.55 ±30.30 -12.59±23.44 -10.52±31.73
MLL -0.76±35.90   0.64 ±46.07    34.15 ±62.17  29.79±58.65
To explain the increased [18F]FDG uptake by PC cells after incubation with docetaxel 
and cabazitaxel, we measured the expression of glut-1 glucose transporters using 
Western blot after incubation at IC90 drug concentrations. The glut-1 transporter 
protein expression appeared not to be upregulated by treatment with either docetaxel 
or cabazitaxel (Figure 3).
Since taxane exposure may lead to increase in cell volume through stabilization of 
microtubules and inadequate cell division, an effect on radiotracer uptake on a per cell 
basis may result. Therefore, the mean volume of PC cells from the four different cell 
lines was determined after 3 days of incubation with IC90 concentrations of docetaxel or 
cabazitaxel. The mean cell volume increased with a factor about 2 or 3 times for all four 
cell lines after incubation with each of the two chemotherapeutic drugs, most notably 
for PC3 and MLL (Figure 4). 
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Figure 3. a Western blot displaying stained antibody incubations using anti-glut-1 antibody on cell homogenates 
of four prostate cancer cell lines PC3, MLL, DU145 and LNCaP, after treatment with IC90 concentrations of docetaxel 
and cabazitaxel. Anti- β actin was used as a loading control. b Expression levels were quantified with the Odyssey 
software.
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Figure 4. Mean cell volume (in fl) of prostate cancer cells, measured after incubation during 3 days with 
concentrations of docetaxel and cabazitaxel aimed at 90% inhibitory effect in four prostate cancer cell lines 
LNCaP, PC3, DU145 and MLL.
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DISCUSSION
In the present study we compared the reduction in cellular uptake of radioactive 
[18F]FCH in prostate tumor cells in vitro under different burdens of docetaxel and 
cabazitaxel, with parameters of cell viability. The radiotracer uptake was proportional 
to the number of cells counted after therapy and these cell numbers correlated to 
clonogenic capacity as an additional sign of (reproductive) viability of the cells surviving 
the treatment. From this comparison we conclude [18F]FCH to be an adequate read-out 
parameter for response to treatment. [18F]FDG, on the other hand, showed in the case 
of PC3 and MLL an overestimation of the viable cell numbers remaining after therapy. 
This could lead to misinterpretation of the treatment outcome. 
Non-invasive and timely therapy monitoring using PET would enable to quickly 
evaluate treatment efficacy in individual cancer patients thereby tailoring therapy, 
improving healthcare and quality of life, while offering economic benefits. Therefore 
we examined the possibility to use [18F]FCH as a novel readout for chemotherapy 
response monitoring in PC cells after treatment with either docetaxel or cabazitaxel, 
which are presently the drugs of choice in clinical PC chemotherapy. 
A panel of different prostatic tumor cell lines was used, comprising both androgen-
sensitive (LNCaP) as well as androgen-insensitive cell lines (PC-3; DU145 and R3327 
MAT-LyLu). An influence of PC differentiation in patients on the level of [18F]FDG uptake 
has been described by Schwarzenböck et al. [35]. It has been shown that the grade of 
differentiation of PC cells is inversely proportional to the level of [18F]FDG uptake. In our 
experiments the relative sensitivity of treatment effects as evidenced by [18F]FCH and 
[18F]FDG uptake was investigated.  The observed differential sensitivity of the various 
cell lines for the respective drugs is thought to reflect differences in expression of 
drug transporters like ABCC4 [30, 36]. All four cell lines investigated were [18F]FCH and 
[18F]FDG avid and the relative changes of tracer uptake and viable cell numbers upon 
exposure to docetaxel and cabazitaxel were closely related. Whether the efficacy of 
chemotherapy in PC in vivo will also be reflected by such a proportional decrease of the 
[18F]FCH signal, remains to be determined. However, in animal experiments employing 
PC xenografts, a reduced uptake of [11C]Choline compared to muscle tissue was shown 
within a week after docetaxel therapy and thereby confirm our present conclusions [37, 
38]. In the present, comparative study we have explored four different PC cell lines, two 
radiotracers (18F- radiolabeled choline and - FDG) and two chemotherapeutic drugs in 
a range of three concentrations.  
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Although we did not measure [18F]FCH and [18F]FDG levels before and after drug 
treatment, the radiotracers were supplied in excess and are therefore not supposed to 
be a limiting factor. Docetaxel/ cabazitaxel may contribute to an effect on the cellular 
uptake of [18F]FCH signal through a modulation of choline metabolism [39]. Choline 
transporters mediate the cellular uptake and the transport is the rate limiting step 
for the synthesis of phosphocholine which is enhanced in malignant transformation. 
Choline transporters of high and low affinity have been found in normal prostate tissue 
and are increased in PC [40]. Expression of choline transporters - and therefore choline 
uptake rate - have been described to be influenced by anticancer drugs [28, 41]. Such 
an effect could become visible in a decreased choline uptake per cell. Nevertheless, in 
the present study the choline uptake signal was correlated closely to the surviving cell 
numbers after treatment with docetaxel and cabazitaxel. Therefore, we conclude that 
interference with choline metabolism is not a confounder in the present observations. 
At present, it is unknown how the increased [18F]FDG uptake after treatment in some cell 
lines is brought about. Especially, the overestimation of viable cell numbers by the [18F]
FDG signal after chemotherapy deserves attention as it may result in a false negative 
interpretation of treatment efficacy. Possible explanations for an observed disjointed 
relationship of [18F]FDG response from viable cell numbers after chemotherapy may 
relate to differential effects on hexokinase and glut-1 expression [42], but mostly 
these effects result in decreased [18F]FDG uptake rather than the opposite. Moreover, 
in our present in vitro study we did not observe changes of glut-1 expression to explain 
increased [18F]FDG uptake after drug treatment. However, a very different cause for this 
effect in our experiments may have been found in the observed increase of cell volume 
after docetaxel or cabazitaxel treatment. The increased volume of such swollen cells 
after therapy may result in increased [18F]FDG signal per cell. The absence of these effects 
in the case of [18F]FCH may be related to different metabolic pathways, but this aspect 
has to be further investigated.  Interestingly, other authors have also found increased 
levels of radiotracer uptake after therapy [28, 43]. Cellular stress resulting in increased 
cellular metabolism or otherwise increased cell permeability have been given as an 
explanation for a flare at 10 minutes after start of treatment [28]. A transient increase 
in FDG uptake has been described by Bjurberg et al. [43] followed by a rapid decrease. 
In general, timing of the monitoring seems to be important. In our analyses uptake of 
the PET tracers was measured after 3 days of drug incubation, thereby bypassing any 
eventual, initial flare phenomena. The observed cell number-independent increase in 
[18F]FDG signal, coupled to other known drawbacks of [18F]FDG PET in PC (general low 
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uptake, disturbing sensitivity to inflammatory processes, scar tissue and radiotherapy 
mediated effects) together with the proportional, observed treatment effects in [18F]
FCH uptake, contribute to a preferential role rising up for [18F]FCH PET compared to [18F]
FDG PET as a candidate drug response monitoring tool in PC patients. 
CONCLUSIONS
Our in vitro data demonstrate that the cellular [18F]FCH uptake correlates well with 
viable tumor cell number after docetaxel and cabazitaxel for all prostate cancer cell 
lines, while [18F]FDG at times overestimated the cell number after drug exposure. This 
suggests that [18F]FCH is more accurate and therefore more suitable than [18F]FDG as a 
response monitoring PET tracer in chemotherapy of prostate cancer using docetaxel 
and cabazitaxel.
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ABSTRACT
Choline kinase is upregulated in prostate cancer (PC), resulting in increased [18F]
fluoromethylcholine ([18F]FCH) uptake. This study used pharmacokinetic modeling to 
validate the use of simplified methods for quantification of [18F]FCH uptake in a routine 
clinical setting. 
METHODS
Forty-minute dynamic PET/CT scans were acquired after injection of 204 ± 9 MBq [18F]FCH, 
from eight patients with histologically proven metastasized PC. Plasma input functions 
were derived using continuous arterial blood sampling (BSIF) as well as using image-
derived (IDIF) methods. Manual arterial blood samples were used for calibration and 
correction for plasma-to-blood ratio and metabolites. Time activity curves (TAC) were 
derived from volumes of interest (VOI) in all visually detectable lymph node metastases 
(LNM). [18F]FCH kinetics were studied by non-linear regression fitting of several single- 
and two-tissue plasma input models to the TAC. Model selection was based on Akaike 
information criterion (AIC) and measures of robustness. In addition, the performance of 
several simplified methods, such as standardized uptake value (SUV), was assessed.
RESULTS
Best fits were obtained using an irreversible compartment model with blood volume 
parameter. Parent fractions were 0.12 ± 0.4 after 20 min, necessitating individual 
metabolite corrections. Correspondence between venous and arterial parent fractions 
was low as determined by the intraclass correlation coefficient (ICC = 0.61). Results 
for IDIF derived from VOI in blood pool structures distant from tissues of high [18F]
FCH uptake, yielded good correlation to those for BSIF (R2 = 0.83). SUV showed poor 
correlation to parameters derived from full quantitative kinetic analysis (R2 < 0.34). In 
contrast, lesion activity concentration normalized to the integral of the blood activity 
concentration over time (SUVAUC) showed good correlation (R
2 = 0.92 for metabolite 
corrected plasma and R2 = 0.65 for whole-blood activity concentrations). 
CONCLUSION
SUV cannot be used to quantify [18F]FCH uptake. A clinical compromise could be SUVAUC 
derived from two consecutive static PET scans, one centered on a large blood pool 
structure during 0-30min after injection to obtain the blood activity concentrations 
and the other a whole-body scan at 30 min after injection to obtain lymph node activity 
concentrations.
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INTRODUCTION
Prostate cancer (PC) is one of the most commonly diagnosed neoplasms in men 
worldwide and incidence is increasing [1]. Accurate diagnostic procedures are essential, 
because therapeutic options vary greatly with extent of the disease [1, 2]. Conventional 
imaging techniques, including transrectal ultrasound, computed tomography (CT) and 
magnetic resonance imaging are used routinely in PC, but their diagnostic accuracy is 
suboptimal [3]. 
Positron emission tomography (PET) provides a sensitive and accurate non-invasive 
method to study metabolic activity of tumor tissue in vivo. The most commonly used 
oncological PET tracer, fluorodeoxyglucose (18F-FDG), shows limited sensitivity for the 
detection of androgen dependent PC [4]. In contrast, encouraging results have been 
published using both 11C and 18F labeled choline derivatives as PET tracers for PC [5–9].
The amino acid choline is an important precursor for the biosynthesis of 
phosphatidylcholine, a key component of the cell membrane phospholipids. Following 
transport into the cell, choline is phosphorylated by choline kinase to phosphocholine 
and trapped within the cell [10]. Most types of cancer, including PC, are characterized 
by increased choline transport and over-expression of choline kinase, in response to 
enhanced demand of phosphatidylcholine in highly proliferating cells [6, 11]. 
Because of its longer half-life [12], 18F-labeled choline is more suitable for routine clinical 
use than 11C-labeled choline. At present, 18F-fluoromethylcholine ([18F]FCH)  is used 
mainly for restaging of PC in case of biochemical relapse. As uptake of [18F]FCH should 
reflect viable tumor tissue, changes over time may serve as a measure of response to 
therapy. For monitoring response to systemic treatment in metastasized PC, however, 
accurate quantification is required.
To date, [18F]FCH biodistribution has been assessed with encouraging results [13–16], 
but full kinetic analysis has not yet been reported. In the present study, pharmacokinetic 
modeling of dynamic PET data, in combination with arterial blood sampling, was 
used to determine the appropriate plasma input compartment model for [18F]FCH. In 
addition, the validity of using an image-derived input function in combination with 
manual venous blood samples instead of arterial blood sampling was investigated and 
the validity of using simplified methods for quantification of [18F]FCH was assessed.
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MATERIALS AND METHODS
Patients
Eight patients with histologically proven PC with lymphatic and/or haematogeneous 
metastases were included. Inclusion criteria were presence of at least 2 metastases 
(diameter ≥ 1.5 cm) and ability to remain supine for 50 min. Exclusion criteria were 
claustrophobia, multiple malignancies and anticoagulant therapy. The study was 
approved by the Medical Ethics Review Committee of the VU University Medical Center. 
Prior to inclusion, each patient signed a written informed consent after receiving verbal 
and written explanation.
Synthesis of [18F]fluoromethylcholine
[18F]FCH was synthesized according to the methods proposed by DeGrado et al. [6] 
with minor modifications and by use of automated modules [17]. Details are given in 
supplemental data 1.
Data acquisition
Each patient received a low dose CT (50 mAs, 120 kVp), followed by a 40-min dynamic 
PET scan with the field of view (FOV) centered over the largest metastases (abdominal 
region: n = 5; lung area: n = 3), on a Gemini TF-64 PET/CT (Philips Medical Systems, 
Cleveland, Ohio, USA). At the start of the PET scan a bolus injection of approximately 
204 ± 9 MBq [18F]FCH (specific activity 94.9 ± 65.7 GBq·µmol-1) was administered 
intravenously using an automated injector (Medrad, Pittsburgh, USA) and flushed 
with 40 mL of saline (5 mL at 0.8 mL·s-1 followed by 35 mL at 2 mL·s-1). 
PET data were normalized and corrected for attenuation, dead time, randoms, scatter 
and decay, and reconstructed into 34 frames (1 x 10, 8 x 5, 4 x 10, 3 x 20, 5 x 30, 5 x 60, 4 x 150, 
4 x 300 s) with a matrix size of 144 x 144 x 45 voxels (4 x 4 x 4 mm3) using a 3-dimensional 
row action maximum likelihood reconstruction algorithm (3D-RAMLA) [18]. 
Arterial blood activity concentration over time was determined by continuous arterial 
blood sampling (5 mL·min-1 for 5min, 2.0 mL·min-1 thereafter) using an automated 
blood sampling device [19] connected to a cannula inserted into the radial artery. At 6 
time points (5, 10, 15, 20, 30 and 40 min after injection) manual arterial blood samples 
were collected, while the blood sampler operation was briefly paused. In addition, 
manual venous blood samples were collected at 5, 15 and 30 min after injection. After 
each sample, the cannula was flushed with heparinized saline to prevent clotting.
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Each manual sample was analyzed for whole-blood activity concentration, plasma-to-
whole blood ratio and presence of radiolabeled metabolites in plasma. After plasma 
protein extraction, metabolite analysis was performed on the remaining plasma 
(extraction efficiency of 88%) using a method based on Sutinem et al. [11] involving 
high performance liquid chromatography. 
Kinetic analysis
In pharmacokinetic modeling, tracer kinetics are assumed to be separable into 
compartments that are connected in series to the arterial blood compartment, 
represented by the plasma input function, by (transport) rate constants. For example, 
in the irreversible two-tissue compartment model (2T3k) the first compartment 
often represents tracer free in tissue while the second represents irreversible specific 
uptake. From the rate constants connecting the compartments, the net influx rate for 
the second compartment can be calculated: Ki=K1k3/ (k2+k3). The supplemental data 2 
provides more details on each of the models and associated quantification parameters.
Metabolite-corrected blood sampler plasma input functions (BSIF) were derived from 
blood sampler data (corrected for intermittent reductions in counts associated with 
saline flushes), calibrated using whole-blood activity concentrations measured from 
manual arterial blood samples. In addition, data were multiplied by the plasma-to-
blood ratio curves and parent fraction curves derived from manual arterial blood 
samples using a single exponential fit and Watabe fit [20], respectively, and corrected 
for delay [21]. Metabolite corrected image-derived plasma input functions (IDIF) were 
derived from volumes of interest (VOIs) (2.85 ± 1.65mL; range: 0.64-5.89 mL) defined 
manually on an early PET frame most clearly displaying the blood pool (Figure 1A), 
within the largest arterial blood pool structures available (left ventricle or aortic, 
femoral or iliac arteries). These VOIs were then projected onto the dynamic PET scan 
to derive time activity curves (TAC), which were processed in the same fashion as BSIF.
TACs were derived from several tissue VOIs. Lesion VOIs were defined using a 50% 
threshold technique with background correction, in all metastatic lymph nodes that 
were clearly visible on the averaged PET image over 25-40min after injection (24 in 
total; 4.76 ± 3.54mL; range: 0.7-12.8 mL) . Healthy tissue VOI were manually defined 
using the lowdose CT (muscle, fat, liver).
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Several standard compartment models were then fitted to the lesion TAC using 
standard non-linear regression analysis (NLR) routines [22], with both BSIF or IDIF as 
input functions. Models evaluated were the general irreversible and reversible single-
tissue compartment models (1T1k and 1T2k, respectively) and the irreversible and 
reversible two-tissue compartment models (2T3k and 2T4k, respectively). To account 
for contribution of blood activity concentrations to the tissue TAC, performance of 
all models was evaluated with and without blood volume parameter (VB). Boundary 
conditions for all estimated kinetic parameters were determined after multiple runs 
(K1: [0, 3], k2: [0, 2], k3/k4: [0, 10] and VB: [0, 1]). Fits with low precision (as indicated by SE 
> 500% in at least one of the estimated rate constants) were considered unsuccessful 
and excluded from further analysis. Robustness of the model was evaluated as the 
percentage of successfully fitted lesion time-activity curves.
Validation
Model selection. The model providing the best fits to the lesion time–activity curves was 
selected on the basis of the Akaike information criterion (AIC) for small sample sizes 
[23] and model robustness. In clinical practice, lengthy (dynamic) scanning procedures 
are less attractive. Therefore, the minimal scan duration required to derive accurate 
results was assessed by comparing relevant uptake parameters resulting from kinetic 
modeling of parts of the dynamic scan (0-5 min, 0-10 min, 0-15 min, 0-20 min, 0-25 
min or 0-30 min after injection) with those of the full dynamic scan (0-40 min after 
injection).
Alternatives to arterial blood sampling. Deriving an accurate plasma input function 
requires insertion of an arterial cannula, automated blood sampling and specialist 
metabolite analysis. As these methods may not be feasible in a routine clinical setting, 
the validity of using IDIF instead of BSIF as well as the need for manual arterial or 
venous blood samples, were assessed.
Simplified methods. Once validated, simplified methods can provide estimates of 
relevant uptake parameters using a far simpler imaging protocol than that required 
for full kinetic modeling. Therefore, performance of several simplified measures was 
evaluated, for example, lesion-to-muscle ratio (LMr), lesion-to-blood ratio (LBr) and 
standardized uptake value (SUV) for several normalization factors: body weight (BW), 
body surface area (BSA), lean body mass (LBM), body mass index (BMI) and ideal body 
weight (IBW).
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RESULTS
Patients
Eight patients diagnosed with PC were included: age 66 ± 8y, weight 89 ± 12kg, height 
185 ± 7cm, T-stage ≥ 2, Gleason score 7 (n = 2) or 9 (n = 6) and high PSA at the time of 
PET/CT imaging (113 ± 91ng/ml). Patients were previously treated by prostatectomy (n 
= 4) or external beam radiotherapy on the prostate in combination with anti-hormonal 
therapy (n = 4). Three patients were receiving therapy at the time of PET/CT imaging: 
luteinizing hormone-releasing hormone (LHRH) antagonists, oral androgen receptor 
inhibitor Enzalutamide and dendritic cell therapy, respectively. Figure 1 shows typical 
[18F]FCH PET/CT images. Two typical examples of acquired blood activity concentrations 
are shown in Figure 2.
Figure 1. Typical example of PET/CT images acquired from patient diagnosed with PC. Shown are low-dose CT 
(gray scale) fused with early PET image acquired from 35 to 40 s after injection displaying blood pool (A) and 
averaged image over 25–40 min after [18F]fluoromethylcholine injection (B) (color).
Validation
Model selection. Typical tissue TACs are shown in Figure 3A. Figure 3B shows the same 
lesion TAC with associated nonlinear regression analysis fits. AIC results indicate 
irreversible kinetics, with 2T3k+VB producing the best fits (preferred model in 7/24 
lesion TAC), followed by the simpler irreversible model 2T3k (7/24) and 1T1k+VB (5/24). 
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Figure 2. Two typical examples of measured whole-blood time–activity curves for patient imaged over thorax 
region (A) and patient imaged over abdominal region (B). Lines represent calibrated blood sampler data; dashed 
lines (image-derived) aortic arch; dash-dot lines (image-derived) abdominal descending aorta; triangles manual 
arterial blood samples; squares manual venous blood samples. 
Figure 3. (A) Typical measured time–activity curves for the same patient shown in Figure 1. Square represents liver, 
circle lesion, diamond muscle and triangle fat tissue. (B) Nonlinear regression fits to lesion time–activity curve 
displayed in A, using various compartment models.
However, as displayed in Table 1, 2T3k+VB was less robust than 1T1k+VB whereas 
correspondence between respective quantification parameters was excellent (R2 = 0.96; 
ICC = 0.94; Table 2) and remained so even for K1 derived from shorter scan durations (R
2 
> 0.92; ICC > 0.89; SE [K1 < 5%]; for scan durations > 20min). 
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Table 1. Comparing scan durations.
      Linear regression analysis
Parameter (model) Scan duration (min) Robustness 
(%)
Slope Intercept R2 ICC*
K1(1T1k+VB) 5 100 0.98 0.05 0.82 0.84
10 100 0.98 0.03 0.94 0.95
15 100 0.99 0.02 0.97 0.98
20 100 1.01 0.01 0.99 0.99
30 100 1.00 0.00 1.00 1.00
Ki(2T3k+VB) 5 60 0.82 0.09 0.59 0.75
10 65 0.93 0.03 0.97 0.98
15 75 1.07 -0.02 0.94 0.97
20 75 1.05 -0.01 0.90 0.95
  30 80 1.03 -0.01 1.00 1.00
Results for comparison of quantification parameters from short scan durations derived from full 40/min 
dynamic scan
Table 2. Comparing 1T1k+VB to 2T3k+VB.
  Linear regression analysis  
Scan duration (min) Slope Intercept R2 ICC*
5 0.98 0.09 0.69 0.65
10 0.98 0.07 0.82 0.79
15 1.01 0.05 0.88 0.85
20 1.03 0.03 0.92 0.89
30 1.04 0.02 0.95 0.93
40 1.04 0.02 0.96 0.94
*Comparison of K1 derived with 1T1k+VB for various scan durations to Ki derived with 2T3k+VB from full 40-min 
dynamic scan.
It is therefore conceivable that Ki can be substituted by K1 produced by the 1T1k+VB 
model without loss of accuracy. Therefore, in the validation analysis presented in this 
article, K1 produced by full kinetic modeling with 1T1k+VB for the 40-min dynamic 
PET scan will be used as reference. One patient was excluded because this patient’s 
estimated K1 values were outside the expected physiologic range (see the “Discussion” 
section). For the sake of completeness, the supplemental data 3 show the results for 
2T3k+VB.
Alternatives to arterial blood sampling.  IDIFs overestimate whole-blood activity 
concentrations at later time points, compared to BSIF (as illustrated in Figure 2), most 
markedly when derived from VOI located near high [18F]FCH uptake structures, such 
as the liver (Figure 2B) or kidneys. Figure 4 shows nonlinear regression analysis results 
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using IDIF derived from VOIs in blood structures located away from the liver or kidneys 
only, compared with those using BSIFs. 
Figure 4. K1 obtained using 1T1k+VB with (A) calibrated and (B) noncalibrated IDIF derived compared with BSIF 
method. Symbols indicate IDIF origin: triangle aortic arch, square descending aorta, plus femoral artery.
To minimize calibration errors due to possible overestimation at late time points, 
calibration of IDIF was performed at approximately 500-1,500 s after injection. For one 
patient, imaged over the abdominal region, no suitable IDIF could be found because 
marked overestimation of blood activity concentrations was observed all along 
the descending aorta. Good correlation was found for calibrated IDIFs (calibration 
factor 0.82 ± 0.13), although a bias was observed (R2 = 0.83, slope = 1.19; ICC = 0.74). 
Figure 4B shows results for noncalibrated IDIFs (R2 = 0.72; ICC = 0.80). Input function 
correction based on venous blood samples was not equivalent to correction based on 
arterial blood samples. Although good correspondence was found for whole-blood 
activity concentrations at late time points, and for plasma-to-blood ratios (ICC = 0.89; 
supplemental data 4), parent fraction measures were significantly different (ICC = 0.61; 
Figure 5). 
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Figure 5. Manual blood sample data as function of time: (A) mean parent fractions (triangle arterial, square 
venous) and (B) ratio of venous to arterial parent fractions. Error bars represent ± SD.
Simplified methods. Correlation between SUV (35-40 min after injection) en K1 was poor 
(Table 3; Figure 6A) with R2 < 0.34, irrespective of the normalization factor used. LMr 
(35-40min after injection; Figure 6B) and LBr (35-40 min p.i) performed somewhat 
better (R2 = 0.50 and R2 = 0.44, respectively).
Table 3. Comparison of simplified parameters to K1 resulting from full kinetic modeling with 1T1k+VB.
  Linear regression analysis
Simplified 
parameter
Slope Intercept R2
SUVBW 13.53 1.18 0.30
SUVBSA 315.39 27.53 0.33
SUVLBM 9.02 0.86 0.32
SUVBMI 4.65 0.20 0.34
SUVIBW 10.96 1.28 0.31
LMr 22.54 −0.36 0.50
LBr 30.38 0.32 0.44
SUVAUC,WB 5.88 −0.02 0.65
SUVAUC,PP 14.73 −0.20 0.92
SUVBW = SUV normalized to body weight; SUVBSA = SUV normalized to body surface area; SUVLBM = SUV 
normalized to lean body mass; SUVBMI = SUV normalized to body mass index; SUVIBW = SUV normalized to ideal 
body weight; LMr=lesion to muscle ratio; LBr=lesion to blood ratio; SUVAUC,WB=SUV whole-blood area under the 
curve; SUVAUC,PP=SUV parent plasma area under the curve.
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In contrast, SUVAUC,PP, calculated by dividing lesion activity concentrations (35-40 min 
after injection) by cumulative delivery, that is,  the area under curve (AUC) of the parent 
plasma input function (0-40 min after injection), provided an excellent correlation 
to K1 (R
2 = 0.92). This correlation reduced to R2 of 0.65 when using whole-blood AUC 
rather than parent plasma AUC (SUVAUC,WB). SUVAUC calculated from lesion activity 
concentrations at 30-40 min after injection and AUC over 0-30 min after injection 
resulted in similar correlations: an R2 of 0.91 for SUVAUC,PP (Figure 6C) and 0.64 for 
SUVAUC,WB (Figure 6D), respectively. Good correspondence was found between SUVAUC 
derived from BSIF and SUVAUC derived from IDIF (calibrated: R
2 = 0.98; ICC = 0.93; non-
calibrated: R2 = 0.86; ICC = 0.91).
Figure 6. Correlation between simplified uptake measures and K1 (1T1k1VB). (A) SUV normalized to body weight 
(SUVBW), (B) LMr and lesion activity concentration in kBq at 30–40 min after injection divided by AUC of parent 
plasma (C), and whole-blood activity concentration (D) in MBq over 0–30 min (SUVAUC,PP and SUVAUC,WB, 
respectively).
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DISCUSSION
This study focused on pharmacokinetic analysis of [18F]FCH in PC metastases and 
investigated the validity of strategies to simplify acquisition and analysis, to enable 
quantification of [18F]FCH uptake in a routine clinical setting.
On the basis of AIC alone, [18F]FCH kinetics in PC lymph node metastases could best be 
described using a 2T3k+VB model. However, the fitting procedure proved nonrobust, 
particularly for shorter scan durations (as shown in Table 1). We hypothesize that this 
is caused by the rapid uptake in combination with limited efflux to the blood pool (k2). 
This renders the model unable to accurately distinguish K1 and k3, which also explains 
why 1T1k+VB yielded similar results (R
2 = 0.96; ICC = 0.94). This also explains why 
1T1k+VB yielded similar results (R
2=0.96; ICC=0.94). This indicates that, even though 
AIC selected 2T3k+VB, 1T1k+VB can be used without loss of quantification accuracy. 
Moreover, 1T1k+VB results were more robust and consistent for shorter scan durations, 
indicating this to be the most suitable model.
An additional issue arising from the fast kinetics observed for [18F]FCH is inability of 
either model to accurately distinguish between the first tissue compartment (influx K1 
and efflux k2) and signal originating from blood volume in the VOI. High VB areas were 
therefore excluded.
One patient was excluded as K1 estimates were found to be unrealistically high (K1>1) 
using either irreversible model. We hypothesize this may be the result of high lesion 
blood volume fraction; despite our efforts to exclude large blood volume structures, 
as described previously, VB estimates were 0.49 ± 0.05. As rapid lesion uptake occurs, 
delayed arrival of blood activity concentrations in blood pool structures may have 
rendered them visually indistinguishable from lesion tissue. Another explanation may 
be markedly different kinetics in this patient, leading to inaccurate estimates caused 
by using the wrong model. We were unable to verify or reject either hypothesis based 
on the available data. Interestingly, all lesions were located within the mediastinum. In 
the rest of the study population, 3 out of 4 mediastinal lesions also showed increased 
VB estimates (0.23 ± 0.11 compared to 0.08 ± 0.05 for all other lesions studied). Also 
of interest is that this particular patient had received an experimental type of therapy 
(dendritic cell therapy; up to 1 month prior to the PET/CT scan). Because many patients 
eligible for [18F]FCH PET will receive some form of therapy, the possible influence of 
drugs on [18F]FCH kinetics should be investigated. For example, it has been suggested 
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that androgen deprivation therapy (ADT), a pharmaceutical used to maintain the 
biochemical castration level in recurrent PC, causes decreased choline uptake in 
hormone-sensitive PC in various studies [24]. In the present study, one patient was on 
ADT during the scan. Nevertheless, results were consistent with the rest of the study 
population, indicating negligible influence on [18F]FCH uptake for this patient.
Having determined the kinetic model and relevant quantification parameter, the 
possibilities for simplifying the acquisition protocol and analysis methods were 
investigated, i.e. alternatives for deriving plasma input functions as well as the validity 
of using simplified methods for quantification.
For several blood VOI locations, overestimation of blood activity concentrations was 
observed (for this reason 1 patient could not be analyzed with IDIF). We hypothesize 
that the apparent increase in image-derived blood activity concentrations near high 
[18F]FCH  uptake structures is caused by incorrect scatter correction in these areas, 
possibly leading to large quantification errors with IDIFs derived from blood VOIs in 
these areas. For other blood VOI, however, good correspondence was found for results 
with IDIF and BSIF (R2 = 0.83 and ICC = 0.74 for calibrated IDIF). The observed 19% bias 
was mainly caused by results for IDIF originating from small (femoral) arteries (Figure 
4), indicating that these may not be suitable for deriving IDIF. In summary, IDIF derived 
from large blood pool structures located away from high-uptake structures, such as the 
aortic arch, can substitute continuous arterial blood sampling. Unfortunately, manual 
arterial blood samples and specialized lab analysis remain necessary as parent fractions 
are greatly reduced shortly after injection and variability between patients is high (12 ± 
4% at 20 min after injection; Figure 5). Parent fractions measured from venous blood 
showed low correspondence to those obtained from arterial blood samples. 
High metabolite formation rates may also complicate quantification when radiolabeled 
metabolites enter tissue. Main metabolite is betaine, an organic osmolyte [10]. Because 
the presence of 18F-betaine will not be specific to lesions and LMr as high as 7.84 ± 3.15 
were observed (Figure 6B), it is unlikely that radiolabeled betaine significantly affected 
observed lesion activity concentrations.
A major simplification of the imaging protocol would be to use simplified methods 
instead of full kinetic modeling. Simplified methods, such as SUV, however, do not take 
into account possible influences on quantification by, for example, VB and metabolite 
35314 Oprea.indd   76 03-12-15   16:47
Quantification of [18F]FCH
77
4
formation. Therefore, results obtained using simplified methods were compared 
to those obtained with full kinetic modeling. Commonly used simplified methods 
showed poor correlation to results from full kinetic modeling (SUV, R2 < 0.34; LMr, 
R2 = 0.50; LBr, R2  = 0.44). We hypothesize that as [18F]FCH kinetics is very rapid and 
irreversible, even late-time lesion activity concentrations will depend heavily on the 
AUC of the plasma input function, a characteristic not accounted for in commonly used 
simplified methods. SUVAUC performs better because it incorporates information from 
the input function itself (R2 = 0.92 for SUVAUC,PP and R
2 = 0.65 for SUVAUC,WB).
In a routine clinical setting, static imaging would be preferable. Whole-blood AUC 
can be image-derived directly from a static PET image acquired over 0-40 min after 
injection (R2 = 0.98), from a VOI within the aortic arch defined using the lowdose 
CT. However, simultaneous imaging of both the lesions and the aortic arch will be 
impossible in the majority of patients, as the typical metastatic pattern of PC usually 
involves the pelvic or abdominal region. Therefore, SUVAUC was also validated when 
obtained from two consecutive time intervals: AUC over 0-30 min after injection and 
lesion activity concentrations averaged over 30-40 min after injection (R2 = 0.91 for 
metabolite-corrected plasma data, and 0.64 for whole-blood data). As lesion activity 
concentrations appear stable from 10 min onward, the latter can also be obtained with 
a whole-body PET scan. To obtain SUVAUC,PP arterial blood sampling and analysis would 
be required. It should also be noted that with the proposed static imaging protocol, 
VOIs cannot be adjusted to exclude high-VB areas because for this purpose an early 
PET image over the lesion is required. Apart from aforementioned modeling issues, 
high VB causes underestimation in simplified parameters. We therefore recommend 
caution when evaluating lesions near arterial structures until the clinical impact of 
these potential errors has been fully investigated.
Characteristics such as metabolism, perfusion and blood volume fraction are likely 
to change over the course of therapy. Therefore, the performance of the parameters 
presented in this paper should be verified in test-retest and longitudinal trials, 
before they can be validated or disqualified for application in a clinical (response 
monitoring) setting. Should [18F]FCH metabolism remain constant throughout the 
response monitoring study, performance of SUVAUC,WB and to a lesser extent SUV may 
be equivalent to SUVAUC,PP as a relative measure of response. Challapalli et al. recently 
reported on a novel 18F-labeled choline tracer that metabolizes less rapidly than [18F]
FCH, with parent fractions gradually decreasing to approximately 0.3 over the first hour 
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after injection [25–26]. With decreased inter-patient variability in parent fractions, 
performance of SUV and SUVAUC,WB may improve with respect to SUVAUC,PP.
CONCLUSION
 18F-fluoromethylcholine uptake should be quantified using full kinetic modeling 
with 1T1k+VB and metabolite-corrected plasma input function based on arterial blood 
sampling. Results indicate that SUV cannot be used to estimate [18F]FCH uptake. A 
clinically feasible alternative could be SUVAUC,WB based on two consecutive static PET 
scans. Further studies are needed to substantiate these findings.
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SUPPLEMENTAL DATA 1
[18F]fluoromethylcholine synthesis
Cyclotron produced 18F-fluoride (30-40 GBq) was reacted with dibromomethane and 
the obtained 18F-fluorobromomethane was purified over 4 in-line connected Waters 
Sep-Pak silica plus long cartridges (Waters, Etten-Leur, The Netherlands) [1] and 
passed over two Waters tC18 Sep-pak plus cartridges connected in-line (pretreated 
with 10 mL of 96% ethanol and subsequently 10 mL of water for injection), containing 
the precursor 2-(dimethylamino)ethanol. Alkylation of the precursor on the Sep-pak 
was done at room temperature. After completion of the reaction, the product was 
rinsed of the tC18 Sep-pak cartridges and passed over a Waters Accell plus CM Sep-
pak cartridge (pretreated with 8 mL of 1M HCl) to trap the precursor. The ethanolic 
solution of [18F]fluorocholine was diluted with a solution of 0.9% NaCl (Fresenius Kabi) 
to a ethanol concentration of less than 2% and passed over sterile 0.22 μm Millex-GV 
filter (Millex, Barendrecht, the Netherlands) yielding 2-5 GBq 18F-fluorocholine (6-16% 
uncorrected yield) as a sterile, isotonic and pyrogen free solution. The radiochemical 
purity was > 99% and no chemical impurities were detected as assessed by analytical 
radio/ultraviolet-HPLC (UV-HPLC). Residual concentrations of dibromomethane 
and 2-(dimethylamino)ethanol were determined by flame ionization detector – gas 
chromatography and were below 25 and 400 ppm respectively.
Reference
1. Iwata R, Pascali C, Bogni A, Furumoto S, Terasaki K, Yanai K. [18F]fluoromethyl triflate, a novel and reactive 
[18F]fluoromethylating agent: preparation and application to the on-column preparation of [18F]
fluorocholine. Appl Radiat Isot. 2002;57(3):347-352
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SUPPLEMENTAL DATA 2 
Compartment models and relevant associated quantification parameters
Supplemental Figure 1s 
Schematic representation of standard single and two tissue compartment models and 
associated quantification parameters. From top to bottom: single tissue irreversible 
model, single tissue reversible model, two tissue irreversible model and two tissue 
reversible model. CP = activity concentration in plasma; CT1 + CT2 = activity concentration 
in tissue; VT = volume of distribution; Ki = net influx rate; BP = binding potential; Dashed 
line indicates compartments (or parts of compartments) a PET VOI can contain. Please 
note that the distinction between tissue compartments denotes a difference in kinetics 
and is not per se associated with a spatial separation. The region where the dashed line 
intersects the blood compartment represents the blood volume fraction (VB).
VT = K1/k2(1+BP)
BP = k3/k4
Ki = K1k3/(k2+k3)
VT = K1/k2
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SUPPLEMENTAL DATA 3  
SUV validation results for 2T3k+VB
Data for the patient excluded from the validation analysis presented in the paper is 
indicated using stars. As the 2T3k+VB model has more parameters available than 
1T1k+VB, it is better equipped to deal with the more complex TAC. Although resulting 
35314 Oprea.indd   82 03-12-15   16:47
Quantification of [18F]FCH
83
4
estimates of individual parameters for this patient remain unrealistic, over- and 
underestimations in individual parameters could cancel out in calculating Ki. Although 
the magnitude correlation coefficients are naturally different, the conclusions about 
the relative performance of the simplified quantification parameters are conserved, i.e. 
SUVAUC,PP performs best, followed by SUVAUC,WB, then LMr and SUVBW.
Supplemental Figure 2s.
Correlation between simplified uptake measures and Ki derived from irreversible two 
tissue compartment model. (A) standard uptake value normalized to body weight 
(SUVBW), (B) lesion-to- muscle ratio (LMr) (C) lesion activity concentration in kBq at 30-
40 min p.i. divided by AUC of parent plasma activity concentration in MBq over 0-30 
min (SUVAUC,PP) and (D) lesion activity concentration in kBq at 30-40 min p.i. divided 
by AUC of whole blood activity concentration in MBq over 0-30 min (SUVAUC,WB). 3 
data points were excluded for unreliable fits (SE > 500% in one of the estimated rate 
constants). Fits for one patient (indicated by star) were suspected to be unreliable. 
Thick regression line (top equation) excludes this patient’s data. Thin regression line 
includes this data.
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SUPPLEMENTAL DATA 4  
Manual blood sample data
Supplemental Figure 3s. 
Manual blood sample data as function of time: (A) ratio of venous to arterial whole-
blood activity concentrations (WB) and (B) ratio of venous to arterial plasma-to-blood 
ratios (PLBL). Error bars represent ± SD.
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ABSTRACT
PURPOSE
Repeatable quantification is essential when using [18F]fluoromethylcholine ([18F]FCH) 
PET/CT for monitoring treatment response in prostate cancer (PC). It has been shown 
that SUV normalized to the area under the curve of the blood activity concentration 
(SUVAUC) provides better correlation with full kinetic analysis than standard SUV. 
However, precision of SUVAUC is not known yet. The purpose of this study was to assess 
repeatability of various semi-quantitative [18F]FCH parameters in PC.
METHODS
Twelve patients (64±8 years) with metastasized PC underwent 2 sets of [18F]FCH PET/CT 
scans, on consecutive days. Each set consisted of a 30 minutes dynamic PET/CT scan of the 
chest, after intravenous administration of 200 MBq [18F]FCH, followed by a whole body 
(WB) PET/CT at 40 minutes. The dynamic scan was used to derive AUC of the blood activity 
concentration. Lesion uptake was derived from the WB scan using various types of volumes 
of interest (VOIs): maximum, peak and mean. Each of these parameters was normalized 
to injected activity/weight, blood AUC and blood concentration itself at 40 minutes, 
resulting in several SUV, SUVAUC and SUVTBR values. Test-retest repeatability of these metrics, 
metabolic tumor volume (MTV) and total lesion choline uptake (TLCU), respectively, were 
studied. The level of agreement between test-retest data and reliability was assessed using 
Bland-Altman plots, repeatability coefficients (RC) and intraclass correlation coefficients.
RESULTS
A total of 67 choline avid metastases were identified, 44 bone and 23 lymph node 
lesions. In case of SUVmax, RC for SUV, SUVAUC and SUVTBR were 26% (ICC=0.95), 
31% (ICC=0.95) and 46% (ICC=0.89), respectively. Similar values were obtained for 
SUVpeak and SUVmean. Repeatability of SUVAUC was comparable with that of SUV, for 
maximum, peak and mean values. Tissue type and tumor localization did not affect 
repeatability. MTV <4.2 cm3 had larger variability than larger volumes (RC 45% versus 
29%, p=0.048). Repeatability did not differ between lesions with SUVpeak above or 
below the median value of 8.3 (RC 19% versus 28%, p=0.264).
CONCLUSION
The repeatability of SUVAUC was comparable to that of standard SUV. RC of various semi-
quantitative [18F]FCH parameters (SUV, MTV, TLCU)  were ~35%. Larger differences are 
likely to represent treatment effects.
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INTRODUCTION
Prostate cancer (PC) is the second most common cancer in men worldwide and was 
the third most diagnosed malignancy in Europe in 2012, with 92,000 death reported 
[1, 2]. This androgen-dependent neoplasm is characterized by a good initial response 
to (anti)hormonal therapy (HT) and an unpredictable latent castration-resistant 
(CR) status [3]. At the beginning of this decennium, molecular profiling studies have 
improved knowledge about the heterogeneous biological behavior of PC. It was found 
that even in the presence of a castrate range (<1.7 nmol/L) of testosterone in the blood 
of castration-resistant PC (CRPC) patients, a proportion of these tumors remains 
dependent on androgen-receptor signaling for growth [4]. Five potential mechanisms 
of development of CRPC were  described, based on ligand and androgen-receptor 
dependence [5].
Nowadays, a multitude of therapeutic options against CRPC is available, including 
either cytotoxic (docetaxel, cabazitaxel), hormonal (abiraterone, enzalutamide), 
immunotherapeutic (sipuleucel-T) and bone-targeting (Ra-223 dichloride) agents 
[6–13]. However, despite this variety of new agents with demonstrated significant 
improvement in life expectancy, proper sequencing (e.g., modality, timing) in 
individual patients with metastatic PC is unclear [14]. Since therapeutic options vary 
greatly with stage and grade of the disease, specific patterns of metastatic spread (i.e., 
hematogeneous and/or lymphatic) and dominant phenotype, accurate diagnostic 
“instruments” for response evaluation are essential [15, 16].
Non-invasive, hybrid positron emission tomography/computed tomography (PET/
CT) has proven to be a valuable diagnostic tool by acquiring and combining metabolic 
and anatomic information in vivo [17]. Encouraging results have been reported on 
the usefulness of radiolabeled-choline PET/CT in PC [18, 19]. Apart from its main 
recognized application in restaging disease in case of biochemical relapse [20, 21], 
[18F]fluoromethylcholine ([18F]FCH) might also qualify as a biomarker of response to 
therapy. Since conceptually, choline uptake represents viable tumor cells, tracer uptake 
changes over time might serve as an improved read-out of treatment efficacy. 
In vitro experiments have shown promising results in the use of radiolabeled-choline 
to monitor anti-androgen treatment or chemotherapy [22, 23]. Recently, simplified 
quantitative methods for [18F]FCH have been developed and validated [24]. It has been 
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shown that standardized uptake value (SUV) normalized to the area under the curve 
(AUC) of the blood activity concentration (SUVAUC) provides better correlation with 
full kinetic analysis than standard SUV [24]. However, precision of SUVAUC, and also 
that of SUV itself, is as yet unknown. The purpose of this study was to prospectively 
assess repeatability of semi-quantitative [18F]FCH PET/CT parameters in PC, also 
including metabolic tumor volume (MTV) and total lesion choline uptake (TLCU). Such 
knowledge is essential for proper interpretation of signal changes of [18F]FCH over time, 
thus improving personalized therapy strategies for PC patients.
MATERIALS AND METHODS
Patients
Twelve patients with histologically proven PC (n=4 CRPC), with lymphatic and/or 
hematogeneous metastases, were included prospectively. Inclusion criteria were 
presence of at least 2 metastases (diameter ≥ 1.5cm) detected by recently (≤ 3 months 
prior to PET/CT) performed conventional imaging and ability to remain supine for 
60 minutes. Exclusion criteria were claustrophobia and coexistence of multiple 
malignancies. The study was approved by the Medical Ethics Review Committee of the 
VU University Medical Center. Prior to inclusion, each patient signed a written informed 
consent, after receiving verbal and written explanation.
Personal and demographic data regarding patient’s age, body weight, Gleason score 
and value of prostate-specific antigen (PSA; ng/ml) at the time of PET/CT, together with 
information on previous therapy were collected. Metastatic lesion characteristics such 
as location (intrathoracically/intra-abdominal or in the pelvic region), number and 
type (bone/ lymph nodes) were also registered. Values are presented as mean±SD.
Data aquisitions 
All patients underwent repeated [18F]FCH (synthesis details see [24]) PET/CT scans at 
the same time on two consecutive days. Patients were not on therapy at the time of 
scanning. The minimal interval of time between last treatment and first PET/CT scan 
was 19 days. Patient preparation was similar to that required for [18F]-2-fluoro-2-deoxy-
D-glucose ([18F]FDG) [25]. Patients were scanned using a Gemini TF-64 PET/CT scanner 
(Philips Medical Systems, Cleveland, Ohio, USA).
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Each patient received a low dose CT (30 mAs, 120 kV), followed by a 30 minutes dynamic 
PET scan of the thoracic region (for details see [24]), which was centered over a large 
blood pool structure (e.g., aorta ascendens), to obtain an image derived input function. 
At the start of the dynamic [18F]FCH scan a bolus injection of 205±9 and 206±7 MBq [18F]
FCH (days 1 and 2, respectively) was administered intravenously using an automated 
injector (Medrad, Pittsburgh, USA) and which was flushed with 40mL of saline (5mL 
at 0.8mL·s-1 followed by 35mL at 2mL·s-1). The dynamic PET data were normalized 
and corrected for decay, scatter, random coincidences and photon attenuation, and 
reconstructed into 25 frames (1x10, 8x5, 5x20, 5x60, 3x150, 3x300 s) with a matrix size of 
144x144x45 voxels (4x4x4 mm3) using a 3-dimensional row action maximum likelihood 
reconstruction algorithm (3D-RAMLA).
After a standard (5 min) micturition break to warrant a proper visual assessment of the 
pelvic region, a whole body (WB) [18F]FCH scan (mid-thigh to skull base) was performed 
40 min post injection. Following this PET acquisition (10 bed positions; each of 2 min), 
a second low dose CT (50 mAs, 120 kV) was acquired for anatomical correlation and 
attenuation correction. WB data were corrected for dead time, decay, scatter and 
randoms, and reconstructed into 34 frames (1x10, 8x5, 4x10, 3x20, 5x30, 5x60, 4x150, 
4x300 s) with a matrix size of 144x144 and voxels of 4x4x4 mm3, using a time of flight 
iterative reconstruction method (BLOB-OS-TF). The transaxial spatial resolution was ~5 
mm full width at half maximum in the center of the field of view, similarly to that of 
the dynamic scan.
Data analysis
Reconstructed images were transferred to off-line workstations for further analysis. 
Data were analyzed on a volume of interest (VOI) basis [26]. The dynamic scan was 
used to derive the AUC of the blood activity concentration, by defining a cylindrical VOI 
with 1.5 cm diameter extending over 5 consecutive axial planes within the lumen of 
the ascending aorta. Next, lesion uptake (defined as [18F]FCH accumulation exceeding 
local background and incompatible with physiological [18F]FCH biodistribution) was 
derived from the WB scan.
The term MTV was used to indicate tumor volumes that were derived directly from 
the PET studies, quantified as the VOI size [26]. VOIs were defined by a semiautomatic 
delineation tool, applying a background adapted 50% of maximum isocontour 
(i.e., contour value equals 50% of maximum + background). For each of these VOIs, 
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maximum, peak and mean uptakes were calculated. In addition, each of these 
parameters was normalized to injected activity/body weight (SUV), AUC of blood 
activity concentration (SUVAUC), as derived from the dynamic scan,  and blood 
concentration at 40 minutes post injection (SUVTBR), as derived from the WB scan. 
For SUVmean associated parameters, also total lesion choline uptake (defined as 
SUVmean x MTV) was calculated, resulting in TLCU, TLCUAUC and TLCUTBR, respectively. 
Test-retest repeatability of all metrics was calculated using both standard repeatability 
coefficients (RC) (defined as 1.96 x SD of the difference between test-retest) and relative 
RC (test-retest difference in percentage).
Statistical analysis 
Data were analyzed using SPSS version 15.0. Test-retest repeatability was quantified 
using intraclass correlation coefficients (ICC; based on absolute agreement), RC and 
displayed graphically using Bland-Altman and/or box plots.  ICCs were calculated for 
each SUV measure as the ratio of between-lesion variability and total variability (both 
between-lesion and within-lesion). Variance components for patient, lesion within 
patient and (repeated) measurements within lesions were estimated using mixed 
models. Total variability was calculated as the sum of these three variance components. 
Between-lesion variability was calculated as the sum of the variance components for 
patient and lesion-within patient. Confidence intervals for ICCs were determined using 
the delta-method. Reliability coefficients were based on the relative difference:
 100%*(SUVtest – SUVretest)/[0.5*(SUVtest + SUVretest)] 
The method in Bland [27] was used to take into account correlation of measurements 
between different lesions within the same patient (intra-patient), when calculating 
RC.  Differences in repeatability of the different SUV measures (max, peak, mean) and 
methods of normalization (SUV, SUVAUC and SUVTBR) were assessed by comparing the 
variances of the relative test-retest differences, using the Pitman-Morgan test [28] for 
correlated variances. Differences in repeatability of SUV measures related to location, 
metastatic lesion type and size were assessed by comparing the variances of the 
relative test-retest differences between the subgroups of lesions, using Levene’s test 
[29]. Overall type I error, within each set of comparisons, was controlled at 5%, using a 
Bonferroni correction.
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RESULTS
Patients
Patient characteristics (Table 1) were: age 64±8 years, weight 88±9 kg, Gleason score 7 
(n=3) or more (n=9) and a median PSA at the time of PET/CT of 46 ng/ml (range 2-226). 
Patients had been treated previously by prostatectomy and lymph node dissection 
(n=3), HT (n=7), external beam radiotherapy (EBRT) on the prostate (n=1), EBRT in 
combination with HT (n=5), chemotherapy (n=4) or immunotherapy (n=1).
67 metastases were identified at PET, with a median of 6 per patient (range 3-8), 44 of 
which were bone and 23 lymph node metastases. Twelve metastases were localized 
above the diaphragm, the others were intra-abdominal and/or in the pelvic region 
(n=55). The malignant nature of the metastases was confirmed radiologically, based 
on progression of pre-existent lesions and/or new metastatic sites. VOI size [median/
interquartile range (IQR)] was 4.9/7.6 cm3 with a lesion SUVpeak (median/IQR) of 
8.3/5.2. 
Repeatability data was analyzed using a volume threshold of 4.2 cm3, based on a 
repeatability study of metabolic tumor volume with 18F-FDG and 18F-fluorothymidine 
(18F-FLT) in lung cancer [26]. In that study, changes of >37% for 18F-FDG in lesions 
larger than 4.2 cm3 were found to represent a biologic effect. This volume threshold 
corresponds by approximation to a diameter of 2 cm (for spherical metastatic lesions), 
which equals about 4 times the spatial resolution of PET below which quantification, 
VOI definition and detectability are hampered by partial-volume effects.
Repeatability of semi-quantitative [18F]FCH parameters
Repeatability of each semi-quantitative [18F]FCH parameters (i.e., SUV, MTV and TLCU) 
was studied as a function of uptake (median SUVpeak 8.3), MTV (larger or smaller than 
4.2 cm3), metastatic tissue type (bone/ lymph node) and location (intrathoracically 
versus abdominal/pelvic), respectively. These test-retest aspects are discussed below.
Repeatability of SUV
In case of SUVmax, RC (for relative differences) were 26%, 31% and 46%, respectively. 
Similar values were observed for SUVpeak and SUVmean. ICCs for SUV and SUVAUC were 
all approximately 0.95, whereas ICCs for SUVTBR were 0.89 (Table 2).
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Table 1. Patient characteristics.
      Gleason     Previous therapy 
Patient Age 
(yr)
Weight 
(kg)
≤6 7 >7 PSAtt 
(ng/ml)
HT CT EBRT RALP LND Immun
1 65 78 9 93 1 1
2 55 89 8 18 1 1 1
3 74 90 7 43 1 1 1
4 68 79 10 8 1 1
5 66 83 8 54 1 1 1
6 60 85 9 137 1 1 1
7 54 98 7 2 1 1
8 72 84 7 54 1 1
9 54 85 9 2 1
10 54 108 9 226 1 1 1
11 71 81 8 39 1 1
12 70 101 8 49 1
PSAtt prostate-specific antigen at the time of performing the PET/CT scans; HT (anti)hormone therapy; CT 
chemotherapy; EBRT external beam radiotherapy; RALP robot assisted laparoscopic prostatectomy; LND lymph 
node dissection; Immun immunotherapy.
Table 2. Test-retest differences, intraclass correlation coefficients and repeatability coefficients, for different types 
of SUVs (max, mean and peak) and their normalizations (SUV, SUVAUC and SUVTBR).
    TRT diff (mean±SD) ICC (95%CI) RC*
SUVmax SUV -0.38±1.45 0.95 (0.91-0.98) 26.1%
SUVAUC 0±0.88 0.95 (0.92-0.99) 30.9%
SUVTBR 1.0±3.9 0.89 (0.81-0.97) 46.2%
SUVpeak SUV -0.26±0.97 0.96 (0.94-0.98) 23.8%
SUVAUC 0.02±0.70 0.95 (0.93-0.98) 27.5%
SUVTBR 0.76±3.02 0.89 (0.83-0.95) 45.4%
SUVmean SUV -0.13±0.76 0.96 (0.94-0.99) 22.3%
SUVAUC 0.05±0.52 0.95 (0.92-0.98) 27.7%
  SUVTBR 0.68±2.3 0.89 (0.81-0.96) 42.4%
TRT diff  test-retest differences; ICC intra class coefficients; RC repeatability coefficients; * for relative 
differences according to Bland (2007) method. 
Nine pairwise comparisons for different methods of SUV normalization were 
performed to estimate variances of relative test-retest differences. After correcting 
for multiple comparisons (Bonferroni corrected significant difference at 5% level p 
<0.0056 and at 1% level p <0.0011, respectively), only SUVTBR parameters were found 
to have consistently larger variances (p <0.001) (Supplemental Table 1s). The relative 
differences (in percentage) between test-retest data and the mean values for the 
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different types of SUVs (max, mean and peak) and their normalizations (SUV, SUVAUC 
and SUVTBR) are presented in Figure 1. The repeatability of SUVAUC for max, peak and 
mean values were comparable with those of the corresponding SUV measures 
(Supplemental Table 2s).  
Figure 1. Relative differences between test-retest data and the mean values for the different types of SUVs (max, 
mean and peak) and their normalizations (SUV, SUVAUC and SUVTBR). Black dots represent outliers (more than 2 
SD). Bonferroni-corrected significance level p < 0.0056 (for significance level of 5%, denoted by *) and p < 0.0011 
(for significance level of 1%, denoted by **).
Repeatability did not differ between lesions with a SUVpeak above or below the median 
value of 8.3 (RC 19% versus 28%, p=0.264) (Fig. 2 and Supplemental Fig. 1s). These 
values were comparable with those of SUVpeakAUC [RC 23% (SUVpeak >8.3) versus 31% 
(SUVpeak <8.3), p=0.136]. Moreover, repeatability of SUVpeak and SUVmean was independent 
of MTV (Fig. 3) as well as of tissue type and tumor location (Supplemental Fig. 2s and 
Supplemental Table 3s).
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Figure 2. Bland-Altman plots for relative differences between test-retest data and mean values for SUVpeak.
Figure 3. Bland-Altman plots for the relative test-retest repeatability of SUVpeak (A) and SUVmean (B), as a function of 
metabolic tumor volume (MTV).
Repeatability of MTV
For MTV, test-retest difference was 0.03±1.63 and the relative test-retest difference 36% 
(Fig. 4). Repeatability of MTV was independent of SUVpeak [RC 34.25% (SUVpeak >8.3) 
versus 36.43% (SUVpeak <8.3), p=0.933]. MTV <4.2 cm
3 had larger variability than larger 
volumes (RC 45% versus 29%, p=0.048) (Supplemental Fig. 1s).  Repeatability of MTV 
did not differ between bone/lymph nodes (RC 34% versus 36.4%, p=0.684) and location 
[RC 36.7% (intrathoracically) versus RC 34.4% (intra-abdominal/pelvic), p=0.820].
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Figure 4. Relative differences between test-retest for metabolic tumor volume (MTV)  as a function of MTV.
Repeatability of TLCU
Repeatability of the TLCU and TLCUAUC were comparable (RC 33% versus 31%, p=0.954), 
while TLCUTBR showed larger variance of 51% (p <0.001) (Supplemental Fig. 3s). No 
significant difference was found between lesions with a total choline uptake below or 
above the median value of 30.9 [RC 40.9% (<30.9) versus 23.1% (>30.9), p=0.093].
Repeatability of TLCU was independent of uptake [RC 31% (SUVpeak <8.3) versus 34% 
(SUVpeak >8.3), p=0.139] and MTV [RC 42.1% (<4.2 cm
3) versus 25.3% (>4.2 cm3), p=0.037], 
respectively. Repeatability of TLCU was also independent of tissue type [RC 30.8% 
(bone) versus 35.7% (lymph nodes), p=0.241] and location [RC 35.5% (intrathoracically) 
versus RC 32.4% (intra-abdominal/pelvic), p=0.778].
An overview of all RC of the semi-quantitative [18F]FCH parameters (SUV, MTV and 
TLCU), as a function of uptake, MTV and metastatic tissue type/location, is presented in 
Supplemental table 4s (relative test-retest difference in percentage) and Supplemental 
table 5s (test-retest difference), respectively. Additionally, individual patient RC for all 
semi-quantitative parameters are provided in the supplemental figures 4s, 5s and 6s. 
Comparable RC across the majority of subjects were observed. Patient 1 had the poorest 
RC regarding SUV (~35% on all 9 combinations of SUV types and normalizations). 
Patients 2, 4 and 7 had the poorest RC regarding MTV (all ~51%) and TLCU (55%, 51% 
and 67%, respectively).
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DISCUSSION
In a previous study we investigated the [18F]FCH kinetics in metastatic PC [24], and 
demonstrated that SUV cannot be used to estimate [18F]FCH uptake. Whole-blood 
activity concentration SUV (SUVAUC), based on two consecutive PET scans was proposed 
as a clinically feasible alternative. In the present study, repeatability of quantitative [18F]
FCH PET/CT parameters in patients with PC was assessed prospectively. We found that 
repeatability of SUVAUC is comparable to that of standard SUV and that [
18F]FCH PET/CT 
uptake differences of 30% or more are likely to represent treatment effects.
Test-retest repeatability is essential for clinical implementation of any parameter 
of response assessment. Due to the heterogeneous biological behavior of PC [4] 
and in the light of rapidly evolving treatment modalities [14], there is a need for 
identification of biological markers that are able to monitor response to therapy in 
an adequate way. Standard treatment response evaluation criteria in solid tumors 
do not apply to metastatic PC, further complicating the issue of treatment response 
[30]. A newly proposed system for measuring functional response with [18F]FDG PET/
CT, PET Response Criteria In Solid Tumours (PERCIST), might potentially be applicable 
to radiolabeled choline as well [31]. Nevertheless, before [18F]FCH PET/CT can be 
implemented as a biomarker for response evaluation in PC, the repeatability of the 
tracer should be known [32].
To the best of our knowledge, repeatability of [18F]FCH measurements in metastatic 
PC has not been assessed previously. A single study of Pegard et al. [33] addressed 
the reproducibility of inter- and intra-observer interpretation (i.e., visual evaluation 
and classification of foci with increased uptake as being malignant or benign) of [18F]
FCH PET/CT examinations in patients suffering from biochemically recurrent PC. 
The authors describe a good concordance when evaluating bone metastases and 
abdominal/pelvic lymphatic recurrences in previously treated patients. A limited 
usefulness was found at the prostate level in untreated patients.
Observed repeatabilities were within the range seen with other commonly used 
radiotracers, such as [18F]FDG and [18F]fluorothymidine ([18F]FLT). When analyzing [18F]
FDG uptake changes, the generally accepted PERCIST response classification system 
assumes the presence of a biological change when SUVpeak changes exceed 30%, 
in combination with 0.8 unit change of the absolute SUVpeak value [31]. In a meta-
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analysis on the repeatability of [18F]FDG uptake measurements in tumors, de Langen 
et al. [34] identified 8 eligible studies. SUVmean was found to have better repeatability 
performance than SUVmax. A minimal relative change of 20% in combination with 1.2 
unit change of SUVmean was presumed to represent a biological change. Comparable 
results were reported by Rockall et al. [35] in a study on repeatability of quantitative 
[18F]FDG PET/CT in recurrent ovarian carcinoma. RC suggested that a decrease in [18F]
FDG uptake (SUV) up to 20% from baseline and a decrease in tumor size up to 15% 
could be used to determine (early) tumor response. In a study addressing repeatability 
and reproducibility of [18F]FDG and [18F]FLT PET tumor volume measurements, Hatt 
et al. [36] found comparable percentage differences for these two tracers datasets. 
Differences larger than 30% were considered indicative for treatment response 
evaluation.
Frings et al. [26] analyzed the repeatability of MTV with [18F]FDG and [18F]FLT in lung 
cancer. Repeatability was better for larger tumors. Changes of  >37% for [18F]FDG in 
lesions larger than 4.2 cm3 represented a biologic effect. We obtained comparable 
results when using this MTV threshold for analyzing [18F]FCH test-retest data. A larger 
variability was found in small metabolic volumes (<4.2 cm3), suggesting that a similar 
lower threshold for MTV in treatment response evaluation studies should be used. In 
case of TLCU, RC were not significantly different for lesions smaller or larger than 4.2 
cm3 (after correcting for multiple comparisons; Bonferroni corrected significance level 
p<0.0056). However, the uncorrected p equaled 0.037, suggesting a trend towards 
poorer repeatability for smaller lesions.
Two recently published papers explored the prognostic value of metabolic parameters 
when using [18F]FCH PET/CT in biochemical recurrent PC [37] or in CRPC [38]. In a 
multivariate analysis, Colombié et al. [37] identified age <70 years, SUVmean ≥3 and 
a standardized metabolic activity ≥23, as being independent prognostic factors for 
disease-free survival. In a prospective study, Kwee et al. [38] found that WB tumor 
indices based on quantifying net metabolically active tumor volume and total lesion 
activity [18F]FCH PET/CT were predictive of overall survival. In our study we used 
comparable metrics, with an emphasis on repeatability of the use of [18F]FCH as a 
potential biomarker for response evaluation in PC.
RC for the individual patients were comparable across the majority of subjects. However, 
patient 1 had the poorest RC regarding SUV, due to a small (1.5 cm short axis diameter) 
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bone metastasis located right paramedian in the anterior aspect of the corpus of the 
10th thoracic vertebra, in the vicinity of the liver. We hypothesize that the relative large 
test-retest difference (~35%) in this particular lesion was caused by incorrect scatter, 
due to an increase in image-derived blood activity concentrations near physiologically 
high avid [18F]FCH structures. This can possibly lead to large quantification errors with 
image derived input function obtained from blood VOI in these areas [24]. Three 
patients (2, 4 and 7) had larger RC for MTV and TLCU than the other subjects. This is 
likely explained by difficulty in lesion segmentation, such that errors in MTV are also 
propagated into poorer repeatability for TLCU. Besides, all these patients presented 
with small metastatic lesions (~1.5cm), with slightly increased [18F]FCH uptake on PET/
CT.
A mention has to be made with regard to the chosen 30% cut-off value for the semi-
quantitative SUV measures. As shown in Figure 2, the test-retest differences pooled 
over all lesions or those with SUV >8.3 are ~20%. However, for the lesions with a SUV 
<8.3, the calculated RC are ~30% (supplemental Table 4s). Since in clinical practice, the 
majority of patients will have a combination of metastatic lesions with SUV above or 
below 8.3, we have decided to adopt the more conservative value of 30%.  
A possible limitation of the present study is the limited number of subjects. The 
minimum required was calculated as a total of 12 patients (with minimal two 
measurements per patient). This sample size yields 80% power for testing the 
hypothesis: ICC ≤0.6 against the one-sided alternative (ICC >0.6) at a significance level 
of 5% when the true ICC is equal to 0.9 [39].  Moreover, this sample size of 12 patients 
resulted in confidence intervals for the limits of agreement ranging to approximately 
1.1 times the standard deviation of the difference scores, at either side of the estimated 
limit of agreement [27]. Thus, present study still provides a reasonable estimate of the 
expected RC.
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CONCLUSION
In patients with metastatic prostate cancer, repeatability of SUVAUC was comparable to 
that of standard SUV and indicated that [18F]FCH PET/CT uptake differences of 30% 
or more are likely to represent treatment effects. Repeatability of MTV and TLCU, 
respectively, was ~35%. Observed repeatabilities are of the same order of magnitude as 
those seen for other commonly used radiotracers, such as [18F]FDG and [18F]FLT.
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SUPPELMENTAL DATA 
Supplemental Figure 1s. Relative test-retest repeatability for mean metabolic volume (left) and SUVpeak (right), 
respectively. Black dots represent outliers (more than 2 SD).
 
Supplemental Figure 2s. Relative differences between test-retest data (SUVpeak) and the type and anatomical 
localization of the metastatic lesions. Black dots represent outliers (more than 2 SD).
LE
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Supplemental Figure 3s. Relative differences between test-retest data (SUVmean) and different types of normalized 
total lesion choline uptake (TLCU, TLCUAUC and TLCUTBR). Black dots represent outliers (more than 2 SD). * p-value 
significant at 5% level (p <0.0056) and ** p-value significant at 1% level (p <0.0011). 
Supplemental Figure 4s. Repeatability coefficients (RC; in percentage) for the individual patients, regarding the 
different types of standardized uptake value (SUVmax, SUVpeak and SUVmean) and their normalization (SUV, 
SUVAUC and SUVTBR).
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Supplemental Figure 5s. Repeatability coefficients (RC; in percentage) for the individual patients, regarding the 
metabolic tumor volume (MTV). Comparable RC across the majority of subjects were observed. However, for 3 
patients (2, 4 and 7) both MTV and total lesion choline uptake (TLCU) were larger than those of the other subjects. 
This is likely explained by difficulty in lesion segmentation, such that errors in MTV are also propagated into 
poorer repeatability for TLCU.
Supplemental Figure 6s. Repeatability coefficients (RC; in percentage) for the individual patients, regarding the 
total lesion choline uptake (TLCU) and corresponding normalizations (TLCU, TLCUAUC and TLCUTBR). Comparable 
RC across the majority of subjects were observed. However, for 3 patients (2, 4 and 7) both metabolic tumor 
volume (MTV) and TLCU were larger than those of the other subjects. This is likely explained by difficulty in lesion 
segmentation, such that errors in MTV are also propagated into poorer repeatability for TLCU.
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Supplemental Table 1s. Comparison of repeatability (variance of relative test-retest difference) for different 
methods of normalization.
  Comparison p-value
  Pitman-Morgan test
SUVmax SUV SUVAUC 0.036
SUV SUVTBR < 0.001 **
SUVAUC SUVTBR < 0.001 **
SUVpeak SUV SUVAUC 0.111
SUV SUVTBR < 0.001 **
SUVAUC SUVTBR < 0.001 **
SUVmean SUV SUVAUC 0.016
SUV SUVTBR < 0.001 **
SUVAUC SUVTBR   0.001 *
p-values for pairwise comparisons of variances of (selected combinations of) measures. * Significant at 5% level 
(Bonferroni-correction for 9 tests: p <0.0056). ** Significant at 1% level (Bonferroni-correction for 9 tests: p 
<0.0011).
Supplemental Table 2s. Comparison of repeatability (variance of relative test-retest differences) between 
SUVmax, SUVpeak and SUVmean using the Pitman-Morgan test.
  Comparison p-value
  Pitman-Morgan test
SUV SUVmax SUVpeak 0.356
SUVmax SUVmean 0.037
SUVpeak SUVmean 0.455
SUVAUC SUVmax SUVpeak 0.184
SUVmax SUVmean 0.081
SUVpeak SUVmean 0.955
SUVTBR SUVmax SUVpeak 0.732
SUVmax SUVmean 0.075
SUVpeak SUVmean 0.219
p-values for pairwise comparisons of variances of (selected combinations of) measures. Bonferroni correction for 
9 tests performed by setting significance levels at 5% (0.05/9 = 0.0056) and at 1% (0.01/9 = 0.0011).
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Supplemental Table 3s. Comparison of variance of relative test-retest differences between groups using the 
Levene’s test (LevT).
    Type: (bone vs. lymph 
node)
Location: (intrathoracically 
vs. abdominal/pelvic)
Size: below median vs. 
median and above1
p-value Lev test p-value Lev test p-value Lev test
SUVmax SUV 0.754 0.944 0.092
SUVAUC 0.247 0.204    0.003 *
SUVTBR 0.082 0.793 0.076
SUVpeak SUV 0.655 0.808 0.264
SUVAUC 0.744 0.805 0.075
SUVTBR 0.226 0.354 0.459
SUVmean SUV 0.718 0.725 0.556
SUVAUC 0.341 0.768 0.046
SUVTBR 0.257 0.541 0.537
1median of the mean of the test and retest measurement; Lev Levene’s test; * Significant at 5% level (Bonferroni-
correction  for 9 tests: p <0.0056)
Supplemental Table 4s. Relative test-retest difference (in percentage) of the semi-quantitative parameters as a 
function of uptake, metabolic tumor volume, metastatic tissue type and location.
RC (%) SUVpeak SUVpeakAUC SUVpeakTBR MTV TLCU TLCUAUC TLCUTBR
All 24 28 45 36 33 31 51
SUVpeak >8.3 19 23 41 34 34 30 50
SUVpeak <8.3 28 31 47 36 31 32 51
MTV >4.2 cm3 23 28 45 29 25 24 41
MTV <4.2 cm3 25 24 44 45 42 40 62
Bone 24 27 47 34 31 30 52
Lymph node 23 28 36 36 36 32 48
Intrathoracically 17 23 39 37 36 40 48
Abdominal/pelvic 24 27 45 34 32 29 51
RC repeatability coefficients; SUV standardized uptake value; AUC area under the curve of blood activity 
concentration; TBR blood concentration 40 minuten after injection; MTV metabolic tumor volume; TLCU total 
lesion choline uptake.
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Supplemental Table 5s. Test-retest difference of the semi-quantitative parameters as a function of uptake, 
metabolic tumor volume, metastatic tissue type and location.
RC (test-retest) SUVpeak SUVpeakAUC SUVpeakTBR MTV TLCU TLCUAUC TLCUTBR
All 1.9 1.4 5.9 3.2 21 11 52
SUVpeak >8.3 2.3 1.7 7.5 3.9 28 13 61
SUVpeak <8.3 1.4 1.0 3.7 2.3 10 8.4 42
MTV >4.2 cm3 2.0 1.6 6.9 3.9 27 14 62
MTV <4.2 cm3 1.8 0.9 2.0 1.3 4.8 2.7 12
Bone 1.6 1.1 5.3 2.8 17 10 57
Lymph node 2.5 1.8 6.6 3.5 25 10 40
Intrathoracically 1.3 0.8 4.8 2.7 16 8.7 27
Abdominal/pelvic 2.0 1.5 6.1 3.3 23 11 51
RC repeatability coefficients; SUV standardized uptake value; AUC area under the curve of blood activity 
concentration; TBR blood concentration 40 minuten after injection; MTV metabolic tumor volume; TLCU total 
lesion choline uptake.
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ABSTRACT
PURPOSE
The purpose of the study was to compare image quality and quantitative accuracy 
of positron emission tomography/ magnetic resonance imaging (PET/MRI) and PET/ 
computed tomography (PET/CT) systems with time of flight PET gantries, using 
phantom and clinical studies.
METHODS
Identical phantom experiments were performed on both systems. Calibration, 
uniformity, and standardized uptake value (SUV) recovery were measured. A clinical 
PET/CT versus PET/MRI comparison was performed using [18F]fluoromethylcholine 
([18F]FCH). 
RESULTS
Calibration accuracy and image uniformity were comparable between systems. SUV 
recovery met EANM/EARL requirements on both scanners. 
Thirty-four lesions with comparable PET image quality were identified. Lesional 
SUVmax differences of 4±26% between PET/MRI and PET/CT data were observed 
(R2=0.79, slope=1.02). In healthy tissues, PET/MRI-derived SUVs were 16±11% lower 
than on PET/CT (R2=0.98, slope=0.86). 
CONCLUSION
PET/MRI and PET/CT showed comparable performance with respect to calibration 
accuracy, image uniformity, and SUV recovery. [18F]FCH uptake values for both healthy 
tissues and lesions corresponded reasonably well between MR- and CT-based systems, 
but only in regions free of MR-based attenuation artifacts.
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INTRODUCTION
Multimodality imaging has improved patient care over the past decade. Non-invasive, 
integrated positron emission tomography/ computed tomography (PET/CT) has 
proven to be a valuable diagnostic tool by combining in vivo metabolic and anatomic 
information [1]. Recently, several hybrid PET/ magnetic resonance imaging (PET/MRI) 
systems have become available clinically [2]. Strengths of MRI include its high soft tissue 
contrast, high spatial resolution, and lack of exposure to ionizing radiation. General 
Electric (GE) has built a tri-modality PET/CT and MRI system (tri-modality, Discovery 
PET/CT 690 & 3T Discovery MRI 750) [3]. Using silicon photomultiplier tubes (SiPMTs), 
GE also has developed a fully integrated PET/MRI system that has time of flight (TF) 
capabilities. However, this system still is a prototype and no (clinical) studies have 
been reported yet. Siemens has a fully integrated PET/MRI (Biograph mMR, Siemens 
Healthcare), which allows simultaneous PET and MRI acquisitions [4], enabling a 
reduction of total scan time. Philips has built a sequential PET and MRI system (Philips 
Ingenuity TF PET/MRI), with TF ability [5]. 
Although PET/CT was rapidly incorporated into routine clinical practice, PET/MRI faces 
a number of technical challenges. MRI requires well-controlled magnetic and radio 
frequency (RF) fields [5]. However, PET photomultiplier tubes (PMTs), which are needed 
to convert and amplify the signal from scintillation crystals into an electronic signal [6], 
do not function properly in a strong magnetic field. Solutions to this have included 
physically separating PET and MRI units [6] or using avalanche photodiodes (APDs), 
which in contrast to PMTs are not affected by the magnetic field [7]. APDs, however, 
have poorer timing resolution than PMTs and consequently they have no TF capability 
[8]. Recently, silicon PMTs (SiPMTs) have been described as a possible alternative to 
conventional PMTs, combining good energy and timing resolution with the ability to 
decode arrays of scintillator elements [9]. 
The second main challenge for PET/MRI is deriving accurate MR-based attenuation 
correction (MRAC) maps to correct corresponding PET data for tissue attenuation. 
Simultaneous Siemens PET/MRI systems use a four-tissue segmentation model, 
dividing a dedicated MR sequence in fat, air, lung, and soft tissue. Philips sequential 
PET/MRI systems employ a two- (air and soft tissue) or three-segmentation model (air, 
lung, and soft tissue). However, a limitation of all these approaches is that bone, the 
most attenuating tissue in the body, is not included in the segmentation process [10]. 
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This yields underestimation of the standardized uptake values (SUVs) in bone lesions 
or lesions localized closed to bone structures. Furthermore, MRAC assumes uniform 
attenuation coefficients in lungs and suffers from MRI truncation due to the relatively 
small transaxial field of view (FOV; 45–50 cm) of the PET/MRI systems. All these 
shortcomings result in quantitative biases in the reconstructed PET images. Therefore, 
MRAC still requires major efforts to make PET/MRI studies accurate and robust [11]. 
PET/CT is used extensively in oncology for diagnosis, initial staging, restaging, therapy 
planning, and response monitoring of a variety of malignancies [12, 13]. Although 
PET/MRI is expected to be able to fulfill the same roles as PET/CT, this needs to be 
confirmed. There are promising initial results for several tumor types, including those 
seen in brain, head/neck, gynecological, and prostate [14–17]. However, just as for 
PET/CT, accurate SUV quantification [18] and, therefore, also accurate attenuation are 
required. With this in mind, it is important to know whether SUVs on PET/CT and PET/
MRI are comparable. 
The phantom and prospective clinical study presented here is distinct from other 
published work [19–20] with respect to two aspects. First of all, it represents a particular 
comparison of image quality and quantitative performance of PET studies using PET/
CT and PET/MR systems from the same vendor with similar hardware and software for 
the PET TF gantries. Secondly, we performed PET/CT and PET/MRI studies in prostate 
cancer (PC) patients using [18F]fluoromethylcholine ([18F]FCH). Its known relatively 
stable biodistribution, with almost no radiotracer redistribution from about 10 to 90 
min post injection (p.i.) [21], enables good scan statistics. This particular setup, the use 
of [18F]FCH and the two TF imaging systems, is suitable for evaluating the impact of 
MRAC on PET image quality and quantification.
MATERIALS AND METHODS
Scanners
The study was performed using a Gemini TF-64 PET/CT system (Philips Medical 
Systems, Best, the Netherlands) [8] and a 3.0 Tesla Ingenuity TF PET/MRI system 
(Philips Medical Systems, Cleveland, Ohio, USA). Both scanners are based on similar 
PET hardware, with some minor modifications necessary to make it compatible with 
the MRI scanner (Achieva 3T X-series MRI) [5]. The PET software version on the PET/
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MRI is 9.7.1.0 and on the PET/CT is 9.5.1.4. Furthermore, on both scanners the same 
reconstruction algorithms are used, except that the attenuation correction maps 
(μ-maps) are different. For PET/CT, the μ-map is based on CT measurements of photon 
attenuation and uses a bilinear equation to convert to attenuation coefficients for 511-
keV photon energies. For PET/MRI system, it is based on acquisition of a dedicated MR 
sequence (atMR), which subsequently is segmented into two (air and soft tissue) or 
three (air, lung, and soft tissue) classes of tissue, depending on the acquisition protocol 
(i.e., only pelvic region or body) and the ability of the software to detect lung contours 
[22]. The axial FOV (18 cm, with 9-cm overlap between bed positions) is the same for 
both systems and both have a 5.5-mm reconstructed isotropic spatial resolution.
Phantom measurements
Multiple phantom experiments were performed to determine specific performance 
characteristics of the PET/CT and PET/MRI systems, i.e. count rate linearity, calibration, 
uniformity, image quality, and contrast recovery. Both systems allow acquisitions in 
two modes: one specifically designed for the brain (brain mode, 2-mm voxels) and 
one for the body (body mode, 4-mm voxels). On both scanners, measurements were 
repeated up to five times, during a period of 1 year, using various acquisition protocols. 
In addition, phantom data were reconstructed using different algorithms and settings. 
All reconstructions included the usual corrections, such as detector normalization, 
decay, dead time, attenuation, as well as random and scatter corrections. 
A cylindrical phantom (20-cm diameter, 9283 mL) filled with short-lived radionuclides 
(oxygen-15 and carbon-11) was used to assess count rate linearity over a wide range 
of radioactivity concentrations. The initial activity concentration was chosen to yield 
a single rate of 40 Mcps body dynamic acquisitions and 20 Mcps dynamic brain 
acquisitions. Data were reconstructed using a sinogram-based algorithm (3D-RAMLA) 
for the body mode and a non-sinogram-based algorithm (LOR-RAMLA) for the brain 
mode. Body mode images had a final voxel size of 4x4x4 mm3 and a spatial resolution 
of 5 –7-mm full width at half maximum (FWHM) [5]. Brain mode images had a final 
voxel size of 2x2x2 mm3 and with similar spatial resolution. The dynamic image data 
was analyzed by defining one global region of interest in the phantom and calculating 
the average activity as a function of time. The calibration offset with regard to the true 
activity in the phantom was plotted versus true activity. 
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PET calibration and uniformity were assessed using the same cylindrical phantom 
as mentioned above. To assess image quality and SUV contrast recovery, the NEMA-
NU2-2007 image quality (IQ) phantom (Data Spectrum Corporation, Durham, USA) 
was used. SUV contrast recovery was defined as the activity measured in the spheres 
relative to the true activity in the spheres (in %). Phantoms were filled with a 2-deoxy-
2-[18F]-fluoro-D-glucose ([18F]FDG) solution using activity ranges of 1.3–3.9 (cylinder), 
14.4–16.3 (spheres IQ), and 1.6-1.8 (background IQ) kBq·mL–1 at the scan start time. 
Samples were taken and measured in a gamma well counter (Wallac 1480 Wizard 3’’ 
automatic gamma counter, Perkin Elmer Life Sciences, Zaventem, Belgium) in order to 
accurately define the activity in the phantoms and to be able to assess the calibration 
offset of the two scanners. 
In the IQ phantom, the sphere to background radioactivity concentration ratio was set 
to ~10:1. Phantoms were scanned using the following acquisition protocols. First, using 
a single bed position, a 15-min acquisition was performed. Data were reconstructed 
using time of flight (blob-os-tf) [8] and sinogram-based (3D-RAMLA) algorithms, both 
resulting in a final voxel size of 4x4x4 mm3 and a spatial resolution of 5–7 mm FWHM. 
In clinical practice, blob-os-tf is used for static images and 3D-RAMLA for dynamic 
acquisitions. Second, a multi-bed position protocol, with 2 min per bed position, was 
performed. 
In addition, the cylindrical phantom was scanned at a single bed position for 15 min in 
(dynamic) brain mode and reconstructed using a line of response-based reconstruction 
algorithm (LOR-RAMLA). This resulted in a final voxel size of 2x2x2 mm3 and the same 
spatial resolution as mentioned above. For the cylindrical phantom, image data 
acquired with and without the use of MR coils were assessed by measuring global and 
local (volumes of interest (VOIs) ~8 mL) calibration offsets and by visual inspection 
for artifacts. Data acquired with the IQ phantom were assessed for SUV performance 
compliance with European Association of Nuclear Medicine/Research Ltd (EANM/
EARL) specifications [23].
Specific parameters and settings for phantom PET/MRI studies
The atMR sequence was used to generate μ-maps for the phantom studies. Specific 
attention to several points was required. Firstly, it is known that the signal from 
phantom walls is not detected by MRI. Therefore, attenuation by phantom walls is 
not corrected for, resulting in a constant underestimation of MRAC images (~5.5% 
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for 6-mm wall thickness). Secondly, for atMR acquisition on the MRI, phantoms were 
filled with a saline solution (~0.48%) in order to approximately match MR relaxation 
factors with those of patients. In addition, some MR processing parameters, such as 
inhomogeneity corrections, needed to be adjusted. Finally, dedicated MR sequences 
and image processing settings based on the two-class segmentation (water and air) 
were used in order to obtain appropriate μ-maps for the IQ phantom.
Patient studies
The clinical study was approved by the Medical Ethics Review Committee of the VU 
University Medical Center, Amsterdam, the Netherlands. All patients participating 
in the study provided written informed consent for undergoing additional PET/
MRI examinations, following PET/CT scans acquired for clinical purposes. Inclusion 
criteria comprised the following: (1) ability to remain supine for an additional 60 min 
in the PET/MRI scanner after undergoing the PET/CT examination and (2) clinical 
indication for performing an [18F]FCH PET/CT scan. Exclusion criteria were the standard 
absolute MRI contraindications (e.g. pacemaker, magnetic metal implants, neuro-
stimulator, etc.). Relative (MRI) contraindications were claustrophobia and present or 
prior employment as a metalworker. For the latter patients, an X-ray of the orbit was 
performed prior to the PET/MRI in order to exclude possible metal splinters. 
A total of 12 consecutive patients with histopathologically proven adenocarcinoma of 
the prostate were examined. Their mean age (±SD) was 66±8 years. In all patients, the 
clinical indication for performing the PET/CT scans was restaging. This means suspected 
residual or recurrent disease after previous therapy, due to biochemical prostate-
specific antigen (PSA) relapse. A PSA relapse was defined as a serum concentration 
level above 0.2 ng·mL–1 after radical prostatectomy (RP) and more than 2 ng·mL–1 above 
the nadir value in patients treated by means of external beam radiotherapy (EBRT) 
[24]. All examinations were performed at the VU University Medical Center between 
November 2012 and February 2014. 
Patient characteristics, including age, year of PC diagnosis, type of primary treatment, 
PSA nadir, and PSA at the time of PET/CT and PET/MRI scans, as well as number, 
location, and visually assessed nature of all choline-avid lesions, are listed in Table 1.
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PET/CT acquisition protocol
Patient preparation was similar to that required for [18F]FDG PET [22]. The standard 
activity of [18F]FCH was 4 MBq per kg body weight [21], resulting in an average (±SD) 
administered activity of 340±57 MBq [18F]FCH. All patients underwent the same [18F]FCH 
PET/CT image acquisition protocol, including a low-dose CT (LD-CT) for anatomical 
localization and attenuation correction (AC), using a beam current of 30–50 mA at 100 
keV. Thirty minutes p.i., a whole-body (WB) PET sequence was performed from mid-
thigh to the base of the skull with arms up. The acquisition time was 2 min per bed 
position with a standard number of nine bed positions. The total acquisition time for 
the WB PET/CT was, on average, 30 min.
PET/MRI acquisition protocol 
Subsequently to the PET/CT scans, PET/MRI acquisitions were obtained at 90±3 min 
p.i., without administering an additional activity of [18F]FCH. The protocol included a 
survey MRI for defining the scan trajectory, followed by an atMR sequence used for AC 
of the subsequent PET scan. Next, a WB PET scan was performed, on average consisting 
of eight bed positions, each with 3-min acquisition time. The acquisition time was 
increased with 50% compared with the PET/CT scan to compensate for radioactive 
decay. The WB PET sequence also extended from mid-thigh to the base of the skull. 
Due to the small MRI gantry of the scanner, for the patient’s convenience, all scans 
were acquired with arms down. Different diagnostic MRI protocols were applied as 
the MRI was done for initial MR optimization and to evaluate MR image quality and 
MR system performance and robustness. The following sequences were acquired: total 
body: coronal T1-weighted fast spin-echo (FSE), coronal short-tau inversion recovery 
(STIR), and axial Dixon sequences; prostatic region: T2-weighted turbo spin-echo (TSE) 
in axial, sagittal, or coronal planes and axial diffusion-weighted sequences. The total 
acquisition time for the WB PET/MRI protocol was, on average, 67 min.
Reconstruction of PET/CT and PET/MRI images
PET/CT and PET/MRI data were both reconstructed using the (same) vendor provided 
time of flight reconstruction algorithm (blob-os-tf), resulting in a final voxel size of 
4x4x4 mm3. 
Image analysis
PET/CT and PET/MR images were interpreted in consensus by four experienced readers 
(two radiologists and two nuclear medicine physicians) who were aware of the clinical 
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history of the patients. Visual analysis of the images was performed on a dedicated 
Philips workstation (Philips Fusion Viewer on Extended BrillianceTM Workspace), 
following the approach used in clinical practice: (1) the lesions were evaluated on a single 
modality (e.g. PET), (2) they were evaluated on PET/CT and PET/MRI independently, 
and (3) PET/CT and PET/MRI findings were compared.
Lesions were defined as choline-avid structures (diffuse or focal [18F]FCH uptake, 
exceeding background), incompatible with physiological uptake and with an 
anatomical substrate on MRI or CT. They were deemed benign or malignant based on 
the metastatic pattern of PC [25, 26]. Choline-avid lymph nodes in the mediastinal, hilar, 
or inguinal region were considered reactive/benign in the absence of a pathological 
lesion [27, 28]. [18F]FCH uptake in all lesions (e.g., prostate, lymph nodes, bone) and 
certain normal tissues (e.g. lung, liver, and spleen) was assessed semi-quantitatively, 
by means of SUVs. This semi-quantitative approach was chosen to evaluate differences 
in [18F]FCH uptake between the PET/CT and PET/MR scans and to eliminate observer 
variability. The method consisted of collecting different types of SUVs in target lesions 
or tissues, as a clinically preferred alternative to the gold standard full kinetic modeling 
[29]. Therefore, VOIs were drawn semi-automatically on PET images, as described 
previously [29, 30]. Maximum and 3D peak SUV, normalized to body weight (SUVmax 
and SUVpeak), were obtained for all lesions. In addition, mean SUV using a 2–3-cm 
diameter VOI was derived for healthy tissues, with one exception. In this patient, a 
VOI in normal lung could not been drawn due to an incomplete scan trajectory of the 
thorax. In all other 11 patients, VOIs were drawn in the left lung in order to avoid the 
effects of scatter effect from the physiologically intense choline uptake in the liver. 
Statistical analysis 
Pearson product moment correlation coefficients (R2) were used to test agreement 
between visual ratings, and mean and maximum SUVs derived from PET/MRI and PET/
CT. Correlations were assessed for bias using linear regression. In addition, percentage 
differences between PET/CT- and PET/MRI-derived SUVmax were plotted as function 
of the PET/CT derived SUVmax to illustrate relative differences in quantitative findings.
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RESULTS
Phantom studies
Count rate linearity in brain mode was comparable between the two scanners. 
Calibration offsets, ranging from 2 to 10 kBq·mL–-1, were less than 10%. However, the 
performance in body mode showed slight differences between the systems with a 
stable performance (calibration offsets less than 5%) for PET/CT, whereas for PET/MRI, 
the calibration offsets were less than 10% with activity concentration ranging from 2 to 
20 kBq·mL–1 (supplemental Figure 1s). The images of the cylindrical phantom scanned 
on both systems showed uniform uptake and no visual artifacts. 
Global calibration accuracy and image uniformity were comparable (within ±10%) 
between PET/MRI and PET/CT systems (Table 2). 
Table 2. Calibration offsets ranges (%) for PET/MRI and PET/CT systems for different reconstruction algorithms 
based on five measurements within 1 year. Calibration offset is defined as global activity of a cylindrical phantom 
in reconstructed PET images relative to the true activity measured using the dose calibrator.
Reconstruction PET/MRI PET/CT
Blob-os-tf −5.8 to −1.5 −4.3 to 2.0
3D-RAMLA −0.6 to 4.8 −6.9 to−0.4
LOR-RAMLA −-2.1 to 3.7 −6.5 to −0.3
PET/MRI studies with additional MRI coils required the use of additional template-
based AC for the coils (Figure 1). However, template-based AC did not fully compensate 
for true attenuation of the coils, resulting in image artifacts in the PET images near the 
denser part of the coils. For example, image non-uniformities measured in a uniform 
source were up to 15% when using the neurovascular coils.
The NEMA NU-2 2007 image quality phantom was measured several times on both 
systems The PET/CT met EANM/EARL requirements in all cases. Slightly higher contrast 
recoveries were found for the PET/MRI in comparison with the PET/CT (Figure 2) for 
smaller spheres (< 6 mL). Note that the AC by the phantom walls was not corrected 
because the signal from these walls (6 mm thick) is not detected by MRI. This resulted 
in a constant underestimation of the true recovery coefficients (5.5% lower activity 
concentration).
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Figure 1. Example of coil attenuation effects: (a) image of the MR head-sense 8 coil, (b) PET acquisition including 
the MR head-sense 8 coil, but without a template for its attenuation correction, and (c) PET acquisition including 
the MR head-sense 8 coil and with a template for attenuation correction.
a b c
Figure 2. Measured activity recoveries (%) derived from the IQ phantom for both PET/MRI and PET/CT together 
with EARL boundaries (solid lines). Volumes of interest (VOIs) were defined based on a single voxel with maximum 
intensity (VOImax) or as an isocontour at 50% of the maximum voxel intensity (VOIA50): (a) PET/MRI VOImax, (b) 
PET/CT VOImax, (c) PET/MRI VOIA50, (d) PET/CT VOIA50. Five experiments were performed during a period of 1 
year, each experiment indicated by a different symbol.
Patient results
A total of 12 benign and 22 suspected malignant lesions were identified on both PET/
MRI and PET/CT systems. Coexistence of benign and malignant lesions was observed 
in five patients. In three patients no cause for an elevated PSA could be identified. 
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Benign/reactive lymph nodes were found in seven patients and were localized in the 
mediastinum (n=2), the lung hilar region (n=3) and the inguinal zone (n=5). In one 
patient, two pre-sacral lymph nodes with slightly increased choline uptake were seen. 
The intensity of uptake was less than on a PET/CT scan performed previously, consistent 
with a response to radiotherapy. Suspected malignant lesions were identified in nine 
patients and were represented by lymph nodes (seven iliac, two para-aortic, two pre-
sacral), bone lesions (two thoracic vertebrae, one solitary acetabulum lesion, one 
rib, one sternal lesion) and residual/recurrent PC (four in the peripheral zone of the 
prostate and two in the seminal vesicles). Visual inspection showed comparable PET 
image quality for all lesions between both modalities (Figure 3). 
Figure 3. [18F]FCH PET/CT and PET/MRI scans of patient 3 with recurrent prostate cancer and a PSA of 17.4 ng·mL−1. 
Both scans show comparable PET image quality in a suspected bone metastasis in the seventh thoracic vertebra: 
(a) attenuation corrected PET image of the PET/CT, (b) non-attenuation corrected PET image of the PET/CT, (c) 
low-dose CT image, (d) fusion image of [18F]FCH PET/CT, (e) attenuation corrected PET image of the PET/MRI, (f) 
non-attenuation corrected PET image of the PET/MRI, (g) MR-derived attenuation image, (h) fusion image of [18F]
FCH PET/MRI.
a
fe
b c
g
d
h
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The semi-quantitative lesion analysis revealed a difference of 4±26% in SUV values 
between PET/MRI and PET/CT data (R2=0.79, slope=1.02) (Figure 4). 
Figure 4. Results of the semi-quantitative analysis for benign (blue) and malignant (red) choline-avid lesions: (a) 
correlation between PET/MRI- and PET/CT-derived SUVmax (R2=0.79, slope=1.02), and (b) corresponding Bland-
Altman plot showing large differences for two intra-thoracic lesions (green ovals: one para tracheal and one hilar 
lymph node), which were due to incorrect lung segmentation of the PET/MRI scan.
a b
In normal tissues, PET/MRI SUV values were 16±11% lower than corresponding 
values derived from PET/CT (R2=0.98 slope=0.86) (Figure 5). The largest quantitative 
differences (up to –37%) were found in the lungs. 
Figure 5. Results of the semi-quantitative analysis for healthy tissues: (a) correlation between PET/MRI- and PET/
CT-derived SUVmax of liver (blue diamonds), spleen (pink squares) and lungs (yellow triangles) (R2=0.98, slope=0.86) 
together with the line of identity, and (b) corresponding Bland-Altman plot showing the largest differences in the 
lungs (up to −37%).
a b
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Two out of 12 patients showed severe artifacts in the thorax region (patient no. 1: one 
lymph node in the right lung hilus; patient no. 2: one mediastinal left lower para tracheal 
lymph node) on PET/MRI images, resulting in discrepancies of more than 50%. These 
were due to incorrect lung segmentation in the MR μ-map (Figure 6).  Incorrect AC in 
the lungs does affect the SUV of the lesions nearby located, such as the lung hilus or 
mediastinal space. This is because the measured lines of response going through both 
the lungs and adjacently regions are not correctly adjusted for attenuation. This means 
that the overall attenuation along each line of response determines the amplitude 
of the AC. Therefore, also activity adjacent to the lungs will suffer from errors in lung 
segmentation.
Figure 6. Impact of incorrect lung segmentation: (a) PET image using CT-based attenuation correction; (b) PET 
image using MRI-based attenuation correction, showing artificially increased uptake in the most of the lung tissue 
(black arrows); and (c) corresponding MRI- based attenuation map with incorrect lung segmentation (red left 
arrow: segmentation of only the apex of the right lung; red right arrow: no segmentation of the left lung).
35314 Oprea.indd   126 03-12-15   16:47
Comparison TF PET/MRI and PET/CT systems
127
6
DISCUSSION
The aim of this study was to directly compare image quality and quantitative 
performance of Philips Ingenuity TF PET/MRI with Gemini TF PET/CT systems, using 
phantoms and clinical data from a homogenous patient group. Because the PET gantries 
of both scanners are similar, it can be assumed that the performance of both PET units 
would be similar. To the best of our knowledge, this comparison has not previously 
been reported. In addition, by performing PET/CT and PET/MR studies in PC patients 
with [18F]FCH, the relatively stable biodistribution with almost no pharmacokinetic 
changes between about 10 and 90 minutes p.i., minimizes radiotracer redistribution, 
and robust scan statistics are expected.
Phantom experiments
The phantom experiments showed comparable performances with respect to 
calibration accuracy, image uniformity, and contrast recovery. Due to differences 
between CT and MRI, some differences related to AC could be anticipated (e.g., 
phantom walls cannot be measured using MRI). This shortcoming, however, seemed 
to have a relatively low impact (not exceeding 5.5%) on final accuracy in the phantom 
studies. The calibration offset of PET/MRI, together with the expected underestimation, 
resulted in comparable calibration accuracy for PET/MRI and PET/CT. Furthermore, a 
cylindrical phantom reconstructed using various available methods showed, on both 
scanners, uniform uptake without visual artifacts. 
Some differences were seen with respect to count rate linearity, which was more 
accurate on PET/CT than on PET/MRI. These might be due to differences in scanner 
calibration software between the systems—the PET/CT is equipped with a more recent 
software version incorporating improved calibration and death time correction tables. 
Furthermore, slightly higher recoveries in the smaller spheres (<6 mL) were observed 
in case of the PET/MRI. These might be due to a combination of calibration offsets and 
shortcomings in the AC of the phantom. Apart from these minor differences, these 
initial phantom evaluations show that basic PET performance characteristics of PET/
CT and PET/MRI systems are comparable. 
MRAC remains challenging, especially when using WB PET/MRI for clinical purposes. 
Firstly, WB PET/MRI scan is a time-consuming procedure, requiring a stepwise 
optimization of the scan sequences [31]. Because of the small diameter of the MR 
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gantry, patients are scanned with arms down. A smaller transaxial MRI field of view 
than the patients’ circumference may result in truncation artifacts in the MR images. 
Lung segmentation is another challenge, due to the diminished signal intensity of these 
air-containing organs in conventional MRI images. Furthermore, the current PET/MRI 
systems have no ability to characterize bone tissue [32], resulting in underestimation 
of the SUVs in bone lesions or in visceral lesions predominantly surrounded by bone 
structures (e.g., pelvic region).
Clinical evaluations
For the clinical comparison, [18F]FCH was used as radiotracer because of its known stable 
pharmacokinetic profile [24] with limited biological redistribution during the protocol 
period. At present, [18F]FCH is seen as one of the preferred tracers for restaging PC. A 
systematic review and meta-analysis [33] showed a pooled sensitivity and specificity to 
identify all recurrent/metastatic localizations (prostatic region, bone, or lymph node) 
of 85.6% (95% CI 82.9–88.1%) and 92.6% (95% CI 90.1–94.6%), respectively.
In the present study, visual assessment of choline-avid lesions showed comparable PET 
image quality on both PET/CT and PET/MRI systems. Although PET/MRI showed the 
same detection rate of lesions compared with PET/CT, severe artifacts due to incorrect 
lung segmentation were identified in a small number or patients. This underlines the 
necessity to always inspect μ-maps, as well as attenuation- (MRAC) and non-attenuation-
corrected (NAC) images to avoid incorrect conclusions from severe AC artifacts. 
Similar observations with respect to lesion detection and quantitative measurements 
were described by Tian et al. [34] in an [18F]FDG PET/CT and PET/MRI comparative study 
of 285 patients with different malignancies. A strong diagnostic concordance between 
[18F]FDG PET/CT and PET/MRI was also found by Kohan et al. [35] in the context of 
lymph node staging of lung cancer patients. The authors addressed both tissue AC and 
anatomical nodal localization issues by using a single morphological MRI sequence 
(3D T1-weighted spoiled gradient echo sequence; T1w 3D GRE). Nevertheless, the 
applied sequence yielded a number of artifacts on the PET/MRI, limiting the confident 
anatomic localization in some mediastinal lesions. Drzezga and colleagues [36] 
described comparable reliability of data derived from [18F]FDG PET/MRI and PET/
CT studies in patients with suspected malignant lesions. Pace et al. [37] showed an 
equivalent performance of the two hybrid modalities in 36 patients with breast cancer 
undergoing initial staging or follow-up scans. 
35314 Oprea.indd   128 03-12-15   16:47
Comparison TF PET/MRI and PET/CT systems
129
6
In PC, comparable results regarding lesion detection were described by Souvatzoglou et 
al. [19] in a study performed for (re)staging patients using [11C]choline PET/CT, followed 
by an integrated PET/MRI. Evaluating 36 patients with histologically proven PC and 
suspected recurrent disease, Wetter et al. [20] found no difference in visual quality of 
PET images between [18F]FCH PET/MRI and PET/CT systems and concluded that the 
new [18F]FCH PET/MRI technique could be used with confidence in daily practice.
In the absence of PET/MRI artifacts (in two cases), the semi-quantitative analysis of the 
present data showed good correspondence in [18F]FCH uptake values between PET/CT 
and PET/MRI for both healthy tissues (R2=0.98) and lesional data (R2=0.79). Analysis 
of various lesions revealed slightly higher SUVs for PET/MRI (4±26%) than for PET/CT, 
while values in normal tissues were systematically lower (16±11%). The lowest SUVs 
were found in lungs, followed by spleen and liver. A possible reason for these differences 
might be a small ongoing redistribution of [18F]FCH with a slightly decreasing trend 
over time in normal or benign lesions and a stable or slightly increasing pattern in 
malignant lesions [28, 38–39]. As there was a mixture of benign and malignant lesions, 
this could have resulted in some over- and underestimations of PET/MR versus PET/
CT data. However, the observed variability is likely also related to differences in AC 
performance between both systems. 
Deriving accurate MRAC correction maps to correct corresponding PET data for tissue 
attenuation in PET/MRI remains a challenging task. Inadequate AC results in under- 
or overestimation of SUVs in different tissues (e.g., underestimation of the SUVs in 
bone lesions or lesions localized closed to bone structures, due to excluding the bone 
tissue in the segmentation process). In the particular case of the lungs, the theoretically 
assumed uniform attenuation coefficients are responsible for the lower SUVs in these 
organs [11]. In clinical practice, due to physiological, variable lung tissues densities, 
these attenuation coefficients lead to attenuation undercorrection and consequently 
to underestimation of the SUVs in the lungs. 
Higher lesional SUVs on PET/MRI were also observed by Souvatzoglou et al. [19] with 
good correlation between [11C]choline PET/MRI and PET/CT (ρ=0.86). In the same 
study, SUVs of various normal organs, except liver, were generally lower for PET/MRI 
and all these differences were attributed to the uptake mechanism of [11C]choline. In 
contrast, statistically significant (p<0.05) lower lesional SUV values were reported by 
Wetter et al. [20] for bone and prostate, with slightly higher SUVs for lymph nodes. The 
35314 Oprea.indd   129 03-12-15   16:47
Chapter 6
130
authors used [18F]choline as radiotracer for performing the scans on a simultaneous 
PET/MRI system. Possible explanations of the discrepancy between their findings and 
those from the group of Souvatzoglou were different techniques for AC and different 
biodistribution and biokinetics of [18F]FCH between early and delayed time points. 
The slight differences between the present findings and those of Wetter et al., while 
using the same radiotracer, underline the role of multiple factors contributing to 
underestimation in SUVs. In this respect, we agree with the German group’s hypothesis 
suggesting that differences in SUVs on PET/MRI are possibly related to different 
examination time points and MRAC.
Although in our study we focused on PET image quality and quantitative accuracy, 
the opportunities of assessing patients with the combined and concurrent use of PET/
CT and PET/MRI will be shortly discussed.  Integrated PET/CT is nowadays recognized 
as a preferred hybrid oncological imaging technique. It combines the anatomical 
information derived from CT with the functional data of tumor metabolism from 
PET, in an efficient whole-body setting. Nevertheless, combining PET with MRI, 
simultaneously or sequentially, offers new perspectives in clinical molecular imaging 
[40]. Three evident advantages of the new hybrid technique are the superior soft 
tissue contrast of MRI above CT, less radiation exposure, and the additional functional 
information. Nevertheless, performing PET/MRI in a whole-body setting is a time-
consuming procedure, in which adequate selection of the MR sequences, clinical 
indications, and workflow-related aspects have to be considered. 
PET/MRI is expected to be more accurate than PET/CT for tumor staging in all 
indications in which MRI has proven to be more valuable than CT (e.g. head and neck 
tumors, breast and liver malignancies, musculoskeletal neoplasms, etc.). Comparable 
performance is expected for lymph node staging as N-disease assessment is mainly 
diagnosed on functional (PET) imaging. For metastatic disease, potential advantages 
of PET/MRI over PET/CT depend on the site of metastatic spread [15]. In case of prostate 
cancer, potential PET/MRI indications are staging in patients with a positive biopsy, 
assessment of tumor recurrence after treatment in patients with increasing PSA, and 
tumor detection in case of increased PSA but negative biopsies [31]. 
With regard to the quantification differences between PET/CT and PET/MRI systems 
in our study, several shortcomings of MR-based AC have to be mentioned. On the one 
hand, there are general aspects, all vendors having difficulties with MRI truncation 
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artifacts, not including bone structures in the segmentation process and assigning 
uniform lung attenuation coefficients. Specific for Philips TF PET/MRI is that it uses a 
three-tissue segmentation model, dividing a dedicated MR sequence in air, lung, and 
soft tissue. Other PET/MRI systems perform a four-segmentation model, including fat 
as an additional class for generating the attenuation maps. Ignoring fat may result in 
a small overall overestimation of the AC. Nevertheless, several approaches have been 
developed and evaluated to mitigate these shortcomings [41]. Furthermore, Philips 
designed a sequential PET/MRI system with TF ability, requiring longer acquisition 
time when compared with the simultaneous (e.g. Siemens) systems. However, MRAC 
is still work-in-progress, future clinical studies being needed to evaluate the usefulness 
of the different PET/MRI designs.  
A limitation of the present study is represented by the sequential character of the 
study design, resulting in a possible redistribution of the tracer between the imaging 
time points of the PET/CT and PET/MRI. Nevertheless, we have specifically chosen 
[18F]FCH as radiotracer for this evaluation in order to minimize these effects. The 
good correspondence in SUVs across most lesions also points into this direction. 
Furthermore, a measurable difference in scan statistics can be expected by performing 
the PET/CT and the PET/MRI with a gap of 60 min. To compensate for this effect, the 
acquisition time on PET/MRI was increased with 50% compared with that applied 
during the PET/CT scan. Another possible limitation is the variability of the used MRI 
protocol, as MR images were acquired in a process of optimizing imaging procedures. 
Yet, the same amount of lesions was identified on both PET/CT as well as PET/MRI. In 
a more optimal MRI setting, it is anticipated that the PET/MRI will outperform PET/CT 
in, e.g., differentiation of benign versus malignant lesions and identification of tumor 
ingrowth in surrounding soft tissue structures, including the seminal vesicles or rectal 
wall. However, this was not the primary aim of the present study and this remains to be 
studied in further studies. 
CONCLUSION
This study demonstrates that PET/MRI and PET/CT systems provide comparable 
performance with respect to calibration accuracy, image uniformity, and contrast 
recovery. In the absence of PET/MRI attenuation correction artifacts, there was 
reasonably good correspondence between [18F]FCH uptake in both healthy tissues and 
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suspect lesions, yet systematically lower SUVs in normal tissues were seen for PET/MRI. 
Therefore, further improvement of MR-based attenuation correction is warranted. 
Furthermore, it is recommended to inspect attenuation corrections maps in order to 
avoid (quantitative) misinterpretations due to attenuation correction artifacts.
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SUPPELEMENTAL DATA
Supplemental Figure 1s. The count rate linearity of the systems, as function of activity: PET/CT (a) and PET/MRI 
(b).
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Prostate cancer (PC) represents a challenging oncological entity, with an increasing 
incidence with age and a very diverse clinical behavior. After treatment with curative 
intent, recurrence is common during the first decade. Despite initial response to anti-
hormonal therapy, the majority of PC patients will ultimately progress and reach a 
castration-resistant (CR) state. Recently, several therapeutic options against castration-
resistant prostate cancer (CRPC) have emerged, flowing from improved molecular 
profiling knowledge about the heterogeneous biological behavior of PC. Nevertheless, 
despite the variety of therapeutic options, proper sequencing (e.g., modality, timing) in 
individual patients with PC is unclear. To this end, it is essential to develop “instruments” 
able to identify which phenotype is predominant within PC patients and timely 
evaluate the response to therapy, thus avoiding futile costly and toxic treatments. 
Hybrid imaging techniques (e.g., PET/CT, PET/MRI) play a pivotal role in clinical 
management of PC, offering both functional and anatomical information. However, 
the most commonly used oncological PET tracer, [18F]fluorodeoxyglucose ([18F]FDG), 
shows limited sensitivity for the detection of androgen dependent PC. Alternatively, 
encouraging results have been reported on the use of radiolabeled choline derivates as 
PET tracers for PC [1–5]. Because of its longer half-life (110 versus 20 minutes) and better 
spatial resolution, [18F]fluoromethylcholine ([18F]FCH) is  more convenient for routine 
clinical use than 11C-labeled choline, by providing more flexibility concerning imaging 
protocols and broader availability. Therefore, the aim of this thesis was to technically 
validate [18F]FCH as initial steps on the road towards imaging guided personalized 
therapy for metastatic PC.
Chapter 1 comprises the introduction and outline of this thesis. Some epidemiological 
aspects and biological characteristics of PC are discussed, followed by an overview 
of current therapeutic options in metastatic PC. The role of hybrid imaging in PC is 
outlined, together with the available qualitative and various quantitative approaches. 
Finally, [18F]FCH is introduced as a promising radioactive tracer, by describing its 
metabolic pathway and current clinical indications, as well as the potential use for 
response evaluation and prediction in PC.
 
Since [18F]FCH is rapidly cleared from the blood pool and, unlike 11C-choline, is excreted 
via the kidneys, acquisition protocols have been designed with pelvic imaging prior 
to bladder filling (i.e., within minutes after injection), followed by a whole body scan 
after e.g., 30 min – the “dual-phase protocol”. Patterns of tracer uptake as a function 
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of time help to characterize intraprostatic tracer uptake, as well as sites of suspected 
haematogeneous metastases. It was suggested that increasing or stable [18F]FCH 
uptake over time is compatible with malignancy. However, for lymph node assessment 
this concept has not been validated. Therefore, in chapter two we investigated the 
diagnostic role of dual-phase [18F]FCH PET/CT in a clinical setting. We studied whether 
time-trends of enhanced radiolabeled choline in lymph nodes (LN) of PC patients can 
help to discriminate reactive from malignant ones, and whether single time point 
standardized uptake value (SUV) measurements may also suffice.
25 PC patients with inguinal (presumed benign) and enlarged pelvic LN (presumed 
malignant) showing enhanced [18F]FCH uptake at dual-phase PET/CT were analyzed. 
Associations between LN status (benign versus malignant) and SUVmax and SUVmeanA50, 
determined at 2 min (early) and 30 min (late) post injection (p.i.), were assessed. We 
considered two time-trends of [18F]FCH uptake: type A (SUV early > SUV late) and 
type B (SUV late ≥ SUV early). Histopathology and/or follow-up were used to confirm 
the assumption that LN with type A pattern are benign, and LN with type B pattern 
malignant.  
We identified 54 LN with enhanced [18F]FCH uptake, both at early (2 min p.i.) as well 
as late (30 min p.i.) time points. Highly significant associations were found between 
the LN status (inguinal/benign vs. enlarged pelvic/malignant) and the SUVmax and 
SUVmeanA50 30 min p.i., and their absolute and relative differences (p< 0.0001). ROC 
analyses of uptake trends over time and of SUVs at either time-point showed that the 
SUVmax relative difference was the best predictor of the LN status.
In our referral-based spectrum of patients with enhanced [18F]FCH uptake in pelvic and 
inguinal lymph nodes, decreasing [18F]FCH uptake over time seems to be a reliable tool 
to differentiate benign and malignant nodes. Together with similar findings by others 
to classify radioactive choline positive lesions suspected to represent hematogeneous 
metastases, our results are relevant for clinical decision making and simplification of 
diagnostic procedures (e.g., in patients with elevated PSA and positive [18F]FCH PET 
findings). Moreover, the results underline the relevance of a sequential PET imaging 
protocol after a single injection of [18F]FCH to account for the time-trend of tracer 
uptake. Single time-point SUV measurements, 30 min p.i., may be a reasonable 
alternative for predicting the nodal status, but this remains to be validated in non-
enlarged pelvic lymph nodes.
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The results presented in our study pertain to the ability of tracer uptake time-trends 
to classify LN with enhanced [18F]FCH uptake. Reported ‘sensitivity’ and ‘specificity’ 
should not be confused with ‘the accuracy’ of [18F]FCH PET/CT to diagnose metastatic 
lymph nodes in prostate cancer. To date, discordant results have been presented in 
the literature on the usefulness of choline PET/CT in LN staging of newly diagnosed 
patients with PC. Sensitivity of this technique is influenced by the diameter of 
metastases and limited by the low PET spatial resolution [6–10]. However, in this 
setting, other imaging modalities [e.g., transrectal ultrasound, computed tomography 
(CT), magnetic resonance imaging (MRI)] are less accurate. In case of restaging patients 
with biochemical relapse, choline PET/CT seems to be a valuable tool, especially in 
presence of higher prostate-specific antigen (PSA) values and faster PSA kinetics [11, 
12]. In this context, the major limitation of the present studies is the histopathological 
confirmation). 
Upon establishing that radioactive choline can play a diagnostic role in clinical 
practice, in chapter three we studied an alternative potential application of [18F]FCH in 
metastatic PC. Since the actual response to (chemo)therapeutic regimens in individual 
PC patients is variable, and potentially effective alternative regimens are available, it 
is important to monitor therapeutic (in)efficacy in time. Presently, this is based on a 
response metrics construct of PSA measurements, CT scans and bone scintigraphy. The 
limitations of the current approach are related to the heterogeneity of metastasized 
PC (i.e., coexistence of androgen sensitive and insensitive components with different 
impact on e.g., PSA) and to its skeletal predominance (with bone- and CT-scans having 
difficulties in timely and accurately detecting response). Therefore, there is a clear need 
for more accurate response monitoring methods.
In-vitro data have shown promising results on the use of PET tracers to monitor 
anti-androgen treatment (e.g., bicalutamide) or chemotherapy (e.g., docetaxel) in 
androgen-independent cell lines [13]. There is some recent evidence that [18F]FCH 
might be also useful as a biomarker of response to anti-androgen therapy in patients 
with metastatic CRPC [14]. Whether [18F]FCH could also be employed in monitoring 
treatment response in patients receiving docetaxel and cabazitaxel therapy is unclear. 
Therefore, we investigated whether accumulation of [18F]FCH, in comparison with [18F]
FDG, accurately reflects chemotherapy efficacy at the tumor cell level in PC, both in 
androgen-dependent and independent cell lines. We analyzed the effects of docetaxel 
and cabazitaxel on viable tumor cell numbers and tracer uptake in four PC cell lines. 
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Cellular uptake of [18F]FDG and [18F]FCH was measured using the sulforhodamine B 
(SRB) assay, cell counting and a colony formation assay (CFA), as metrics for viable 
tumor cell numbers. 
Comparing the reduction in cellular uptake of radioactive [18F]FCH in prostate tumor 
cells in vitro as a function of different dosages of docetaxel and cabazitaxel, with 
parameters of cell viability, we found that the radiotracer uptake was proportional 
to the number of residual cells after therapy. These cell numbers correlated well 
to clonogenic capacity as an additional sign of (reproductive) viability of the cells 
surviving the treatment. Our in vitro data demonstrate that the cellular [18F]FCH uptake 
fits well with viable tumor cell number after docetaxel and cabazitaxel for all PC cell 
lines, while [18F]FDG at times overestimated the cell number after drug exposure. This 
suggests that [18F]FCH is more accurate and therefore more suitable than [18F]FDG to 
measure the response to docetaxel and cabazitaxel. Therefore, we propose to design 
clinical studies to validate these findings in vivo.
Since experiments in vitro suggested radiolabeled choline to be a suitable tracer 
for response monitoring in PC, in chapter four we investigated how [18F]FCH can be 
applied and reliably measured in a routine clinical setting. As uptake of [18F]FCH should 
reflect viable tumor tissue, changes over time may serve as a measure of response to 
therapy. For monitoring response to systemic treatment in metastasized PC, however, 
accurate quantification is required, preferably with clinically applicable, simple 
quantitative methods. Such simplifications need to be validated versus the standard 
kinetic modelling PET methods. Omitting this validation step may seriously confound 
the clinical biomarker validation process, as has been demonstrated with [18F]FDG and 
[18F]FLT. Therefore, pharmacokinetic modeling of dynamic PET data in combination 
with arterial blood sampling was used to determine the appropriate plasma input 
compartment model for [18F]FCH. In addition, the validity of using an image-derived 
input function in combination with manual venous blood samples, instead of arterial 
blood sampling, was investigated, and the validity of using simplified methods for 
quantification of [18F]FCH was assessed. 
Forty-minute dynamic PET/CT scans were acquired after injection of 204 ± 9 MBq [18F]
FCH, from eight patients with histologically proven metastasized PC. Plasma input 
functions were derived using continuous arterial blood sampling (BSIF) as well as 
using image-derived (IDIF) methods. Manual arterial blood samples were used for 
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calibration and correction for plasma-to-blood ratio and metabolites. Time activity 
curves (TAC) were derived from volumes of interest (VOI) in all visually detectable LN 
metastases. [18F]FCH kinetics were studied by non-linear regression fitting of several 
single- and two-tissue plasma input models to the TAC. Model selection was based 
on Akaike information criterion (AIC) and measures of robustness. In addition, the 
performance of several simplified methods, such as SUV, was assessed.
Best fits were obtained using an irreversible compartment model with blood volume 
parameter. Correspondence between venous and arterial parent fractions was low, 
as determined by the intraclass correlation coefficient (ICC = 0.61). Results for IDIF 
derived from VOI in blood pool structures distant from tissues of high [18F]FCH uptake, 
yielded good correlation to those for BSIF (R2 = 0.83). SUV showed poor correlation to 
parameters derived from full quantitative kinetic analysis (R2 < 0.34). In contrast, lesion 
activity concentration normalized to the integral of the blood activity concentration 
over time (SUVAUC) showed good correlation (R
2 = 0.92 for metabolite corrected plasma 
and R2 = 0.65 for whole-blood activity concentrations). 
We concluded that [18F]FCH uptake should be quantified using full kinetic modeling 
with 1T1k+VB and metabolite-corrected plasma input function based on arterial blood 
sampling. Results indicate that SUV cannot be used to estimate [18F]FCH uptake. A 
clinically feasible alternative could be SUVAUC,WB based on two consecutive PET scans.
Before clinical validation of [18F]FCH PET as a predictive biomarker of response can be 
initiated, it is essential to know the physiological range of  day-to-day variability of the 
tracer uptake measures. This should help to assess whether observed changes during 
therapy represent true signal change instead of noise.  This “repeatability” of a test is 
defined as the the measurement precision with conditions that remain unchanged 
between replicate measurements (repeatability conditions) [15]. Knowledge of 
these operational characteristics of tests is an essential component of the technical 
biomarker validation process. Traditionally, changes of tracer uptake have dominated 
as PET-based response prediction biomarkers. More recently, evidence has emerged 
that measures of metabolically active tumor volume may also provide relevant 
information. To this end, in chapter five, we assessed the repeatability of various 
quantitative [18F]FCH parameters, including metabolic tumor volume (MTV) and total 
lesion choline uptake (TLCU), in PC.
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Twelve patients (64±8 years) with metastasized PC underwent 2 sets of [18F]FCH PET/CT 
scans, on two successive days. Each set consisted of a 30 minutes dynamic PET/CT scan 
of the chest, after intravenous administration of 200 MBq [18F]FCH, followed by a whole 
body (WB) PET/CT at 40 minutes. The dynamic scan was used to derive the area under 
the curve (AUC) of the blood activity concentration. Lesion uptake was derived from 
the WB scan using various volumes of interest (VOI): maximum, peak and mean. Each 
of these parameters was normalized to injected activity/weight, blood AUC and blood 
concentration itself at 40 minutes, resulting in several SUV, SUVAUC and SUVTBR values. 
Repeatability of these semi-quantitative parameters, MTV and TLCU, respectively were 
studied. The level of agreement between test-retest data and reliability was assessed 
using repeatability coefficients (RC), intraclass correlation coefficients and Bland-
Altman plots.
We identified 67 choline avid metastases, 44 bone and 23 lymph node lesions. 12 
metastases were located in the chest. In case of SUVmax, repeatability coefficients for 
SUV, SUVAUC and SUVTBR were 26, 31 and 46%, respectively. Similar values were obtained 
for SUVpeak and SUVmean. Repeatability of SUVAUC was comparable with that of standard 
SUV, for maximum, peak and mean values. Tissue type (e.g., bone versus lymph 
node) and tumour location did not affect repeatability. Repeatability did not differ 
between lesions with SUVpeak above or below the median value of 8.3 (p=0.264). The 
relative test-retest difference for MTV was 36%. Repeatability of MTV was independent 
of uptake, tissue type and location. MTV smaller than 4.2 cm3  had larger variability 
than larger volumes (RC 45 versus 28%, p=0.048). Repeatability of TLCU and TLCUAUC 
were comparable (RC 33 versus 31%, p=0.954), while TLCUTBR showed larger variance of 
51% (p<0.001). Repeatability of TLCU was independent of uptake, MTV, tissue type or 
location.
We concluded that repeatability of SUVAUC was comparable to that of standard 
SUV, indicating that [18F]FCH PET/CT uptake differences of 30% or more are likely to 
represent treatment effects. Repeatability of MTV and TLCU, respectively was ~35%. 
Observed repeatabilities are of the same order of magnitude as those seen for other 
commonly used radiotracers, such as [18F]FDG and [18F]Fluorotymidine ([18F]FLT).
Since MRI is an important and potentially powerful diagnostic method in PC, perhaps 
challenging or complementing PET, we questioned if the knowledge acquired about 
the use of [18F]FCH PET/CT is also applicable to PET/MRI. Therefore, in chapter six we 
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performed a clinical and technical validation of [18F]FCH in PC, by comparing image 
quality and quantitative accuracy of PET/MRI and PET/CT systems with identical 
time-of-flight PET gantries, using phantom and clinical studies. The same phantom 
experiments were performed using both systems, by measuring calibration, uniformity, 
and SUV recovery. The clinical PET/CT versus PET/MRI comparison was performed 
using [18F]FCH. 
Calibration accuracy and image uniformity were comparable between systems. 
SUV recovery met EANM/EARL requirements on both scanners. Thirty-four lesions 
with comparable PET image quality were identified. Lesional SUVmax differences of 
4±26% between PET/MRI and PET/CT data were observed (R2=0.79, slope=1.02). In 
healthy tissues, PET/MRI-derived SUVs were 16±11% lower than on PET/CT (R2=0.98, 
slope=0.86). Our main conclusion was that PET/MRI and PET/CT showed comparable 
performance with respect to calibration accuracy, image uniformity, and SUV recovery. 
[18F]FCH uptake values for both healthy tissues and lesions corresponded reasonably 
well between magnetic resonance (MR)- and computed tomography (CT)-based 
systems, but only in regions free of MR-based attenuation artifacts. Nevertheless, the 
usefulness of PET/MRI remains to be elucidated in clinical, prospective studies with 
large cohorts of patients.
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SYNTHESIS AND PERSPECTIVES
Taken together, [18F]FCH PET/CT may qualify as a biomarker of response in PC, based 
on its appropriate lesion to background contrast, its promising in vitro performance in 
detection of changing viable load during therapy, and the apparent accuracy of generally 
applicable, simplified quantitative whole body measures. The semi-quantitative 
methods have  repeatability characteristics comparable with those observed with 
other broadly used tracers (e.g., [18F]FDG, [18F]FLT). As imaging plays an increasing role 
in the clinical management of PC, we also performed a technical and clinical validation 
of PET/CT and PET/MRI systems with identical time-of-flight gantries, using [18F]FCH. 
We found comparable performance between the systems with regard to the technical 
characteristics and an acceptable clinical correspondence, with limitations mainly due 
to inherent MR-based attenuation artifacts.
In case of PC, PET/MRI is presumed to be more accurate than PET/CT for primary 
staging, e.g., by combining high-resolution prostate images (e.g., diffusion weighted 
imaging (DWI)) and metabolic/molecular imaging ([18F]FCH PET). Comparable PET/
CT and PET/MRI performance is expected for LN staging, as nodal disease (especially 
small < 8 mm metastatic LN) assessment is mainly diagnosed on functional (PET) 
imaging. For distant metastases, possible advantages of PET/MRI over PET/CT depend 
on the site of metastatic spread. Potential PET/MRI indications are staging in patients 
with a positive biopsy, assessment of tumor recurrence after treatment in patients with 
increasing PSA, and tumor detection in case of increased PSA but negative biopsies. 
However, MR attenuation correction remains a limiting factor, demanding research 
for technical improvement [16]. With regard to the whole body PET/MRI systems 
currently available, there is a clear preference for fully integrated PET/MRI scanners in 
daily practice. Truly simultaneous PET and MRI acquisitions carry less risk of patient 
movement since scan time is shorter than with sequential PET/MRI, improving patient 
throughput at the same time. [16].
Significant progress has recently been made in improving acquisition and interpretation 
of multiparametric MRI (mpMRI), with an extended role of mpMRI from local staging 
toward lesion detection and biopsy guidance [17]. Combining both anatomical and 
functional pulse sequences (i.e., T1-weighted MRI, T2-weighted MRI, DWI or MR 
spectroscopy), mpMRI shows promising results for biopsy planning and targeting. 
MpMRI is also useful in the evaluation of extracapsular extension, neurovascular bundle 
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involvement, seminal vesicle invasion and/or invasion of adjacent structures, such as 
rectum and urinary bladder, thus preventing futile curative surgery [18]. Developments 
in the acquisition of mpMRI are ongoing. The DW technique is improved by the use 
of high b-value DW-MRI. Progress in this field has resulted in implementation of 
high b-value DW-MRI as a component of the prostate imaging reporting and data 
system (PIRADS) evaluation criteria [19]. However, an important drawback of mpMRI 
is the difficulty in detecting small malignant foci in the prostate (<0.5 cm3) and low-
risk Gleason score lesions [20]. Future well-structured studies investigating the best 
manner to calculate high b-value DW-MRI are needed since functional information 
hereby provided may guide the optimal therapeutic choice.
Apart from radiolabeled choline, new tracers such as 18F-16β-18F-fluoro-5α-
dihydrotestosterone ([18F]FDHT), and 68Ga-PSMA are demonstrating promising 
results in recurrent and metastatic PC. [18F]FDHT is a biomarker for androgen receptor 
(AR) expression in human PC, mainly useful in the CRPC state. It has good  imaging 
characteristics, with rapid uptake in malignant cells at metastatic sites expressing AR 
[21]. Research is ongoing to investigate its role in stratification of patients for systemic 
therapy and in monitoring treatment effects in patients undergoing novel anti-
androgen therapies.
Serial experiments have recently demonstrated the importance of targeting the 
prostate-specific membrane antigen (PSMA) with either 68Ga- or 123I-labelled PSMA 
inhibitors [22, 23]. PSMA is a membrane-type zinc protease which is negatively 
regulated by androgen and significantly overexpressed in androgen-independent PC. 
Increased PSMA expression in PC is associated with higher tumor grade and a high 
risk of disease progression, as defined by biochemical recurrence after initial curative 
therapy [24]. Since PSMA elevation is inversely correlated to time to prostate-specific 
antigen (PSA) progression and disease-free survival, this tracer has the potential to 
serve as a biomarker for estimating the aggressiveness of PC [24]. Furthermore, PSMA 
represents an ideal biological target for accurate functional imaging of PC, due to an 
improved sensitivity to detect small LN-, bone- and liver- metastases [22]. Advantages 
of 68Ga- labelled PSMA ligands above choline tracers are twofold: a better signal to 
background ratio and no cyclotron requirement, since 68Ga can be extracted from a 
commercially available 68Ge/68Ga radionuclide generator [18]. The role of labeled PSMA 
in PC is currently under investigation. 
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Another tracer, a radiolabeled leucine analogue, 1- amino-3-fluorocyclobutane-1-
carboxylic acid in the ‘anti’ configuration ([18F]FACBC), can be also used to depict amino 
acid transportation in PC. Since only a small fraction is excreted through the urinary 
tract after intravenous administration, its imaging characteristics seem to be favorable 
in the evaluation of prostate cancer [25]. Research data indicate that [18F]FACBC can 
be successfully used in the assessment of primary and metastatic PC. Preliminary 
results indicate also that [18F]FACBC may be superior to radiolabeled choline for the 
identification of disease recurrence in case of biochemical failure [26, 27]. Nevertheless, 
these findings have to be confirmed in larger, prospective studies.
An important aim of any “diagnosis-treatment” combination is to improve the quality 
of life of patients with metastatic PC. To validate that [18F]FCH may contribute to 
this purpose, we suggest the following research, beyond the technical validation 
described in this thesis. Firstly, [18F]FCH reproducibility studies (measuring test-retest 
variability in a multicenter setting) are needed to complete the technical validation. 
Secondly, clinical ‘biological validation’ studies to define the accuracy and optimal 
methodology of [18F]FCH to predict clinical response to systemic therapy are needed. 
Thirdly, comparative [18F]FCH PET/CT and DWI studies may be considered: if DWI and 
[18F]FCH PET have similar value in overall response prediction, a combination of [18F]
FDHT and DWI might help to separate and quantify the androgen-receptor phenotype 
from the overall tumor load, before and during therapy. Moreover, by opting for 
active surveillance in case of a coexistent phenotype, these studies will provide the 
opportunity to timely start effective treatment in case of PC progression. Finally, cost-
effectiveness  of any diagnosis-therapy combination should be evaluated to support 
appropriate decision-making by clinicians, patients and health care providers during 
the management of  metastatic prostate cancer.
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List of abreviations
AC Attenuation correction
ADT Anti-androgen therapy
AIC Akaike information criterion
APD Avalanche photodiodes
AR Androgen receptor
AUC Area under the curve
BMI Body mass index
BSA Body surface area
BSIF Blood sampling input function
BT Brachytherapy
BW Body weight
CFA Colony formation assay
CK Choline kinase
CR Castration resistant
CRPC Castration resistant prostate cancer
CSS Cancer specific survival
CT Computed tomography
DNA Deoxyribonucleic acid
EANM/EARL European Association of Nuclear Medicine/ Research Ltd
EBRT External beam radiation therapy
FDHT 16β-18F-fluoro-5α-dihydrotestosterone 
FID-GC Flame ionization detector-gas chromatography
FOV Field of view
FWHM Full width at half maximum
[18F]FCH [18F]fluoromethylcholine
[18F]FDG [18F]fluorodeoxyglucose
[18F]FLT [18F]fluorothymidine
HPLC High performance liquid chromatography
HT Hormonal Therapy
IBW Ideal body weight
ICC Intraclass correlation coefficient
IDIF Image derived input function
IQ Image quality
IQR Interquartile range
LBM Lean body mass
LBr Lesion to blood ratio
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LD-CT Low dose- computed tomography
LMr Lesion to muscle ratio
LN Lymph node
LNM Lymph node metastasis
MLL R 3327-MATLyLu
mpMRI Multiparametric magnetic resonance imaging
MRAC Magnetic resonance based attenuation correction
MRI Magnetic resonance imaging
MTV Metabolic tumor volume
NAC Non attenuation correction
NLR Non linear regression
p.i. Post injection
PC Prostate cancer
PET Positron emission tomography
PLND Pelvic lymph node dissection
PMT Photomultiplier tubes
PSA Prostate-specific antigen
PTS Portable test system
PVDF Polivinylidenedifluoride
ROC Receiver operating characteristics
ROI Region of interest
RP Radical prostatectomy
RT Radiation therapy
SiPMT Silicon photomultiplier tubes
SRB Sulforhodamine B
STIR Short tau inversion recovery
SUV Standardized uptake value
TAC Time activity curve
TF Time of flight
TLCU Total choline lesion uptake
TSE T2-weighted turbo spin echo
VOI Volume of interest
WB Whole body
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Op weg naar geïndividualiseerde therapie voor 
gemetastaseerd prostaatcarcinoom:  
een technische validatie van [18F]fluormethylcholine
PROSTAATKANKER
Prostaatkanker is de op een na meest voorkomende vorm van kanker bij mannen. 
Het komt vooral voor bij mannen van boven de 50 jaar, en de incidentie stijgt met de 
leeftijd. De uiting van prostaatkanker is heel divers. Sommige tumoren zijn indolent, 
goed gedifferentieerd, en geven geen klinische symptomen. Echter, bij een aanzienlijk 
percentage patiënten is er sprake van een agressievere vorm van prostaatkanker, 
waarbij uitzaaiingen (metastasen) ontstaan, die uiteindelijk tot de dood kunnen 
leiden. 
De eerste vorm van systemische therapie, die wordt gegeven aan patiënten met een 
uitgezaaid prostaatcarcinoom, is hormonale behandeling. Hoewel bij de meeste 
patiënten de hormoontherapie aanvankelijk goed aanslaat, ontstaat er vaak progressie 
van ziekte onder therapie. Op dat moment is de prostaatkanker castratie refractair. Dit 
gebeurt meestal in een tijdsbestek van 18 tot 36 maanden. 
Tot enkele jaren geleden was docetaxel chemotherapie elke 3 weken in combinatie 
met prednison de standaardbehandeling voor patiënten met een castratie refractair 
prostaatcarcinoom (CRPC). Deze behandeling geeft een overlevingswinst van enkele 
maanden. De laatste jaren zijn nieuwe behandelmogelijkheden ontwikkeld voor 
patiënten met CRPC, allen met een bewezen overlevingsvoordeel van enkele maanden. 
Cabazitaxel, een ander taxaan, is een vorm van tweedelijns chemotherapie. Daarnaast, 
zijn er op basis van moleculaire studies nieuwe middelen ontwikkeld die interfereren 
met de androgene stimulatie van tumorgroei. Zowel enzalutamide als abiraterone in 
combinatie met prednison hebben de mediane overleving van patiënten met CRPC 
verbeterd. Dit effect is aangetoond zowel pre- als postdocetaxel. Sipuleucel-T is een 
vorm van immuuntherapie, waarbij  eigen mononucleaire cellen zodanig worden 
bewerkt dat zij de prostaatkankercellen gaan herkennen en ‘aanvallen’. Hoewel 
Sipuleucel-T geen verbetering geeft van de progressie-vrije overleving, is er wel 
een bewezen positief effect op de mediane overleving. Sipuleucel-T is in Nederland 
niet beschikbaar. Tot slot is het botzoekende radionuclide Radium-223-chloride 
geregistreerd voor de behandeling van patiënten met vooral botmetastasen.
omethylcholine
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Doordat al deze nieuwe behandelmogelijkheden in een kort tijdsbestek zijn onderzocht 
en geïntroduceerd, is er onduidelijkheid ontstaan over de beste volgorde waarin deze 
middelen aan de patiënten kunnen worden voorgeschreven. Daarnaast moet rekening 
gehouden worden met de economische gevolgen van deze therapieën vanwege de 
relatief hoge kosten. Zowel uit ethisch als uit economisch oogpunt, is dus behoefte 
ontstaan om methoden te ontwikkelen die kunnen zorgen voor ‘therapie-op-maat’. 
Hiervoor zijn instrumenten nodig waarmee het phenotype van de prostaatkanker 
in de individuele patiënt kan worden gekarakteriseerd. Als dit wordt gecombineerd 
met klinische parameters, zoals evaluatie van de respons op de behandeling, kan in 
de toekomst hopelijk beter voorspeld worden welke patiënt baat zal hebben van een 
bepaalde behandeling. Hiermee kunnen zinloze, dure en toxische behandelingen 
worden vermeden. 
DE ROL VAN BEELDVORMING BIJ PROSTAATKANKER
Nauwkeurige diagnostiek bij prostaatkanker is essentieel, omdat de therapeutische 
mogelijkheden afhankelijk zijn van, onder andere, het stadium en de graad van 
de ziekte, en de manier van metastasering  (dat wil zeggen: via de bloed- of de 
lymfebanen). Conventionele beeldvormingstechnieken, zoals transrectale echo, 
computertomografie (CT) en magnetische resonantie imaging (MRI) worden 
routinematig gebruikt bij prostaatkanker, maar hun diagnostische nauwkeurigheid 
is niet optimaal. Multimodale beeldvorming heeft de patiëntenzorg verbeterd in 
de afgelopen tien jaar. De niet-invasieve functionele positronemissietomografie /
computertomografie (PET/CT) blijkt een waardevol diagnostisch instrument. Het 
combineert “in vivo” metabolische en anatomische informatie.
PET is een beeldvormende techniek gebaseerd op de waarneming van gelijktijdig 
uitgezonden fotonen, afkomstig van de annihilatie van positronen met elektronen in 
de omliggende weefsels. PET maakt gebruik van radiofarmaca. Deze bestaan uit een 
radionuclide, in het geval van PET een positron emitter, gekoppeld aan een andere stof 
(ligand). De radiofarmaca worden via de aders toegediend aan patiënten en verzamelen 
zich op bepaalde plaatsen in het lichaam (bijvoorbeeld een tumor). Het radionuclide 
vervalt onder uitzending van een positron. Dit positron annihileert na het afleggen 
van een korte weg (1-2 mm)  met een elektron, waarbij twee annihilatiefotonen met 
een energie van 511 keV onder een hoek van 180 graden ontstaan. De PET detectoren 
registreren deze fotonen “in coïncidentie”. Voor elke annihilatie kan zo vastgelegd 
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worden, waar hij heeft plaatsgevonden en op die manier wordt een beeld gevormd 
van de verdeling van het radionuclide in het lichaam.
PET is een uiterst gevoelige beeldvormende modaliteit, waarvoor zeer kleine 
hoeveelheden radioactief gemerkte moleculen (tracers, ~ nM) worden geïnjecteerd. De 
meting van de tracerdistributie maakt kwantitatieve beoordeling van de weefselfunctie 
mogelijk, zonder dat de onderliggende fysiologie wordt veranderd. Tegenwoordig is 
het met de huidige generatie PET/CT systemen met time-of-flight (TF) mogelijk de 
exacte locatie van het annihileren van de fotonen te bepalen. Dit geeft beelden met 
een hoge resolutie en een betere signaal-ruisverhouding.  
Een visuele, kwalitatieve beoordeling van de verzwakte en niet-verzwakte PET beelden 
vormt de basis van elke PET-interpretatie. Een tumor wordt op PET gedefinieerd als 
een gebied met hogere opname van radioactiviteit  (bijv. radioactief gelabeld choline) 
dan de omringende achtergrond, die tevens incompatibel is met de fysiologische 
accumulatie van de tracer. 
De belangrijkste valkuil met betrekking tot de beoordeling van PET-scans vormen 
significante verschillen in de PET-interpretatie tussen verschillende beoordelaars. 
Om dit te voorkomen is de juiste kwantificering van een nieuw radiofarmacon nodig. 
Dit vereist kinetische modellering met behulp van een dynamische PET-scan vanaf 
injectie van de tracer, in combinatie met arteriële bloedafname (om informatie over 
de verdeling van het radiofarmacon in een interesse gebied te verkrijgen en potentiële 
tracermetabolieten te meten). Voor een vereenvoudigde kinetische modellering is 
slechts een statische scan met enkele veneuze bloedmonsters tijdens de scan nodig.
Slechts een decennium na de succesvolle implementatie van PET met CT als geheel 
wordt de integratie van PET met magnetische resonantie beeldvorming (PET/MRI) 
geïntroduceerd als de volgende hybride beeldvorming. Sterke punten van MRI 
zijn onder meer het betere wekedelen contrast, hoge ruimtelijke resolutie, en het 
ontbreken van blootstelling aan ioniserende straling. Verschillende hybride PET/MRI-
systemen zijn beschikbaar: een geïntegreerd systeem met beide componenten in één 
frame, of een gescheiden PET en MRI component aan weerszijden van een draaibare 
tafel. De eerste heeft het voordeel van echt simultane beeldacquisitie, maar de laatste 
doet geen concessie aan de beeldkwaliteit van een van beide componenten (PET of 
MRI) en is uitgerust met TF. Huidige klinische toepassingen met PET/MRI staan nog in 
de kinderschoenen.
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RADIOACTIEF GELABELD CHOLINE
De implementatie van efficiënte PET hard- en software in combinatie met 
de vooruitgang in de moleculaire biologie van het prostaatcarcinoom, biedt 
mogelijkheden voor de ontwikkeling van nieuwe beeldvormende biomarkers en 
veelbelovende radiotracers. Voor multimodale beeldvorming (zoals PET/CT, PET/
MRI) zijn meerdere radiofarmaca beschikbaar om fysiologische en metabole routes 
waar te nemen en te kwantificeren. De meest gebruikte oncologische PET tracer, [18F]
fluorodeoxyglucose ([18F]FDG), heeft een beperkte sensitiviteit voor de detectie van het 
androgeen afhankelijke prostaatcarcinoom. 
In tegenstelling tot [18F]FDG, worden bemoedigende resultaten gemeld bij het gebruik 
van 11C en 18F gelabeld choline als PET-tracers voor het prostaatcarcinoom.
Het aminozuur choline is een belangrijke voorloper voor de biosynthese van 
fosfatidylcholine, een essentieel bestanddeel van de celmembraanfosfolipiden. Na 
transport in de cel, wordt choline gefosforyleerd door cholinekinase tot fosfocholine en 
opgesloten binnen de cel. De meeste soorten kanker, waaronder ook prostaatkanker, 
worden gekenmerkt door een verhoogd cholinetransport en over-expressie van 
cholinekinase, als reactie op een verhoogde vraag naar fosfatidylcholine in sterk 
prolifererende cellen.
Omdat de opname van [18F]fluoromethylcholine ([18F]FCH) in normaal, hyperplastisch 
(nog wel goedaardig) danwel kwaadaardig prostaatweefsel overlapt, zijn er gemengde 
resultaten met betrekking tot de potentiële bruikbaarheid van deze tracer in de 
diagnose en stadiëring van een primair prostaatcarcinoom. Momenteel wordt  [18F]FCH 
vooral gebruikt voor restadiëring van het prostaatcarcinoom bij een (biochemische) 
terugval, met een diagnostische waarde die lijkt te verbeteren bij een toenemende 
prostaat-specifiek antigen (PSA) waarde. Het gebruik van [18F]FCH PET/CT in de praktijk 
wordt niet aanbevolen bij een PSA niveau lager dan 1 ng/mL.
Als de opname van radioactief gelabeld choline vitaal tumorweefsel weergeeft, kan 
uit de  veranderingen van het cholinesignaal in de tijd, de mate van respons op de 
therapie bepaald worden. Voor het meten van respons op systemische behandeling 
bij uitgezaaide prostaatkanker is kwantificatie nodig. Tot op heden is de  [18F]FCH 
biodistributie en stralingsdosimetrie bestudeerd, maar een volledige kinetische 
analyse is nog niet gerapporteerd.
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RESPONS EVALUATIE EN VOORSPELLING IN 
PROSTAATKANKER
De respons op (chemo)therapeutische regimes is bij elke prostaatkankerpatiënt 
anders. Het is daarom belangrijk om de (in)efficiëntie van de therapie te monitoren. 
Zo wordt voorkomen dat  patiënten een nutteloze en dure behandeling te lang 
ondergaan. Alternatieve en mogelijk effectieve geneesmiddelen zijn beschikbaar. 
Momenteel wordt de monitoring van de voortgang gedaan met een combinatie van 
onderzoeken, waaronder een PSA-meting, een CT en een botscan. De beperkingen 
van de huidige aanpak zijn gerelateerd aan de heterogeniteit van het uitgezaaide 
prostaatcarcinoom  (bijv. co-existentie van androgeen gevoelige en ongevoelige delen, 
met elk verschillende effecten op bijvoorbeeld het PSA) en het feit dat de ziekte meestal 
vooral ossaal gemetastaseerd is (waarbij het lastig is op bot- en CT-scans de respons op 
therapie tijdig en nauwkeurig waar te nemen). Daarom is er behoefte aan alternatieve 
en nauwkeurigere methoden om de respons op therapie te evalueren.
Met elk nieuw radiofarmacon is het de uitdaging om betrouwbare vereenvoudigde 
kwantitatieve methoden in te voeren, die in de dagelijkse klinische praktijk en op 
het hele lichaam toegepast kunnen worden. Of [18F]FCH  ook kan worden gebruikt 
bij het monitoren van de respons op de behandeling van prostaatkankerpatiënten 
die behandeld worden met docetaxel of cabazitaxel, is onduidelijk. Definitieve 
gegevens uit klinische studies zijn nog niet beschikbaar. Desalniettemin tonen in-vitro 
experimenten veelbelovende resultaten voor het gebruik van PET-tracers bij patiënten 
die een hormonale (anti-androgeen) of chemotherapeutische behandeling krijgen.
Samengevat is PET-beeldvorming een veelbelovende aanpak, zowel in klinische als 
in wetenschappelijke toepassingen. PET maakt kwantitatieve metingen met een 
hoge sensitiviteit mogelijk. Het verschaft non-invasieve informatie over biologische 
processen in het lichaam. Standaard methoden van PET-kwantificering zijn moeilijk 
te implementeren in de dagelijkse klinische praktijk. Vereenvoudigde methoden voor 
kwantificering zijn beschikbaar, maar moeten worden gevalideerd ten opzichte van de 
standaardmethoden. Om biologische verandering van ruis te onderscheiden, moet 
informatie over de herhaalbaarheid van een scan met een tracer bekend zijn. 
Door de toename van gebruik van [18F]FCH  PET bij het prostaatcarcinoom zijn 
klinisch haalbare protocollen, op basis van betrouwbare en herhaalbare indices voor 
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tumoractiviteit, essentieel voor het monitoren van respons op de therapie. Complexe 
kwantitatieve analysemethoden worden waarschijnlijk overal in klinische setting 
beschikbaar. Dit vergroot het potentieel van de radioactief gemerkte choline PET bij de 
“op maat” behandeling, door een tijdige evaluatie van de effectiviteit van de therapie. 
Hierdoor worden ineffectieve, dure of risicovolle behandelingen vermeden.
INHOUD VAN DEZE THESIS
Het doel van dit proefschrift was het technisch valideren van [18F]FCH  als eerste stap 
op weg naar een door beeldvorming geleide, geïndividualiseerde therapie voor het 
gemetastaseerd prostaatcarcinoom.
In hoofdstuk twee bestuderen we de diagnostische rol van twee-fase [18F]FCH  PET/
CT in een klinische setting. Hiervoor hebben we onderzocht of de tijd-trends van de 
intensiteit van choline opname  in de lymfklieren van prostaatkankerpatiënten kunnen 
helpen om onderscheid te maken tussen goedaardige (reactieve) en kwaadaardige 
klieren, en of een enkel tijdstip meting met behulp van standardized uptake value (de 
zo genoemde SUV), ook kan volstaan.
In hoofdstuk drie bestuderen we een alternatieve toepassing van [18F]FCH  in uitgezaaid 
prostaatcarcinoom. In deze context is onderzocht of opname van [18F]FCH, vergeleken 
met [18F]FDG, de chemotherapiewerking op tumorcel niveau in prostaatcarcinoom 
accuraat weergeeft.
In hoofdstuk vier onderzoeken we hoe de opname van [18F]FCH betrouwbaar kan 
worden gemeten in een klinische setting. Hiervoor worden farmacokinetische 
modellen van dynamische PET-data in combinatie met arterieel bloed sampling 
gebruikt om het correcte compartiment model voor [18F]FCH te bepalen. Aanvullend, is 
de geldigheid van het gebruik van vereenvoudigde werkwijzen voor het kwantificeren 
van [18F]FCH bepaald.
In hoofdstuk vijf onderzoeken we of de vereenvoudigde methoden voor het meten 
van [18F]FCH opname, zoals voorgesteld in hoofdstuk vier, herhaalbaar zijn in de 
dagelijkse praktijk. Hiervoor onderzoeken we de herhaalbaarheid van verschillende 
kwantitatieve [18F]FCH  parameters, waaronder het metabole tumorvolume en de 
totale laesie cholineopname.
In hoofdstuk zes voeren we een klinische en technische validatie uit van [18F]FCH 
in prostaatcarcinoom. Daarvoor vergelijken we beeldkwaliteit en kwantitatieve 
nauwkeurigheid van PET/MRI en PET/CT-systemen met identieke TF PET frames, met 
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behulp van fantomen en klinische studies. De fantoom experimenten zijn gebaseerd 
op onderzoek naar de kalibratie nauwkeurigheid, beeld uniformiteit, en SUV herstel 
van de hybride systemen. Bij de klinische studies is de mate van [18F]FCH opname 
geanalyseerd, in zowel gezonde weefsels als pathologische tumoren.
In hoofdstuk zeven worden de resultaten  in het algemeen beschreven en samengevat, 
en de perspectieven gegeven.
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